Medizin
Refine
Year of publication
Document Type
- Article (3561) (remove)
Has Fulltext
- yes (3561)
Is part of the Bibliography
- no (3561) (remove)
Keywords
- inflammation (47)
- glioblastoma (29)
- apoptosis (27)
- breast cancer (26)
- cancer (26)
- Inflammation (19)
- biomarker (18)
- COVID-19 (17)
- autophagy (17)
- Depression (15)
- immunotherapy (15)
- mitochondria (15)
- Cancer (14)
- Germany (14)
- pain (14)
- Apoptosis (13)
- Breast cancer (13)
- depression (13)
- macrophage (13)
- prevention (13)
- prostate cancer (13)
- reactive oxygen species (13)
- Biomarkers (12)
- Cirrhosis (12)
- HIV (12)
- Mammakarzinom (12)
- Neuroscience (12)
- chemotherapy (12)
- Biomarker (11)
- SARS-CoV-2 (11)
- Stroke (11)
- aging (11)
- diagnosis (11)
- epilepsy (11)
- microRNA (11)
- obesity (11)
- schizophrenia (11)
- Chemotherapy (10)
- Gene expression (10)
- Human behaviour (10)
- Mitochondria (10)
- Research article (10)
- angiogenesis (10)
- attention (10)
- cirrhosis (10)
- cytokines (10)
- glioma (10)
- hypoxia (10)
- multiple sclerosis (10)
- ADHD (9)
- COPD (9)
- Children (9)
- Hemorrhage (9)
- MRI (9)
- Oncology (9)
- Primary care (9)
- Treatment (9)
- cell death (9)
- children (9)
- complications (9)
- human (9)
- invasion (9)
- leukemia (9)
- macrophages (9)
- migration (9)
- neuroblastoma (9)
- proliferation (9)
- quality of life (9)
- surgery (9)
- treatment (9)
- Atrial fibrillation (8)
- Behandlung (8)
- Evaluation (8)
- General practice (8)
- Hepatocellular carcinoma (8)
- Liver diseases (8)
- Metastasen (8)
- NADPH oxidase (8)
- Parkinson’s disease (8)
- Prognosis (8)
- Prävention (8)
- Quality of life (8)
- ROS (8)
- cognition (8)
- data science (8)
- differentiation (8)
- fMRI (8)
- mTOR (8)
- psoriasis (8)
- radiotherapy (8)
- Autophagy (7)
- Blood (7)
- Diagnostic markers (7)
- Drug therapy (7)
- Europe (7)
- HDAC (7)
- Immunotherapy (7)
- Machine learning (7)
- Multimorbidity (7)
- Outcome (7)
- Patients (7)
- Schizophrenia (7)
- Surgery (7)
- Survival (7)
- child (7)
- development (7)
- endothelial cells (7)
- epidemiology (7)
- epigenetics (7)
- hepatitis C virus (7)
- hereditary angioedema (7)
- macrophage polarization (7)
- medical education (7)
- metabolism (7)
- metastases (7)
- natural killer cells (7)
- proteomics (7)
- sepsis (7)
- Borrelia (6)
- CDK4/6 (6)
- Cancer treatment (6)
- Cardiovascular magnetic resonance (6)
- Death rates (6)
- Diabetes mellitus (6)
- Hepatitis C virus (6)
- Liver transplantation (6)
- Magnetic resonance imaging (6)
- Mental health and psychiatry (6)
- NASH (6)
- PD1/PDL1 (6)
- PI3K (6)
- Pain (6)
- Radiotherapy (6)
- Studien (6)
- Suicide (6)
- Surgical and invasive medical procedures (6)
- TRAIL (6)
- VEGF (6)
- bipolar disorder (6)
- brain metastases (6)
- diffusion tensor imaging (6)
- extracellular matrix (6)
- gender (6)
- infection (6)
- information theory (6)
- innate immunity (6)
- integrins (6)
- lung cancer (6)
- medizinische Ausbildung (6)
- metastasis (6)
- miRNA (6)
- microbiome (6)
- monocytes (6)
- mouse (6)
- neurodegeneration (6)
- outcome (6)
- particulate matter (6)
- physical activity (6)
- portal hypertension (6)
- prophylaxis (6)
- safety (6)
- targeted therapy (6)
- therapy (6)
- toxicity (6)
- ubiquitin (6)
- vitamin D (6)
- ACLF (5)
- Acute myeloid leukemia (5)
- Angiogenesis (5)
- Atherosclerosis (5)
- Cell signalling (5)
- Clinical trial (5)
- Crohn’s disease (5)
- DNA methylation (5)
- Diagnosis (5)
- EEG (5)
- EGFR (5)
- Epidemiology (5)
- Experimental models of disease (5)
- HCV (5)
- HIV-1 (5)
- Heart failure (5)
- Histology (5)
- IL-6 (5)
- MEG (5)
- Macrophages (5)
- Malaria (5)
- Medical education (5)
- Molecular biology (5)
- Morbidity (5)
- Mortality (5)
- Multiple sclerosis (5)
- Multivariate analysis (5)
- NKG2D (5)
- Non-small cell lung cancer (5)
- Obesity (5)
- Oral anticoagulation (5)
- PCR (5)
- PD-L1 (5)
- RUCAM (5)
- Smac (5)
- T cell (5)
- T cells (5)
- Targeted therapy (5)
- Trauma (5)
- Viral load (5)
- acute coronary syndrome (5)
- acute-on-chronic liver failure (5)
- adhesion (5)
- aortic stenosis (5)
- asthma (5)
- ataxia telangiectasia (5)
- atherosclerosis (5)
- atrial fibrillation (5)
- bevacizumab (5)
- biomarkers (5)
- cardiac surgery (5)
- cell therapy (5)
- chimeric antigen receptor (5)
- chronic kidney disease (5)
- cochlear implant (5)
- colorectal cancer (5)
- complement (5)
- conduct disorder (5)
- coronavirus (5)
- curcumin (5)
- cytotoxicity (5)
- efficacy (5)
- elderly (5)
- environmental tobacco smoke (5)
- fibrosis (5)
- forensic entomology (5)
- gene therapy (5)
- guideline (5)
- integrin (5)
- liver (5)
- magnetic resonance imaging (5)
- mutual information (5)
- natural killer cell (5)
- ovarian cancer (5)
- p53 (5)
- periodontitis (5)
- plasticity (5)
- polytrauma (5)
- prevalence (5)
- prognosis (5)
- regeneration (5)
- renal cell carcinoma (5)
- resistance (5)
- signal transduction (5)
- sphingosine-1-phosphate (5)
- stroke (5)
- transcranial magnetic stimulation (5)
- trauma (5)
- valproic acid (5)
- ABCB1 (4)
- ATM (4)
- Age groups (4)
- Anticoagulation (4)
- Aortic valve (4)
- Ascites (4)
- Aspergillus fumigatus (4)
- Attention (4)
- Autism spectrum disorder (4)
- B cells (4)
- Bipolar disorder (4)
- CIK cells (4)
- CRISPR/Cas9 (4)
- Cell biology (4)
- Cell staining (4)
- Cell therapy (4)
- Clinical trials (4)
- Communication (4)
- Consensus (4)
- Cytokines (4)
- DILI (4)
- DNA damage (4)
- Decision making (4)
- Denosumab (4)
- Developmental biology (4)
- Diagnostic medicine (4)
- Diagnostik (4)
- E-Learning (4)
- Emotions (4)
- Epilepsy (4)
- Ewing sarcoma (4)
- Fibrosis (4)
- Flow cytometry (4)
- Gastric cancer (4)
- Gender (4)
- Guidelines (4)
- Hematology (4)
- Hodgkin lymphoma (4)
- Homeostasis (4)
- IAP proteins (4)
- Immunohistochemistry (4)
- Immunology (4)
- Kinematic analysis (4)
- Liver cirrhosis (4)
- MRSA (4)
- MSD (4)
- Mechanisms of disease (4)
- Medizindidaktik (4)
- MicroRNAs (4)
- Molecular medicine (4)
- Mouse models (4)
- NK cell (4)
- NK cells (4)
- NK-92 (4)
- Neonates (4)
- Neutropenia (4)
- NoxO1 (4)
- OSCE (4)
- Osteoporosis (4)
- Outcomes (4)
- Parkinson's disease (4)
- Personalized medicine (4)
- Physicians (4)
- Portal hypertension (4)
- Pregnancy (4)
- Prevention (4)
- Proliferation (4)
- Proteomics (4)
- Psychiatric disorders (4)
- Randomized controlled trial (4)
- Reactive oxygen species (4)
- Risiko (4)
- Roussel Uclaf Causality Assessment Method (4)
- Sepsis (4)
- Sex differences (4)
- Stem cells (4)
- Surgical oncology (4)
- Thrombosis (4)
- Ubiquitination (4)
- Validation (4)
- XIAP (4)
- acute kidney injury (4)
- acute lymphoblastic leukemia (4)
- adjuvant therapy (4)
- adjuvante Therapie (4)
- adolescents (4)
- aggression (4)
- alirocumab (4)
- anaemia (4)
- antibodies (4)
- antioxidants (4)
- bibliometry (4)
- cancer stem cells (4)
- cell biology (4)
- climate change (4)
- clinical trial (4)
- cytomegalovirus (4)
- dementia (4)
- dendritic cells (4)
- dental implants (4)
- direct-acting antivirals (4)
- drug resistance (4)
- early breast cancer (4)
- entropy (4)
- evaluation (4)
- faculty development (4)
- fibroblasts (4)
- frühes Mammakarzinom (4)
- gene expression (4)
- graph theory (4)
- heart failure (4)
- hematopoietic stem cell transplantation (4)
- hepatitis C (4)
- hepatocellular carcinoma (4)
- immune evasion (4)
- liver cirrhosis (4)
- liver transplantation (4)
- management (4)
- melanoma (4)
- meningioma (4)
- metabolic syndrome (4)
- mortality (4)
- p21 (4)
- pancreatic cancer (4)
- peripheral artery disease (4)
- precision medicine (4)
- pregnancy (4)
- proteome (4)
- qualitative research (4)
- radiation (4)
- radical prostatectomy (4)
- rapamycin (4)
- registry (4)
- rhabdomyosarcoma (4)
- risk (4)
- risk factors (4)
- seizure (4)
- smoking (4)
- sphingolipids (4)
- spirochetes (4)
- survival (4)
- transfusion (4)
- trials (4)
- tumor microenvironment (4)
- tumor progression (4)
- vector (4)
- working memory (4)
- (surface) partial differential equations (3)
- Acute inflammation (3)
- Adverse events (3)
- Aging (3)
- Allgemeinmedizin (3)
- Alzheimer's disease (3)
- Aortic valve replacement (3)
- Aspergillus (3)
- Attitude (3)
- Autism (3)
- B-cell lymphoma (3)
- BCR/ABL (3)
- BRAF (3)
- Blood pressure (3)
- Blood-brain barrier (3)
- Brain metastasis (3)
- C-reactive protein (3)
- C. elegans (3)
- CXCR3 (3)
- CXCR4 (3)
- Cancer chemotherapy (3)
- Cancer detection and diagnosis (3)
- Cancer genetics (3)
- Cardiac surgery (3)
- Cardiology (3)
- Cardiovascular disease (3)
- Catheter ablation (3)
- Cell proliferation (3)
- Chromatin accessibility (3)
- Citation analysis (3)
- Clinical competence (3)
- Clinical genetics (3)
- Cognition (3)
- Cognitive neuroscience (3)
- Cohort studies (3)
- Colorectal cancer (3)
- Complex I (3)
- Complications (3)
- Conduct disorder (3)
- Cytoskeleton (3)
- DMEK (3)
- DNase1-seq (3)
- DTI (3)
- Data processing (3)
- Data science (3)
- Decorin (3)
- Density equalizing mapping (3)
- Diabetes (3)
- Dopamine (3)
- EEG microstates (3)
- Endoscopy (3)
- Endothelial cells (3)
- European Union (3)
- Everolimus (3)
- Exercise (3)
- Eyes (3)
- FTY720 (3)
- Fingolimod (3)
- Finite Volumes (3)
- Fistula (3)
- Functional clustering (3)
- Genetics (3)
- Genome-wide association studies (3)
- Glioblastoma (3)
- Global health (3)
- HAE (3)
- HBV (3)
- HCC (3)
- HER2/neu (3)
- HNSCC (3)
- HPV (3)
- Heart (3)
- Heart transplantation (3)
- Hereditary angioedema (3)
- Hippocampus (3)
- Hospitals (3)
- Human genetics (3)
- Hypertension (3)
- IAPs (3)
- IBD (3)
- In vitro (3)
- Incidence (3)
- Inflammatory diseases (3)
- Innate immunity (3)
- Intensive care (3)
- Kidney transplantation (3)
- Knees (3)
- Knowledge (3)
- Kommunikation (3)
- LCMV (3)
- Langerhans cell histiocytosis (3)
- Language (3)
- Lehrqualifikation (3)
- Lesions (3)
- Liver fibrosis (3)
- Long non-coding RNAs (3)
- Lumbar spine (3)
- MCAK (3)
- MLL (3)
- Machine-learning (3)
- Mesenchymal stem cells (3)
- Messenger RNA (3)
- Molecular neuroscience (3)
- Morphogenesis (3)
- Motor control (3)
- Mouse (3)
- Musculoskeletal disorder (3)
- Musculoskeletal system (3)
- NF-κB (3)
- Neuroinflammation (3)
- Nivolumab (3)
- Nox4 (3)
- Observational study (3)
- PARK2 (3)
- PDGFRβ (3)
- Patient blood management (3)
- Pediatric patients (3)
- Phosphorylation (3)
- Pneumonia (3)
- Prediction (3)
- Predictive markers (3)
- Prevalence (3)
- Prostate cancer (3)
- Public health (3)
- Quantitative MRI (3)
- RITA (3)
- Radiomics (3)
- Rare diseases (3)
- Reaction time (3)
- Rectal cancer (3)
- Registries (3)
- Regression analysis (3)
- Respiration (3)
- Rheumatoid arthritis (3)
- STAT3 (3)
- Signaling (3)
- Statistical data (3)
- Stereotactic body radiation therapy (3)
- Surgeons (3)
- TKI (3)
- Tacrolimus (3)
- Tissue engineering (3)
- Torque (3)
- Training (3)
- Transcription factors (3)
- Transfusion (3)
- Translational research (3)
- Zika virus (3)
- Zoonosis (3)
- acetaminophen (3)
- adaptation (3)
- ageing (3)
- allogeneic stem cell transplantation (3)
- anal cancer (3)
- animal (3)
- anti-angiogenic therapy (3)
- antiviral (3)
- antiviral therapy (3)
- arteriogenesis (3)
- artificial intelligence (3)
- ascites (3)
- astrocytes (3)
- augmentation (3)
- autism spectrum disorder (3)
- bioinformatics (3)
- blood (3)
- body mass index (3)
- brachytherapy (3)
- breast (3)
- cGMP (3)
- cardiac (3)
- caspase-2 (3)
- caspase-8 (3)
- catheter ablation (3)
- ceramides (3)
- cerebellum (3)
- chemoresistance (3)
- cholesterol (3)
- cisplatin (3)
- clinical benefit (3)
- clinical study (3)
- clock genes (3)
- combination therapy (3)
- computational virology (3)
- connectivity (3)
- cortex (3)
- cortisol (3)
- cystic fibrosis (3)
- cytokine-induced killer cells (3)
- dental profession (3)
- dentate gyrus (3)
- dentist (3)
- diabetes mellitus (3)
- didactic (3)
- doxorubicin (3)
- drug induced liver injury (3)
- echocardiography (3)
- electroencephalography (3)
- electrolytic cleaning (3)
- endocannabinoids (3)
- endoplasmic reticulum (3)
- everolimus (3)
- exercise (3)
- exosomes (3)
- fatigue (3)
- flow cytometry (3)
- focal adhesion (3)
- functional magnetic resonance imaging (3)
- gamma (3)
- gastric cancer (3)
- head and neck cancer (3)
- health-related quality of life (3)
- hematopoietic stem and progenitor cells (3)
- herb induced liver injury (3)
- histology (3)
- histone acetylation (3)
- hyperglycemia (3)
- imaging (3)
- immune reconstitution (3)
- immunity (3)
- immunohistochemistry (3)
- immunology (3)
- impulsivity (3)
- inflammasome (3)
- iron (3)
- irradiation (3)
- leukocytes (3)
- lipocalin-2 (3)
- liver fibrosis (3)
- liver injury (3)
- lyme disease (3)
- lymphoma (3)
- mTORC1 (3)
- machine learning (3)
- mass spectrometry (3)
- massively parallel multigrid solvers (3)
- medical students (3)
- memory (3)
- mesenchymal stromal cells (3)
- mesenchymal stromal/stem cells (3)
- metastatic (3)
- metformin (3)
- miRNAs (3)
- mice (3)
- mitophagy (3)
- mitosis (3)
- molecular mechanisms (3)
- mouse model (3)
- multimorbidity (3)
- mycophenolic acid (3)
- neoadjuvant therapy (3)
- neoplasms (3)
- neuropathic pain (3)
- oncology (3)
- osteoarthritis (3)
- osteoporosis (3)
- oxidative stress (3)
- p47phox (3)
- patient blood management (3)
- perfusion (3)
- periimplantitis (3)
- platelets (3)
- polypharmacy (3)
- predictive coding (3)
- preeclampsia (3)
- primary care (3)
- primary health care (3)
- primary immunodeficiency (3)
- prognostic factors (3)
- prostaglandins (3)
- psoriatic arthritis (3)
- rat (3)
- realistic geometries (3)
- reliability (3)
- remodelling (3)
- renal cell cancer (3)
- renal function (3)
- resting state (3)
- review (3)
- rheumatoid arthritis (3)
- screening (3)
- senescence (3)
- skeletal muscle (3)
- sphingolipid (3)
- sphingosine 1-phosphate (3)
- spinal cord (3)
- stress (3)
- stress response (3)
- tobacco prevention (3)
- transplantation (3)
- tumor growth (3)
- tumor-associated macrophages (3)
- ubiquitination (3)
- ultrasound (3)
- viral dynamics (3)
- working conditions (3)
- wound healing (3)
- 3D spatio-temporal resolved mathematical models (2)
- A/D transition (2)
- ABCC1 (2)
- ABCG2 (2)
- AKI (2)
- ALL (2)
- AML (2)
- AMPK (2)
- ATP-citrate lyase (2)
- Academic medicine (2)
- Access (2)
- Acoustics (2)
- Acute lymphocytic leukaemia (2)
- Addison’s disease (2)
- Adenocarcinoma (2)
- Adipose tissue (2)
- Adipose-derived mesenchymal stem cells (2)
- Adolescents (2)
- Adults (2)
- Alcohol consumption (2)
- Alcoholic liver disease (2)
- Alleles (2)
- Allergic asthma (2)
- Allergy (2)
- Alpelisib (2)
- Alzheimer (2)
- Alzheimer’s disease (2)
- Amblyopia (2)
- Anemia (2)
- Antibodies (2)
- Anticoagulant therapy (2)
- Antiretroviral therapy (2)
- Antiretrovirals (2)
- Antiviral therapy (2)
- Aortic dissection (2)
- Apheresis (2)
- Artificial intelligence (2)
- Asphyxia (2)
- Assessment (2)
- Atezolizumab (2)
- Aurora A (2)
- Austria (2)
- Autopsy (2)
- BCL2 (2)
- BCL6 (2)
- BDNF (2)
- BMC (2)
- BRCA1 (2)
- BRCA2 (2)
- BRD4 (2)
- Babesia divergens (2)
- Babesia microti (2)
- Bacterial infection (2)
- Benefit (2)
- Big Data (2)
- Biochemistry (2)
- Bioinformatics (2)
- Biopsy (2)
- Biosynthetic mesh (2)
- Bladder cancer (2)
- Blood groups (2)
- Body mass index (2)
- Bone defect (2)
- Bone marrow (2)
- Bone marrow-derived mesenchymal stem cells (2)
- Bone regeneration (2)
- Bone tissue engineering (2)
- Brain tumor (2)
- Breast neoplasms (2)
- Breast tumors (2)
- Brustkrebs (2)
- Burden of disease (2)
- C1 inhibitor (2)
- CAD/CAM (2)
- CAR (2)
- CBA (2)
- CC16 (2)
- CD19 (2)
- CD36 (2)
- CDKN1A (2)
- CLP (2)
- CPE (2)
- CT (2)
- CTGF (2)
- CUELA (2)
- CV9202 (2)
- CXCL12 (2)
- Calcium (2)
- Callous-unemotional traits (2)
- Cancer epidemiology (2)
- Cancer genomics (2)
- Cancer models (2)
- Candida (2)
- Cannabidiol (2)
- Cannabis (2)
- Capecitabine (2)
- Capsule endoscopy (2)
- Cardiac hypertrophy (2)
- Cardiac magnetic resonance (2)
- Cardioprotection (2)
- Cardiovascular diseases (2)
- Case management (2)
- Cats (2)
- Causality assessment (2)
- Celiac disease (2)
- Cell binding (2)
- Cell differentiation (2)
- Cell salvage (2)
- Cerebrospinal fluid (2)
- Cesarean section (2)
- Chaperone (2)
- Checkpoint inhibitor (2)
- Chemical biology (2)
- Chemoradiotherapy (2)
- Chronic disease (2)
- Chronic diseases (2)
- Chronic hepatitis (2)
- Chronic kidney disease (2)
- Chronic obstructive pulmonary disease (2)
- Clinical presentation (2)
- Clinical studies (2)
- Clinical study (2)
- Cocaine (2)
- Cognitive behavioral therapy (2)
- Cognitive impairment (2)
- Community based intervention (2)
- Compliance (2)
- Complication management (2)
- Connective tissue (2)
- Coronary heart disease (2)
- Cortex (2)
- Costs (2)
- Croatia (2)
- Crohn's disease (2)
- Crystal structure (2)
- CspZ (2)
- Cuela (2)
- CyberKnife robotic radiosurgery (2)
- Cytogenetics (2)
- Cytoskeletal proteins (2)
- DAA (2)
- DMARDs (biologic) (2)
- DNA damage response (2)
- DNA mismatch repair (2)
- DSM (2)
- Daptomycin (2)
- Data visualization (2)
- Decision (2)
- Decision trees (2)
- Dentist (2)
- Dentistry (2)
- Deutschland (2)
- Diagnose (2)
- Diagnostics (2)
- Differentiation (2)
- Digestive system procedures (2)
- Direct current electrical stimulation (2)
- Disease Activity (2)
- Docetaxel (2)
- Dose response (2)
- Dravet syndrome (2)
- Drug development (2)
- Drug resistance (2)
- E3 ligase (2)
- ECMO (2)
- EEG-fMRI (2)
- ENCODE-DREAM in vivo Transcription Factor binding site prediction challenge (2)
- EQ-5D (2)
- Ears (2)
- Eccentric fixation (2)
- Education (2)
- Efficiency (2)
- Ejection fraction (2)
- Elderly (2)
- Electroencephalography (2)
- Emotion regulation (2)
- EndMT (2)
- Endothelial permeability (2)
- Ensemble learning (2)
- Enzyme-linked immunoassays (2)
- Epidermal growth factor receptor (2)
- Epigenetics (2)
- Epstein-Barr virus (2)
- Ergonomics (2)
- Etiology (2)
- Evidence-based medicine (2)
- Extended donor criteria (2)
- Extracellular matrix (2)
- Eye movements (2)
- Face (2)
- Family practice (2)
- Fatty liver (2)
- Fibroblasts (2)
- Flaps (2)
- Forensic entomology (2)
- Fortbildung (2)
- Frailty (2)
- Früherkennung (2)
- Frühgeburt (2)
- Functional magnetic resonance imaging (2)
- Funding (2)
- G-CSF (2)
- GFAP (2)
- GWAS (2)
- Gadobutrol (2)
- Galaktografie (2)
- Galaktomosynthese (2)
- Gene regulation (2)
- Gene therapy (2)
- General practitioners (2)
- Genetic testing (2)
- Genetics research (2)
- German people (2)
- Glucose metabolism (2)
- Grafts (2)
- Growth factors (2)
- HDACi (2)
- HER2 (2)
- HOD (2)
- HSCT (2)
- HSV (2)
- Head and neck cancer (2)
- Health economics (2)
- Health services research (2)
- Healthcare worker (2)
- Hematologic malignancies (2)
- HepG2 (2)
- Hepatocytes (2)
- Herb induced liver injury (2)
- High-density lipoprotein (2)
- Hirnforschung (2)
- Holmes tremor (2)
- Hypoxia (2)
- ICU (2)
- IHC (2)
- IL-10 (2)
- IL-1β (2)
- IR-A (2)
- Image analysis (2)
- Immune suppression (2)
- Implementation (2)
- Incisional hernia (2)
- Indirect-binding (2)
- Infection (2)
- Infection control (2)
- Infectious diseases (2)
- Inflammatory bowel disease (2)
- Intensive care units (2)
- Interdisciplinarity (2)
- Interleukin-22 (2)
- Interleukin-6 (2)
- Internet (2)
- Iron deficiency anemia (2)
- Ischemia (2)
- Ischemia/reperfusion injury (2)
- Jaw (2)
- KGF (2)
- Katherine (2)
- Klebsiella pneumoniae (2)
- Klinische Kompetenz (2)
- Kompetenzen (2)
- L2 (2)
- LPS (2)
- LVAD (2)
- Labor and delivery (2)
- Left hemisphere (2)
- Legs (2)
- Leukemias (2)
- Linear regression analysis (2)
- Lipid signalling (2)
- Liver Transplantation (2)
- Lokalrezidiv (2)
- Long-term care (2)
- Longitudinal (2)
- Low back pain (2)
- Luciferase (2)
- Lyme disease (2)
- Lymph nodes (2)
- Lymphocytes (2)
- Lysosome (2)
- MALAT1 (2)
- MCAO (2)
- MCI (2)
- MICA (2)
- MMP9 (2)
- MRT (2)
- MYC (2)
- Macroautophagy (2)
- Mamma (2)
- Markovianity (2)
- Masquelet technique (2)
- Mass spectrometry (2)
- Maxillary sinus (2)
- Medical risk factors (2)
- Medication Appropriateness Index (2)
- Medicine (2)
- Medizinstudium (2)
- Meldepflicht (2)
- Membrane potential (2)
- Mesh (2)
- Metastatic breast cancer (2)
- Microbiome (2)
- Microsurgery (2)
- Migrants (2)
- Minimal residual disease (2)
- Mitosis (2)
- MitraClip (2)
- Mixed methods (2)
- Molecular profiling (2)
- Morphometry (2)
- Multidrug resistance (2)
- Multiple chronic conditions (2)
- Musculoskeletal diseases (2)
- Mutation (2)
- Myocardial infarction (2)
- NADH:ubiquinone oxidoreductase (2)
- NAFLD (2)
- NK cells (2)
- NOTCH1 (2)
- Nachsorge (2)
- Neoplasms (2)
- Nepal (2)
- Nerve fibers (2)
- Nerve regeneration (2)
- Neural circuits (2)
- Neuroimaging (2)
- Neurology (2)
- Neuronal morphology (2)
- Neurons (2)
- Nevirapine (2)
- Next-generation sequencing (2)
- Nitric oxide (2)
- Non-REM sleep (2)
- Non-interventional study (2)
- Normal distribution (2)
- Nox (2)
- Nox1 (2)
- Nrf2 (2)
- OSPE (2)
- Occlusion treatment (2)
- Operation/Chirurgie (2)
- Ophthalmology (2)
- Optogenetics (2)
- Oral surgery (2)
- Organ dysfunction (2)
- Organ dysfunctions (2)
- Oroantral (2)
- Osteogenic differentiation (2)
- Outcome assessment (2)
- Ovarian cancer (2)
- Oxidative stress (2)
- P600 (2)
- PARP (2)
- PD1/ PDL1 (2)
- PD‑L1 (2)
- PET (2)
- PINK1 (2)
- Palliative care (2)
- Palliative care [MeSH] (2)
- Parkin (2)
- Parkinson disease (2)
- Patient-centred care (2)
- Pediatric (2)
- Pediatric infections (2)
- Percutaneous coronary intervention (2)
- Periodontitis (2)
- Peritonitis (2)
- Persistence (2)
- Personal- und Organisationsentwicklung (2)
- Philadelphia chromosome (2)
- Phylogenetic analysis (2)
- Physiology (2)
- Plasmodium (2)
- Platelet-rich fibrin (2)
- Platelets (2)
- Plerixafor (2)
- Plk1 inhibitors (2)
- Podospora anserina (2)
- Polypharmacy (2)
- Portal veins (2)
- Post-translational modifications (2)
- Postoperative radiochemotherapy (2)
- Postural control (2)
- Practical skills (2)
- Professionalisierung (2)
- Prognosefaktoren (2)
- Prognostic (2)
- Prognostic markers (2)
- Programm (2)
- Progranulin (2)
- Prophylaxis (2)
- Prostatic neoplasms (2)
- Protease inhibitor therapy (2)
- Proteasome (2)
- Protein translation (2)
- Prädiktivfaktoren (2)
- Psychology (2)
- Pulmonary hypertension (2)
- Pulmonary veins (2)
- Quality of care (2)
- Questionnaires (2)
- RIPK3 (2)
- RNA binding proteins (2)
- RNA interference (2)
- RNA interference (RNAi) (2)
- RNA isolation (2)
- Red blood cell transfusion (2)
- Regeneration (2)
- Register (2)
- Registry (2)
- Reliabilität (2)
- Renal cell carcinoma (2)
- Renal system (2)
- Research architecture (2)
- Respiratory chain (2)
- Rhabdomyosarcoma (2)
- Rheumatoid Arthritis (2)
- Richtlinie (2)
- Roussel Uclaf Causality Assessment Method (RUCAM) (2)
- S1P (2)
- SARS (2)
- SARS‐CoV‐2 (2)
- SD-OCT (2)
- SKAP1 (2)
- SPTAN1 (2)
- STING (2)
- Safety (2)
- Sarcoidosis (2)
- Sarcoma (2)
- Schmerz (2)
- Scientists (2)
- Screening (2)
- Senescence (2)
- Sensory processing (2)
- Sestrin 2 (2)
- Simulated patients (2)
- Skills (2)
- Sleep (2)
- Social participation (2)
- Socioeconomic status (2)
- Sorafenib (2)
- Sphingolipids (2)
- Sports and exercise medicine (2)
- Staff development (2)
- Stem cell (2)
- Stem-cell therapies (2)
- Strength training (2)
- Streptococcus pneumoniae (2)
- Structural plasticity (2)
- Study protocol (2)
- Subarachnoid hemorrhage (2)
- Sunitinib (2)
- Superoxide (2)
- Supportivtherapie (2)
- Survival analysis (2)
- Survivin (2)
- Sweden (2)
- Synaptic plasticity (2)
- Systematic reviews (2)
- TBSS (2)
- TF-complexes (2)
- TGFβ (2)
- Target identification (2)
- Teeth (2)
- Tele-EEG (2)
- Tenofovir (2)
- Thailand (2)
- Therapie (2)
- Therapy (2)
- Thermoregulation (2)
- Thoracic trauma (2)
- Thromboembolism (2)
- Thrombolysis (2)
- Toll-like receptor (2)
- Tomosynthese (2)
- Toxicity (2)
- Transarterial chemoembolization (2)
- Transcription Factors (2)
- Transmission (2)
- Traumatic injury (2)
- Treatment outcome (2)
- Tumor microenvironment (2)
- T‑DM1 (2)
- Ulcerative colitis (2)
- Ultraschall (2)
- Ultrasonography (2)
- Ultrasound (2)
- Urology (2)
- VDR (2)
- VIGALL (2)
- Vaccination (2)
- Validität (2)
- Vascularization (2)
- Veins (2)
- Video (2)
- Vision (2)
- Visual acuity (2)
- Vitamin D (2)
- Vitamin D deficiency (2)
- Vmem (2)
- Warburg effect (2)
- Working memory (2)
- Wound healing (2)
- Wundheilung (2)
- abuse (2)
- acetyl-CoA (2)
- acute decompensation (2)
- acute lung injury (2)
- acute myeloid leukaemia (2)
- acute myeloid leukemia (2)
- adalimumab (2)
- additives (2)
- adenosine (2)
- adenovirus (2)
- adherence (2)
- adipose-derived mesenchymal stem cells (2)
- admission test (2)
- adoptive cancer immunotherapy (2)
- advanced (2)
- advanced care planning (2)
- adverse reaction (2)
- age (2)
- age-related macular degeneration (2)
- aged (2)
- air flow (2)
- albumin (2)
- alcohol (2)
- alpelisib (2)
- alveolar ridge augmentation (2)
- analgesics (2)
- animal experiment (2)
- animal models (2)
- antibacterial activity (2)
- antibiotic therapy (2)
- anticonvulsants (2)
- antiepileptic drugs (2)
- antisocial behavior (2)
- arousal (2)
- arthritis (2)
- astrocytoma (2)
- atezolizumab (2)
- audiovisual (2)
- autoimmune diabetes (2)
- autoimmune disease (2)
- autoimmunity (2)
- autologous stem cell transplantation (2)
- behavior (2)
- betulinic acid (2)
- biocompatibility (2)
- biologics (2)
- biopsy (2)
- blood flow restriction (2)
- bone healing (2)
- bone metabolism (2)
- borrelia (2)
- brain imaging (2)
- brain states (2)
- brain-derived neurotrophic factor (2)
- brainstem (2)
- burden of illness (2)
- cAMP (2)
- cART (2)
- calcitriol (2)
- calretinin (2)
- cancer immunotherapy (2)
- capsaicin (2)
- carbapenemase (2)
- carbapenemases (2)
- cardiovascular (2)
- cardiovascular disease (2)
- case-referent study (2)
- cell migration (2)
- cell motility (2)
- cell proliferation (2)
- cells (2)
- ceramide (2)
- cerebrospinal fluid (2)
- cervical cancer (2)
- chemoradiotherapy (2)
- chemotherapy resistance (2)
- chest trauma (2)
- chronic myeloid leukemia (2)
- chronic thromboembolic pulmonary hypertension (2)
- cigarette (2)
- circadian (2)
- circadian rhythm (2)
- circadian rhythms (2)
- cisplatin resistance (2)
- citation (2)
- classical Hodgkin lymphoma (2)
- cleaning (2)
- clinical research (2)
- clinical studies (2)
- cochlea (2)
- collagen (2)
- colon cancer (2)
- colon carcinoma cells (2)
- colorectal carcinoma (2)
- communication (2)
- complementary and alternative medicine (2)
- complex I (2)
- compliance (2)
- computed tomography (2)
- continuous performance test (2)
- corneal edema (2)
- corneal transplantation (2)
- coronary artery bypass graft surgery (2)
- coronary artery disease (2)
- critical care (2)
- criticality (2)
- cryoballoon (2)
- cyclooxygenase (2)
- cyclosporin A (2)
- cytochrome P450 2E1 (2)
- cytotoxic T cells (2)
- dabrafenib (2)
- deafness (2)
- decision making (2)
- decompensated liver cirrhosis (2)
- dental assistants (2)
- dental education (2)
- dental implant (2)
- dentists (2)
- detoxification (2)
- diabetes (2)
- dietary supplements (2)
- dihydroceramide (2)
- disease models (2)
- disintegration (2)
- distress (2)
- drug discovery (2)
- drug release (2)
- drug-induced liver injury (2)
- dual task (2)
- e-Learning (2)
- eLearning (2)
- education (2)
- eicosanoids (2)
- elderly patients (2)
- electrocardiography (2)
- electron transport chain (2)
- encoding (2)
- endothelial (2)
- endothelial cell (2)
- entorhinal cortex lesion (2)
- epigenetic (2)
- epileptogenesis (2)
- esophageal cancer (2)
- event-related potentials (2)
- expertise (2)
- extraversion (2)
- factor H (2)
- fasting (2)
- feedback (2)
- femoral artery ligation (2)
- fenfluramine (2)
- follow‑up (2)
- fortgeschritten (2)
- fracture (2)
- functional connectivity (2)
- functional genetics (2)
- functional genomics (2)
- gait analysis (2)
- galactography (2)
- galactomosynthesis (2)
- gene regulation (2)
- general practice (2)
- genetics (2)
- glucose metabolism (2)
- growth (2)
- growth factor (2)
- growth inhibition (2)
- guidelines (2)
- health (2)
- health information exchange (2)
- heart rate (2)
- hedgehog signaling (2)
- hematopoiesis (2)
- hematopoietic stem cells (2)
- hemodialysis (2)
- hemolysis (2)
- hepatic encephalopathy (2)
- hepatitis B (2)
- hepatitis C virus (HCV) (2)
- herbal hepatotoxicity (2)
- hippocampus (2)
- histological validation (2)
- histone deacetylase inhibitor (2)
- human biology and medicine (2)
- human cytomegalovirus (2)
- hyperactivity (2)
- hyperhomocysteinemia (2)
- iDILI (2)
- iPS (2)
- immune escape (2)
- immune response (2)
- immune system (2)
- immunocytochemistry (2)
- in vitro (2)
- induced membrane (2)
- inertial motion capture (2)
- infiltration (2)
- inflammatory bowel disease (2)
- inner ear (2)
- insulin resistance (2)
- integration (2)
- interferon (2)
- interferon gamma (2)
- interleukin-18 (2)
- interleukin-22 (2)
- interleukin-4 (2)
- interleukins (2)
- invasive fungal disease (2)
- invasive fungal infection (2)
- job-exposure matrix (2)
- kidney (2)
- kidney transplantation (2)
- kinase inhibitor (2)
- kinase regulation (2)
- kinematics (2)
- klinischer Nutzen (2)
- knowledge discovery (2)
- lapatinib (2)
- leukopenia (2)
- levetiracetam (2)
- lipoxygenase (2)
- liver disease (2)
- liver metastases (2)
- lncRNA (2)
- local control (2)
- local information dynamics (2)
- local recurrence (2)
- long-term prophylaxis (2)
- long-term survival (2)
- longevity (2)
- lung function (2)
- machine-learning (2)
- magnetoencephalography (2)
- maintenance (2)
- mandatory reporting (2)
- marginal bone loss (2)
- mathematical modeling (2)
- mathematical models of viral RNA cycle (2)
- matrix (2)
- medical studies (2)
- melatonin (2)
- metabolomics (2)
- methylprednisolone (2)
- microdosing (2)
- microenvironment (2)
- microglia (2)
- microwave ablation (2)
- mild cognitive impairment (2)
- minimalinvasive Biopsie (2)
- minimally invasive biopsies (2)
- mitochondrial disease (2)
- modeling (2)
- modularity (2)
- molecular mimicry (2)
- morphogenesis (2)
- motility (2)
- multidrug resistance (2)
- multinucleated giant cells (2)
- musculoskeletal (2)
- musculoskeletal disorders (2)
- music (2)
- myelodysplastic syndrome (2)
- nanoparticles (2)
- natural product (2)
- necroptosis (2)
- neoadjuvant chemotherapy (2)
- neoadjuvante Chemotherapie (2)
- neoadjuvante Therapie (2)
- neonate (2)
- network analysis (2)
- neural network (2)
- neural oscillations (2)
- neurocritical care (2)
- neurogenesis (2)
- neuroimaging (2)
- neuromodulation (2)
- neurophysiology (2)
- neuroticism (2)
- neutrophils (2)
- newborn (2)
- next generation sequencing (2)
- next generation sequencing (NGS) (2)
- nitric oxide (2)
- non-coding RNA (2)
- nursery schools (2)
- nutlin-3 (2)
- observational study (2)
- occupational exposure (2)
- occupational health (2)
- omega-3 fatty acids (2)
- oncogene (2)
- oscillations (2)
- osteogenesis (2)
- outcomes (2)
- overall survival (2)
- overweight (2)
- paclitaxel (2)
- paired associative stimulation (2)
- palatal tremor (2)
- pandemic (2)
- partial information decomposition (2)
- patient (2)
- patient safety (2)
- patient triage (2)
- pelvic packing (2)
- peptide aptamer (PA) (2)
- perception (2)
- perforant path transection (2)
- peri‐implantitis (2)
- phagocytosis (2)
- pharmacodynamics (2)
- pharmacoresistance (2)
- pharmacovigilance (2)
- phosphate (2)
- plasmid (2)
- platelet-rich fibrin (2)
- polo-like kinase 1 (2)
- poly(lactic-co-glycolic acid) (PLGA) (2)
- polygenic risk score (2)
- polymerase chain reaction (2)
- polymorphism (2)
- population dynamics (2)
- postoperative complications (2)
- posttraumatic stress disorder (2)
- predictive factors (2)
- prefrontal cortex (2)
- preterm birth (2)
- primary cilium (2)
- primary sclerosing cholangitis (2)
- prognostic value (2)
- prostaglandin (2)
- proteasome inhibitor (2)
- protein kinase (2)
- protein quality control (2)
- proteoglycan (2)
- proximal tubule (2)
- psychophysiology (2)
- psychosis (2)
- public health (2)
- pulmonary hypertension (2)
- pulmonary vein isolation (2)
- quality (2)
- quality assurance (2)
- quantitative MRI (2)
- questionnaire (2)
- rare diseases (2)
- re-osseointegration (2)
- real-world data (2)
- recommendations (2)
- reference values (2)
- reproducibility (2)
- research (2)
- revision surgery (2)
- ribavirin (2)
- risk prediction (2)
- rituximab (2)
- school-based prevention (2)
- scientometrics (2)
- scientometry (2)
- second-hand smoke (2)
- secretion (2)
- secretome (2)
- secukinumab (2)
- seizures (2)
- sensory neuropathy (2)
- severe acute respiratory syndrome coronavirus 2 (2)
- sex (2)
- sex differences (2)
- short essay questions (2)
- shunt (2)
- siRNA (2)
- signal transducer and activator of transcription 5 (Stat5) (2)
- signaling (2)
- signature (2)
- simulation (2)
- simulation training (2)
- single-sided deafness (2)
- skin (2)
- sleep (2)
- smoking cessation (2)
- soft tissue sarcoma (2)
- soluble MICA (2)
- spiking neural networks (2)
- spreadsheet (2)
- stability (2)
- stationarity (2)
- status epilepticus (2)
- stem cell transplantation (2)
- studies (2)
- sulforaphane (2)
- supportive therapy (2)
- surgical procedures (2)
- survival rate (2)
- survivin (2)
- synchronization (2)
- synchrony (2)
- synergy (2)
- systematic review (2)
- telemedicine (2)
- temozolomide (2)
- temperature (2)
- temporal lobe epilepsy (2)
- temsirolimus (2)
- therapy monitoring (2)
- therapy resistance (2)
- thymus (2)
- tissue Doppler imaging (2)
- tobacco (2)
- tobacco smoke (2)
- tomosynthesis (2)
- training (2)
- transcriptome (2)
- transient elastography (2)
- trastuzumab (2)
- treatment/therapy (2)
- trophoblast (2)
- tumor angiogenesis (2)
- tumor infiltrating lymphocytes (2)
- tumor suppressor (2)
- tumor-infiltrating lymphocytes (2)
- undergraduate medical education (2)
- ustekinumab (2)
- uteroglobin (2)
- vaccination (2)
- vaccine (2)
- validity (2)
- vemurafenib (2)
- vitamin B deficiency (2)
- von Willebrand factor (2)
- weight loss (2)
- within-host viral modelling (2)
- workflow (2)
- zebrafish (2)
- zinc (2)
- (cardiac) surgery (1)
- (novel) brominated flame retardants ((N)BFR) (1)
- 1,2-dichloroethane (1)
- 1,25-Dihydroxyvitamin D (1)
- 14-3-3 gene family (1)
- 15-PGDH (1)
- 16 segment AHA model (1)
- 16S rRNA sequencing (1)
- 16p11.2 (1)
- 17-AAG (1)
- 17‐OH itraconazole (1)
- 19F MR spectroscopy (1)
- 1H MR spectroscopy (1)
- 1α,25(OH)2D3 (1)
- 2-deoxyglucose (2-DG) (1)
- 2-hydroxyglutarate (1)
- 2019-nCoV (1)
- 2‑methoxyestradiol (1)
- 3-hydroxyanthranilic acid (1)
- 32D progenitor cells (1)
- 3Cs technology (1)
- 3D printed cell-free scaffold (1)
- 3D printing (1)
- 3D rapid prototyping (1)
- 3D spatiotemporal resolved mathematical models (1)
- 3D tissue models (1)
- 3years (1)
- 4-1BB (1)
- 4-FA (1)
- 5 lipoxygenase (1)
- 5' UTR (1)
- 5-lipoxygenase (1)
- 6-Schritt-Methode (1)
- 90% or more improvement in baseline Psoriasis Area and Severity Index (1)
- 99mTc-MIBI (1)
- 99mTc-pertechnetate (1)
- A-FFIP (1)
- A-PRF+ (1)
- A2BP1 (1)
- A375 human melanoma cell line (1)
- A375 human melanoma cells (1)
- A549 (1)
- AA-amylodosis (1)
- AB-serum (1)
- ABS (1)
- ABT-737 (1)
- ACE-Bestimmung (1)
- ACE-inhibitor (1)
- ACL (1)
- ACURATE neo (1)
- ADAM-17 (1)
- ADAM10 (1)
- ADAM15 (1)
- ADAMTS-13 (1)
- ADHD differential diagnosis (1)
- AGC kinase (1)
- AICAR (1)
- AIDS (1)
- AIH immunopathogenesis (1)
- AIS (1)
- AJAP1 (1)
- ALF (1)
- ALK gene (1)
- ALK-rearranged NSCLC (1)
- AMD3100 (1)
- AMH (1)
- AML – acute myeloid leukemia (1)
- AMP-activated kinase (1)
- AOSpine (1)
- AOSpine injury score (1)
- APMPPE - acute posterior multifocal placoid pigment epitheliopathy (1)
- APP (1)
- APP processing (1)
- APRI (1)
- ARA (1)
- ARDS (1)
- ARID5B (1)
- ASA404 (1)
- ASAP (1)
- ASCT (1)
- ASD-specific (1)
- ASO (1)
- AT-101 (1)
- ATO (1)
- ATP (1)
- ATXN2 (1)
- AVM hemorrhage (1)
- AZD7762 (1)
- Abatacept (1)
- Abdominal aortic aneurysm (1)
- Abdominal infections (1)
- Abdominal surgery (1)
- Abdominal trauma (1)
- Abdominelles Aortenaneurysma (1)
- Abiraterone acetate (1)
- Abl kinase inhibitors (1)
- Absenteeism (1)
- Academic health centres (1)
- Academics (1)
- Accelerometry (1)
- Accessibility (1)
- Acellular dermis (1)
- Acer platanoides (1)
- Acid ceramiase (1)
- Acquired drug resistance (1)
- Actin (1)
- Actinomycin D (1)
- Action potential (1)
- Activities of daily living (1)
- Activity control (1)
- Acute HIV infection (1)
- Acute Hemiparesis (1)
- Acute Myeloid Leukemia (1)
- Acute Myeloid Leukemia (AML) (1)
- Acute bronchitis (1)
- Acute calcolous cholecystitis (1)
- Acute coronary syndrome (1)
- Acute cough (1)
- Acute decompensation (1)
- Acute heart failure (1)
- Acute hospital (1)
- Acute leukemia (1)
- Acute lymphoblastic leukemia (1)
- Acute myeloid leukaemia (1)
- Acute-on-chronic liver failure (1)
- Adenylyl cyclase (1)
- Adherence (1)
- Adherence junctions (1)
- Adhesion (1)
- Adipose tissue-derived mesenchymal stem cells (1)
- Adjustment of dosage at steady state (1)
- Adjuvant therapies (1)
- Adolescence (1)
- Adult (1)
- Adult T-cell acute lymphoblastic leukemia (1)
- Adult neurogenesis (1)
- Advanced biliary tract cancer (1)
- Advanced breast cancer (1)
- Advanced glycation endproducts (1)
- Adverse drug reaction (1)
- Aedes aegypti (1)
- Aedes albopictus (1)
- Affective disorders (1)
- Africa (1)
- Age (1)
- Age determination by skeleton (1)
- Aggregation (1)
- Aggressive periodontitis (1)
- Agoraphobia (1)
- Agreement (1)
- Air traffic (1)
- Airways (1)
- Akaike information criterion (AIC) (1)
- Akute Leukämie (1)
- Akutes Koronarsyndrom (1)
- Algorithms (1)
- Aliphatic halogenated hydrocarbons (1)
- Alisertib (1)
- All oral (1)
- All-trans retinoic acid (1)
- Allergen immunotherapy (1)
- Allergic rhinitis (1)
- Allergoid (1)
- Allochromatium vinosum (1)
- Allogeneic Stem Cell Transplantation (SCT) (1)
- Allogeneic hematopoietic stem (1)
- Allogeneic stem cell transplantation (1)
- Allograft bone block (1)
- Allosteric inhibition (1)
- Alpha oscillations (1)
- Alpha-synuclein (1)
- Alpha-synuclein deficiency (1)
- Alternative oxidase (1)
- Alveolar ridge augmentation (1)
- Alzheimer’s dementia (1)
- Ambroxol (1)
- Ameloblastoma (1)
- Amino acid analysis (1)
- Aminosäuremetabolismus (1)
- Aminosäuren (1)
- Aminotransferases (1)
- Amizon (1)
- Amygdala (1)
- Amyloid precursor protein (1)
- Amyloid-beta 42 (1)
- Amyotrophic lateral sclerosis (1)
- Anaemia (1)
- Anaesthesia (1)
- Anal cancer (1)
- Anamneseerhebung (1)
- Anaplastic astrocytoma (1)
- Anatomic competence (1)
- Anatomie (1)
- Anatomie und Histologie (1)
- Anatomy (1)
- Andersen-Tawil syndrome (1)
- Andexanet alpha (1)
- Andropogon virginicus (1)
- Anesthesia, Intravenous (1)
- Aneurysm (1)
- Aneurysmal subarachnoid hemorrhage (1)
- Aneurysms (1)
- Angioedema (1)
- Angiogenèse (1)
- Angiography (1)
- Angioplasty (1)
- Angiotensin Converting Enzyme (1)
- Angiotensin-converting enzyme (1)
- Animal wings (1)
- Ankle arthrometer (1)
- Anopheles (1)
- Anosmia (1)
- Antagonist (1)
- Antarctic marine sponges (1)
- Anterior cingulate cortex (1)
- Anterior cruciate ligament reconstruction (1)
- Anti platelet therapy (1)
- Anti-CMV IgG (1)
- Anti-Müller-Hormon (1)
- Anti-TNF (1)
- Anti-tumor immunity (1)
- Antiangiogenesis (1)
- Antibiotic (1)
- Antibiotic generic drugs (1)
- Antibiotic stewardship (1)
- Antibiotic therapy (1)
- Antibiotics (1)
- Antibody isotypes (1)
- Antibody-mediated rejection (1)
- Anticoagulants (1)
- Anticoagulants [MeSH] (1)
- Antidepressant (1)
- Antifungal agents (1)
- Antigen-presenting cells (1)
- Antigens (1)
- Antihormone therapy (1)
- Antimicrobial resistance (1)
- Antimicrobial treatment (1)
- Antiplatelet therapy (1)
- Antireflux surgery (1)
- Antirheumatic agents (1)
- Antithrombotic therapy (1)
- Antivenom (1)
- Antiviral agents (1)
- Antiviral immune response (1)
- Antiviral response (1)
- Anura (1)
- Anxiety (1)
- Aortic Valve Replacement (1)
- Aortic arch replacement (1)
- Aortic debranching (1)
- Aortic stenosis (1)
- Aortic stiffness (1)
- Aortic valve sparing (1)
- Apes (1)
- Apixaban (1)
- Aquaporins (1)
- Arabin pessary (1)
- Arabin-Pessar (1)
- Area deprivation (1)
- Arms (1)
- Aromatase Inhibitors (1)
- Arrhythmia (1)
- Arrhythmia/all (1)
- Artemether-lumefantrine (1)
- Artemisinin-combination-therapy (1)
- Arteriogenesis (1)
- Artesunate (1)
- Arthroscopy (1)
- Asian bush mosquito (1)
- Aspergillosis (1)
- Aspergillus species (1)
- Assay variation (1)
- Assessment of care (1)
- Asthma (1)
- Asthma and allergic disorders (1)
- Astrocytoma grades (1)
- Ataxia (1)
- Ataxia telangiectasia (1)
- Ataxia-telangiectasia (1)
- Atazanavir (1)
- Atelopus carbonerensis (1)
- Atelopus mucubajiensis (1)
- Atelopus tamaense (1)
- Atención centrada en el paciente (1)
- Atrial appendage occlusion (1)
- Atrial function (1)
- Attack (1)
- Attention Deficit Hyperactivity Disorder (1)
- Attention-deficit / hyperactivity disorder (1)
- Atxn2 (1)
- Audio equipment (1)
- Audio signal processing (1)
- Audiology (1)
- Auditory (1)
- Auditory cortex (1)
- Auditory system (1)
- Auric nanoparticles (1)
- Aurora (1)
- Aurora Ax (1)
- Aurora kinase inhibitor (1)
- Australia (1)
- Autism spectrum disorders (1)
- Autistic Behavior (1)
- Autistic disorder (1)
- Auto transfusion (1)
- Autogenous bone block (1)
- Autoimmune encephalomyelitis (1)
- Autoimmunity (1)
- Autologous stem cell transplantation (1)
- Automated Tube Potential Selection (1)
- Automatic Environmental Tobacco Smoke Emitter (1)
- Autonomic nervous system (1)
- Autosomal recessive cutis laxa type 1C (1)
- Awareness (1)
- Axon (1)
- Axons (1)
- Azacitidine (1)
- Azan trichrome stain (1)
- Azathioprine (1)
- Azidothymidine (1)
- B cell malignancies (1)
- B cell precursor acute lymphoblastic leukemia (1)
- B cell receptor (1)
- B cell subpopulations (1)
- B-cell antigen receptor (1)
- B-cell immunology (1)
- B-cell non-Hodgkin lymphoma (1)
- B-cell receptor (1)
- B16 cells (1)
- BAG3 (1)
- BATF3 (1)
- BBB (1)
- BCL-2 (1)
- BCL11b (1)
- BCR signaling (1)
- BCR-ABL (1)
- BCX7353 (1)
- BFIS (1)
- BG-index (1)
- BI1361849 (1)
- BIAM switch assay (1)
- BIAM-switch (1)
- BIRC5 (1)
- BK channel (1)
- BMAC (1)
- BMI (1)
- BMSC (1)
- BNC2 (1)
- BPD (1)
- BPDCN (1)
- BRAF V600E (1)
- BRAF inhibitors (1)
- BRAF mutation (1)
- BRD4-NUT (1)
- BRUCE (1)
- BRVO (1)
- BTC (1)
- BTK (1)
- BV6 (1)
- Babesia venatorum (1)
- Back pain (1)
- Backpropagating action potential (1)
- Bacterial meningitis (1)
- Bacterial pathogenesis (1)
- Bacterial pathogens (1)
- BadA, (1)
- Bag6 (1)
- Ballet (1)
- Bariatric surgery (1)
- Barlow disease (1)
- Bartonella (1)
- Basal Ganglia (1)
- Basel Consensus Statement (1)
- Basler Consensus Statement (1)
- Bathyergidae (1)
- Batten disease (1)
- Bayesian (1)
- Bayesian inference (1)
- Bayesian model (1)
- Bcl-2 (1)
- Bcr-Abl (1)
- Becton Dickinson (1)
- Bee venom allergy (1)
- Behavior (1)
- Behavioral analysis (1)
- Benchmarks (1)
- Benign disorder (1)
- Benign pulmonary diseases (1)
- Benigne Lungenerkrankungen (1)
- Beratung (1)
- Berci needle (1)
- Best practice (1)
- Best-practice model (1)
- Bestimmungsmethoden (1)
- Bevacizumab (1)
- Bewegungsanalyse mit Inertialsensoren (1)
- Bias (1)
- Bibliometric analysis (1)
- Bibliometrics (1)
- Bidirectional genes (1)
- Big Five (1)
- Big data (1)
- Big five (1)
- Biglycan (1)
- Bilateral cochlear implant (1)
- Bildung (1)
- Biliary physiology (1)
- Biliary tree (1)
- Biliary tree stones (1)
- Bilirubin (1)
- Bioactivity-guided fractionation (1)
- Bioavailability prediction (1)
- Biofilm (1)
- Biofluids (1)
- Biological (1)
- Biological Activity (1)
- Biological heart valves (1)
- Biological invasion (1)
- Biological markers (1)
- Biomarkers & Diagnostic Imaging (1)
- Biomechanical analysis (1)
- Biophysical models (1)
- Bioprosthesis (1)
- Biotechnology (1)
- Bipolar (1)
- Birth weight (1)
- Bisphosphonates (1)
- Blended learning curriculum · (1)
- Blended-Learning-Curriculum (1)
- Blended-learning (1)
- Blog (1)
- Blood cells (1)
- Blood loss (1)
- Blood plasma (1)
- Blood transfusion (1)
- Bloodstream infection (1)
- Bloodstream infections (1)
- Blow fly (1)
- Blowflies (1)
- BluePrint (1)
- Blurred vision (1)
- Body limbs (1)
- Body-contouring surgery (1)
- Bologna process (1)
- Bologna-Prozess (1)
- Bone and joint mechanics (1)
- Bone cancer (1)
- Bone marrow aspirate concentrate (1)
- Bone marrow aspiration (1)
- Bone marrow cells (1)
- Bone marrow fibrosis (1)
- Bone marrow mononuclear cells (1)
- Bone metastasis (1)
- Bone strength assessment (1)
- Borrelia Garinii (1)
- Borrelia burgdorferi (1)
- Borrelia miyamotoi (1)
- Bortezomib (1)
- Bottom-up (1)
- Bradykinin (1)
- Brain (1)
- Brain anatomy (1)
- Brain damage (1)
- Brain development (1)
- Brain injury (1)
- Brain ischemia (1)
- Brain repair (1)
- Brain tumors (1)
- BrainNet Europe consortium (1)
- Breast neoplasm (1)
- Breast reconstruction (1)
- Breathing (1)
- Breech delivery (1)
- Bright light therapy (1)
- Brij 35 (1)
- BrijL23 (1)
- Brms (1)
- Bronchial inflammation (1)
- Bronchitis severity scale (1)
- Bronchodilator agents (1)
- Bronchopulmonary dysplasia (1)
- Bufonidae (1)
- Bungarus niger (1)
- Burst (1)
- Bypass liner (1)
- C-clamp (1)
- C-reactive proteins (1)
- C1 esterase inhibitor (human) (1)
- C1-INH (C1 inhibitor, C1-esterase inhibitor) (1)
- C1-esterase inhibitor protein (1)
- C1-inhibitor (1)
- C1-inhibitor deficiency (1)
- C2 domain (1)
- C3M (1)
- C4M (1)
- C5 acylcarnitine (1)
- C57BL/6J mice (1)
- C57BL/6N mice (1)
- C6 ceramide (1)
- CA (1)
- CA1 (1)
- CAKUT (1)
- CAM (1)
- CAR-NK cell (1)
- CAR-T cell (1)
- CAT (1)
- CCL2 (1)
- CCN2 (1)
- CD137 (1)
- CD16 (1)
- CD23 (1)
- CD271 (1)
- CD3 (1)
- CD3/19 depletion (1)
- CD3/CD19 depletion (1)
- CD34 (1)
- CD34 selection (1)
- CD4 binding site (1)
- CD41 (1)
- CD44 (1)
- CD45RA naïve lymphocytes (1)
- CD49d (1)
- CD56 (1)
- CD62P (1)
- CD74 (1)
- CD8 (1)
- CD8+ T cell (1)
- CD8+ T lymphocytes (1)
- CD8+ T-cell mediated tumor suppression (1)
- CD8+ tumor infiltrating lymphocytes (1)
- CD95/Fas receptor (1)
- CDK inhibitor (1)
- CDK4/6 inhibitor (1)
- CDK4/CDK6 (1)
- CDK9 (1)
- CDKN2A (1)
- CEBPE (1)
- CGD (1)
- CGN codon (1)
- CHA2DS2-VASc-score (1)
- CHIP (1)
- CHRNA10 (1)
- CHRNA7 (1)
- CHRNA9 (1)
- CIK cell (1)
- CIOMS (1)
- CLEC-2 (1)
- CMS (1)
- CMVepidemiology (1)
- CNS (1)
- CNS cancer (1)
- CNS toxicity (1)
- CNVs (1)
- CO2-induced forced ventilation (1)
- COBAS Taqman (1)
- COI (1)
- COII (1)
- COMT (1)
- COPD course and therapy (1)
- CPT1A (1)
- CRE-dependent transcription (1)
- CRE-luciferase (1)
- CREB inhibitor (1)
- CRISPR/Cas (1)
- CRISPR/dCas9 (1)
- CRM (1)
- CRM1 (1)
- CRP (1)
- CRT-D (1)
- CRVO (1)
- CSC marker (1)
- CT pulmonary angiography (1)
- CT radiation exposure (1)
- CT-guidance (1)
- CT-guided interventions (1)
- CTLA-4 (1)
- CTX (1)
- CUELA system (1)
- CUP (1)
- CVD biomarker (1)
- CVID (1)
- CWS Studiengruppe (1)
- CXCL10 (1)
- CXCL16 (1)
- CY-503 (1)
- CYBA/p22phox (1)
- CYP1A1 (1)
- Ca2+ imaging (1)
- Caco 2 cells/metabolism (1)
- Caco-2 cells (1)
- Caco‐2 cells (1)
- Caffeine (1)
- Calcium signalling (1)
- Calliphoridae (1)
- Calnexin (1)
- Canada (1)
- Cancer Staging (1)
- Cancer detection (1)
- Cancer epigenetics (1)
- Cancer of unknown primary (1)
- Cancer risk factors (1)
- Cancer staging (1)
- Cancer stem cells (1)
- Cancer therapeutic resistance (1)
- Candida spp (1)
- Carbapenem-resistente Gram-negative Bakterien (CRGN) (1)
- Carbapenemasen (1)
- Carbohydrates (1)
- Carbon tetrachloride (1)
- Carcinoma, Ductal, Breast (1)
- Cardiac (1)
- Cardiac Fibrosis (1)
- Cardiac acoustic biomarkers (1)
- Cardiac device therapy (1)
- Cardiac fibroblast (1)
- Cardiac function (1)
- Cardiac masses (1)
- Cardiac monitoring (1)
- Cardiac necroenzymes (1)
- Cardiac output (1)
- Cardiac remodelling (1)
- Cardiac surgery patients (1)
- Cardiac troponin (1)
- CardioMEMS™ HF system (1)
- Cardiogenic shock (1)
- Cardiomyocyte signaling pathways (1)
- Cardiomyopathy (1)
- Cardiopulmonary bypass (1)
- Cardiovascular Magnetic Resonance (CMR) (1)
- Cardiovascular biology (1)
- Cardiovascular epidemiology (1)
- Cardiovascular genetics (1)
- Cardiovascular mortality (1)
- Career promotion (1)
- Careers (1)
- Carrier-bound fibrin sealant (1)
- Cas9 inhibitor (1)
- Case management [MeSH] (1)
- Case report (1)
- Castleman’s disease (1)
- Catch-up validation study (1)
- Causality (1)
- Cause of death (1)
- Cdk1/cyclin B1 (1)
- Cell Adhesion (1)
- Cell adhesion (1)
- Cell cortex (1)
- Cell cultures (1)
- Cell cycle (1)
- Cell distribution (1)
- Cell division (1)
- Cell membranes (1)
- Cell metabolism (1)
- Cell motility (1)
- Cell plasticity (1)
- Cell processing (1)
- Cell-assisted lipotransfer (1)
- Cell-based therapies (1)
- Cell-to-Cell Spread (1)
- Cellular (1)
- Cellular imaging (1)
- Cellular inflammatory response (1)
- Cellular neuroscience (1)
- Cellular stress (1)
- Cellular stress responses (1)
- Cementation (1)
- Center-specific time in therapeutic range (cTTR) (1)
- Central nervous system (1)
- Central nervous system metastases (1)
- Centrifugation (1)
- Ceramic (1)
- Cerasorb (1)
- Cerclage (1)
- Cerebellar ataxia (1)
- Cerebellum (1)
- Cerebral Vasospasm (1)
- Cerebral cortex (1)
- Cerebral ischemia (1)
- Cerebral toxoplasmosis HIV (1)
- Cerebral vasospasm (1)
- Cerebrovascular (1)
- Certification (1)
- Cervical (1)
- Cesarean delivery (1)
- Change Management (1)
- Checkpoint kinase (1)
- Checkpoints (1)
- Chemical company (1)
- Chemical ecology (1)
- Chemical modification (1)
- Chemiluminescence (1)
- Chemobrain (1)
- Chemoembolization (1)
- Chemokine CCL2 (1)
- Chemokines (1)
- Chemoradiation (1)
- Chemorefractory advanced gastric cancer (1)
- Chemosensitivity (1)
- Chest pain unit (1)
- Chikungunya virus (1)
- Child (1)
- Child adiposity (1)
- Children and adolescents (1)
- Chimerism (1)
- Chlorides (1)
- Chloroform (1)
- Cholecystectomy (1)
- Cholesterin (1)
- Cholesterol (1)
- Chondral Lesion (1)
- Chondrocyte (1)
- Chondrocyte signalling (1)
- Chondrocytes (1)
- Chorion (1)
- Chromatin and Epigenetics (1)
- Chromatin conformation (1)
- Chromoendoscopy (1)
- Chromosomal deletion (1)
- Chromosomale Translokation (1)
- Chronic Hepatitis C (1)
- Chronic ankle instability (1)
- Chronic care model (1)
- Chronic conditions (1)
- Chronic depression (1)
- Chronic disease [MeSH] (1)
- Chronic health condition (1)
- Chronic heart failure (1)
- Chronic hepatitis C virus (1)
- Chronic illness (1)
- Chronic infection (1)
- Chronic inflammation (1)
- Chronic intestinal failure (1)
- Chronic medical conditions (1)
- Chronic obstructive airway disease (1)
- Chronic pancreatitis (1)
- Chronic periodontiti (1)
- Chronification (1)
- Chronology of disease (1)
- Cigarettes (1)
- Cinnarizine (1)
- Cinryze® (1)
- Circadian rhythms and sleep (1)
- Circulation (1)
- Cirugía (1)
- Citation (1)
- Citationrate (1)
- Cities (1)
- Classification (1)
- Claudin 5 (1)
- Cleanliness level (1)
- Cleft palate (1)
- Clincial pharmacology (1)
- CliniMACS (1)
- Clinical Global Impression of Change (1)
- Clinical Skills (1)
- Clinical Trials and Observations (1)
- Clinical effectiveness (1)
- Clinical frailty scale (1)
- Clinical outcome (1)
- Clinical pathways (1)
- Clinical psychometry (1)
- Clinical skills (1)
- Clinical variation (1)
- Cln3 (1)
- Clonidine (1)
- Clostridioides difficile (1)
- Clostridium (1)
- Closure (1)
- Cluster (1)
- Cluster randomization (1)
- Clustering (1)
- Co-culture (1)
- Co-morbidity (1)
- Coagulopathy management (1)
- Coexistence (1)
- Cofilin (1)
- Cognitive neurology (1)
- Cognitive psychology (1)
- Cohort Analysis (1)
- Cohort study (1)
- Colchicum (1)
- Cold pain (1)
- Colitis Ulcerosa (1)
- Collagen antibody-induced arthritis (1)
- Collagen hemostat (1)
- Collagen type I (1)
- Collagen type III (1)
- Collagens (1)
- Colloids (1)
- Colon cancer (1)
- Colon capsule endoscopy (1)
- Colonisation (1)
- Combined immune checkpoint blockade (1)
- Combo® DTS (1)
- Communicable diseases (1)
- Community health services (1)
- Comorbidities (1)
- Comorbidity (1)
- Comparative effectiveness research (1)
- Comparative study (1)
- Comparators (1)
- Compartmental modeling (1)
- Competencies (1)
- Complement Regulator (1)
- Complement cascade (1)
- Complement system (1)
- Complementary medicine (1)
- Complementation rate (1)
- Complete heart block (1)
- Complex II (1)
- Complex hernia (1)
- Complex networks (1)
- Complexin 1 (1)
- Complexin-1 (1)
- Complexome profiling (1)
- Complication (1)
- Comprehensive cancer centers (1)
- Computational biology and bioinformatics (1)
- Computational model (1)
- Computed axial tomography (1)
- Computed tomography pulmonary angiography (CTPA) (1)
- Computer hardware (1)
- Computer science (1)
- Computer simulation (1)
- Computer software (1)
- Computer-aided drug design (1)
- Computers (1)
- Concept paper (1)
- Conception (1)
- Concurrent chemoradiotherapy (1)
- Conditional gene trap (1)
- Conduct problems (1)
- Conduit function (1)
- Confocal endomicroscopy (1)
- Conformational change (1)
- Congenital CMVinfection (1)
- Congenital anomalies (1)
- Congenital duodenal obstruction (1)
- Congenital ocular motor apraxia (1)
- Coniosporium corticale (1)
- Consciousness (1)
- Consensus methods (1)
- Conservative (1)
- Consortia (1)
- Constrained posture (1)
- Contact precautions (1)
- Contractile function (1)
- Contrast-Enhancing Lesions (1)
- Contrast-enhanced (1)
- Conventional Chemotherapeutic (1)
- Conventional synthetic disease-modifying antirheumatic drug (1)
- Coping (1)
- Copy number variation (1)
- Cord blood transplantation (1)
- Core needle biopsy (1)
- Cornea (1)
- Coronary artery disease (1)
- Coronary artery disease (CAD) (1)
- Coronary intervention (1)
- Cost-effectiveness (1)
- Cost-effectiveness analysis (1)
- Couch tracking (1)
- Council for International Organizations of Medical Sciences (1)
- CoxVa (1)
- Coxibs (1)
- Craniomandibular disorders (1)
- Credentialing (1)
- Creeping Disease (1)
- Crispr/Cas (1)
- Critical Online Reasoning Assessment (1)
- Critical bleeding (1)
- Critical care (1)
- Critical care and emergency medicine (1)
- Critical haematocrit (1)
- Critical pathway (1)
- Cross-contamination (1)
- Cross-sectional (1)
- Cross-sectional study (1)
- Crosscorrelation (1)
- Crossmodal (1)
- Cryo-electron microscopy (1)
- Cryoablation (1)
- Cryoballoon (1)
- Cryptococcus (1)
- Cryptostroma corticale (1)
- CspA (1)
- Cumulative dose (1)
- Cure (1)
- Curriculum (1)
- Curvilinear dose response (1)
- CyberKnife (1)
- Cyp46a1 (1)
- CysLTR1 (1)
- Cysteine‐Rich Domain (CRD) (1)
- Cystic fibrosis (1)
- Cytokine (1)
- Cytology (1)
- Cytomegalovirus (CMV) (1)
- Cytoplasm (1)
- Cytoplasmic staining (1)
- Cytotoxic CD8+ T cell (1)
- C‐reactive protein (1)
- D-dimer (1)
- D2-autoreceptor (1)
- DAMP (1)
- DAMPs (1)
- DBH genotype (1)
- DCM (1)
- DDA (1)
- DDIT4 (1)
- DEE (1)
- DFNB9 (1)
- DHA (1)
- DILI database case quality (1)
- DKK1 (1)
- DKTK-ROG (1)
- DLBCL (1)
- DMARDs (synthetic) (1)
- DME (1)
- DMXAA (1)
- DNA Damage (1)
- DNA double-strand break repair (1)
- DNA repair (1)
- DNA replication (1)
- DNA sequence analysis (1)
- DNA sequencing (1)
- DNA-binding proteins (1)
- DNA-protein crosslinks (1)
- DOK1 (1)
- DR5 (1)
- DSAEK (1)
- DSS /AOM (1)
- DTHR (1)
- DUBs (1)
- DYRK1A (1)
- DYT1 (1)
- Dabigatran (1)
- Dancer (1)
- Darmerkrankung (1)
- Darreichungsform (1)
- Darunavir (1)
- Data acquisition (1)
- Data mining (1)
- Data monitoring (1)
- Data protection (1)
- Data validation (1)
- Database (1)
- Database searching (1)
- Databases (1)
- Dataset bias (1)
- Datenqualität (1)
- Datenschutz (1)
- David technique (1)
- Decision impact (1)
- Decision-making (1)
- Decolonization (1)
- Deep brain stimulation (1)
- Deficient Inhibition (1)
- Deformation (1)
- Delayed Cerebral Ischemia (1)
- Delayed union (1)
- Deletion mutation (1)
- Delivery mode (1)
- Delivery quality assurance (1)
- Delphi Survey (1)
- Delphie-Befragung (1)
- Dementia (1)
- Dendritic cell (1)
- Dendritic cell population (1)
- Dendritic cells (1)
- Dendritic spines (1)
- Denervation (1)
- Dengue (1)
- Dengue fever (1)
- Dengue virus (1)
- Denguefieber (1)
- Density equalizing (1)
- Density-equalizing mapping (1)
- Dental implants (1)
- Dental phobia (1)
- Dental training (1)
- Dentition (1)
- Depolarization (1)
- Dermal fat (1)
- Dermatomyositis (1)
- Desinfektion von Flugzeugen (1)
- Desmin (1)
- Determination method (1)
- Developmental disorders (1)
- Devic disease (1)
- Devic syndrome (1)
- Diabetic nephropathy (1)
- Diagnostic differentiation (1)
- Diagnostic techniques and procedures (1)
- Diagnostic test (1)
- Diagnostik von MLL Translokationen (1)
- Diary Data (1)
- Dicer (1)
- Dichloromethane (1)
- Didaktik (1)
- Diesel (1)
- Dietary intake (1)
- Differential expression (1)
- Diffuse astrocytoma (1)
- Diffuse large B cell lymphoma (1)
- Diffusion of Innovations (1)
- Digenic model (1)
- Digestive system (1)
- Digital breast tomosynthesis (DBT) (1)
- Digital ethics (1)
- Digital hybrid visualization (1)
- Digital mammography (1)
- Digital rectal examination (1)
- Digital transformation (1)
- Digitale Ethik (1)
- Digitale Transformation (1)
- Digitalisierung (1)
- Digitalization (1)
- Dilated cardiomyopathy (1)
- Dimer (1)
- Dimers (Chemical physics) (1)
- Dipeptide (1)
- Diphosphonates (1)
- Direct Acting Antivirals (DAA) (1)
- Direct acting antiviral therapies (1)
- Direct-acting antiviral agents (DAAs) (1)
- Disabilities (1)
- Disabling back pain (1)
- Disc herniation (1)
- Discs large (1)
- Disease burden (1)
- Disease management (1)
- Diseases (1)
- Disinfection of aircraft (1)
- Disintegration (1)
- Dissemination (1)
- Dissociative seizures (1)
- Distance to water (1)
- Distress (1)
- Distress screening (1)
- Distribution (1)
- Dog (1)
- Dogs (1)
- Domestic (1)
- Donor Selection (1)
- Dorsolateral prefrontal cortex (1)
- Dose optimization (1)
- Doubling time (1)
- Down's syndrome (1)
- Doxorubicin (1)
- Drug (1)
- Drug Discovery (1)
- Drug Therapy (1)
- Drug discovery (1)
- Drug hepatotoxicity (1)
- Drug induced liver injury (1)
- Drug interactions (1)
- Drug permeability (1)
- Drug resistance/synergy (1)
- Drug screens (1)
- Drug targeting (1)
- Dual energy CT (1)
- Dual therapy (1)
- Dual-Source CT (1)
- Duchenne’s muscular dystrophy (1)
- Dumon stents (1)
- Duodenal atresia (1)
- Duodenal stenosis (1)
- Dvc1 (1)
- E protein structure (1)
- E-cadherin (1)
- E-cadhérine (1)
- E-learning (1)
- E. coli (1)
- E/I-Balance (1)
- E3-Ligases (1)
- EBM (1)
- ECLS (1)
- ECM (1)
- EDB (1)
- EDTA-plasma (1)
- EEG reference choices (1)
- EFP1 (1)
- EGF (1)
- EGFL7 (1)
- EGFP (1)
- EGFR inhibitor (1)
- EGFR pathway (1)
- EGR1-dependent transcription (1)
- EIIIB (1)
- ELISA (1)
- ELSID-Diabetes (1)
- EMD 55900 (1)
- EMD 72000 (1)
- EMT (1)
- EPA (1)
- EQ (1)
- EQIP (1)
- ER stress (1)
- ERBB2 (1)
- ERBB2 (HER2/neu) (1)
- ERK3/MAPK6 (1)
- ERM (1)
- ERMS (1)
- ERP (1)
- ERSCongress (1)
- ES (1)
- ES cells (1)
- ESBL (1)
- ESMO-MCBS (1)
- ET (1)
- ETP-ALL (1)
- ETS (1)
- EWS/Fli1 (1)
- EZ-IO® needle driver (1)
- Early Rheumatoid Arthritis (1)
- Early diagnosis (1)
- Early goal-directed therapy (1)
- Early intervention (1)
- Early recurrence (1)
- Ebola virus (1)
- Echocardiography (1)
- Echovirus-30 (1)
- Eclampsia (1)
- Ecological momentary assessment (1)
- Economic analysis (1)
- Economic benchmarks (1)
- Economic evaluation (1)
- Economic impact (1)
- Economics (1)
- Ectopic bone formation (1)
- Edentulous jaw (1)
- Edoxaban (1)
- Educación médica (1)
- Efavirenz (1)
- Effective connectivity (1)
- Effectivity (1)
- Efficacy (1)
- Eicosanoids (1)
- Eignungsprüfung (1)
- Einfachauswahlverfahren (1)
- Eingangstest (1)
- Einreibetechnik (1)
- Elastogenesis (1)
- Elderly patients (1)
- Elective caesarean section (1)
- Electrical accident (1)
- Electrical instability (1)
- Electrical stimulation (1)
- Electroencephalography – EEG (1)
- Electrolytes (1)
- Electron transport chain (1)
- Electronic cigarettes (1)
- Electrophysiology (1)
- Electrotonic analysis (1)
- Elektroenzephalographie (1)
- Elektronenmikroskopie (1)
- Elevation (1)
- Elimination (1)
- Ellipsoids (1)
- Embolization (1)
- Embryos (1)
- Emergency (1)
- Emergency medicine (1)
- Emotion (1)
- Emotion processing (1)
- Emotional recognition (1)
- Empathy (1)
- Empfehlungen (1)
- Emphysema (1)
- Employment (1)
- Employment effect (1)
- End-of-life decisions (1)
- Endocrine cancer (1)
- Endometrial cancer (1)
- Endometriosis (1)
- Endoplasmic reticulum (1)
- Endoscopic coronary revascularisation (1)
- Endoscopic retrograde Cholangiopancreatography (ERCP) (1)
- Endoscopic ultrasound (1)
- Endoskopik koroner revaskülarizasyon (1)
- Endosomes (1)
- Endothelial cell (EC) (1)
- Endothelial nitric oxide synthase (1)
- Endothelium (1)
- Endotoxins (1)
- Endovascular repair (1)
- Endovaskuläre Behandlung (1)
- Endpoints (1)
- Enfermedades crónicas (1)
- England (1)
- Enteral nutrition (1)
- Enteric nervous system (1)
- Enterobacteriaceae (1)
- Enterostomy (1)
- Enterostomy closure (1)
- Enterostomy formation (1)
- Entfernung (1)
- Entorhinal cortex lesion (1)
- Entrenamiento práctico (1)
- Entzündung (1)
- EnvZ signalling (1)
- Envenomation (1)
- Environmental chemistry (1)
- Enzyme kinetics (1)
- Enzyme mechanisms (1)
- Enzyme regulation (1)
- Epidemiological data (1)
- Epidermolysis bullosa simplex with muscular dystrophy (1)
- Epidural block (1)
- Epilepsie (1)
- Epileptic seizures (1)
- Epileptische Anfälle (1)
- Epithelial cells (1)
- Epstein–Barr virus (1)
- Equipment (1)
- Equity (1)
- Eradication (1)
- Ergonomic analysis (1)
- Ergonomie am Arbeitsplatz (1)
- Ergonomische Analyse (1)
- Erythema migrans (1)
- Erythrocytes (1)
- Erythropoiesis (1)
- Esophageal adenocarcinoma (1)
- Esophageal adenocarcinoma (EAC) (1)
- Esophagectomy (1)
- Esophagogastric (1)
- Estradiol (1)
- Estrogen Receptor Modulators (1)
- Ethnicity (1)
- European Society for Immunodeficiencies (ESID) (1)
- European babesiosis (1)
- European registry for idiopathic pulmonary fibrosis (eurIPFreg) (1)
- Evaluation in microsurgery (1)
- Evaluationspraxis (1)
- Everolimus resistance (1)
- Evidence based medicine (1)
- Evidence-based dentistry (1)
- Evidence-based guidelines (1)
- Evidenzbasierte Medizin (1)
- Evolutionary biology (1)
- Exacerbations (1)
- Examination questions (1)
- Excitability (1)
- Exercise challenge at an ambient temperature (1)
- Exercise challenge in a cold chamber (1)
- Exercise testing (1)
- Exercise therapy (1)
- Exercise-induced bronchoconstriction (1)
- Exosomes (1)
- Experimental autoimmune encephalomyelitis (1)
- Experts (1)
- Expression (1)
- Extended Glasgow outcome scale (eGOS) (1)
- Extension study (1)
- External-/self-assessment (1)
- Extinction (1)
- Extracellular RNA (1)
- Extracellular RNA (eRNA) (1)
- Extracellular matrix proteins (1)
- Extracellular signal-regulated kinase 1/2 (1)
- Extracellular vesicles (1)
- Extracorporeal circulation (1)
- Extracorporeal life support (1)
- Extracorporeal purification (1)
- Extreme hypo-fractionation (1)
- F508del homozygous (1)
- FAAM (1)
- FAIR (1)
- FAK (1)
- FAM134B (1)
- FAV00A (1)
- FEV1 (1)
- FFLU (1)
- FFPE (1)
- FGFR (1)
- FIB-4 (1)
- FIV (1)
- FLT3 (1)
- FOLFIRI (1)
- FOXO3a (1)
- FREEDOM (1)
- FSS (1)
- FX06 (1)
- Facet joint osteoarthritis (1)
- Factor H (1)
- Factor analysis (1)
- Faculty Development (1)
- Falciparum (1)
- Fallbeispiele (1)
- Family Physician (1)
- Fascia (1)
- Fast-track (1)
- Fat layer (1)
- Fatty acids (1)
- Fbw7 (1)
- Fc receptor (1)
- Fear conditioning (1)
- Feasibility (1)
- Feature tracking (1)
- Feedback (1)
- Feedback loop (1)
- Feline bartonellosis (1)
- FemNAT-CD (1)
- Female (1)
- Female adolescents (1)
- Females (1)
- Feminismus (1)
- Femoral neck (1)
- Fertigkeiten (1)
- Fertilität (1)
- Fertilité (1)
- Fetal bovine serum (1)
- Fever (1)
- Fevers (1)
- Fibrinolytic (1)
- Fibroblast growth factor (1)
- Fibronectin (1)
- Fibrotest (1)
- Fibulin-4 (1)
- Fibulin-5 (1)
- Filovirus cell entry; attachment factors redundancy; SH-SY5Y cell line; host–pathogen interactions (1)
- Finanzierung (1)
- Finite Element Method (1)
- First experience with patients (1)
- First site of metastatic disease (1)
- First-line combination antiretroviral therapy (1)
- First-line regimen (1)
- Five-Konzept (1)
- Fleas (1)
- FlexTouch (1)
- Flexibility (1)
- Flexible Endoscopic Evaluation of Swallowing (1)
- Fluorescence imaging (1)
- Fluorescence-in-situ-hybridization (FISH) (1)
- Fluorescent Probes (1)
- Foam rolling (1)
- Folic acid (1)
- Follow-up (1)
- Food effects (1)
- Foramen ovale (1)
- Forensics (1)
- Forkhead box (1)
- Formation dance (1)
- Foxp1 (1)
- Fracture risk (1)
- Francisella tularensis (1)
- Francisella tularensis subspecies holarctica (1)
- Frankfurt <Main> / Klinikum (1)
- Frankfurt microsurgery course (1)
- Fresh frozen plasma (1)
- Frontotemporal dementia (1)
- Frühgeborenes (1)
- Fuchs endothelial dystrophy (1)
- Fuctional connectivity (1)
- Functional ankle instability (1)
- Functional capacity (1)
- Functional characterization (1)
- Functional connectivity (1)
- Functional electrical stimulation (1)
- Functional mitral regurgitation (1)
- Functional outcome (1)
- Functionally-impaired elderly (1)
- FungiScope® registry (1)
- Fusarium (1)
- Fusion Proteins, BCR-ABL (1)
- G-protein (1)
- G-protein-coupled receptors (1)
- G/P (1)
- G2A (1)
- G3BP (1)
- G9a/EHMT2/KMT1C (1)
- GABA (1)
- GABAergic interneurons (1)
- GHQ-28 (1)
- GLI inhibitors (1)
- GLUT1 (1)
- GM-CSF (1)
- GPCR (1)
- GPVI (1)
- GRADE (1)
- GRK2 (1)
- GRX1-roGFP2 (1)
- GSK2334470 (1)
- GSK3α (1)
- GSK3β (1)
- GVHD (1)
- GVL (1)
- Gaba (1)
- Gadopentate dimeglumine (1)
- Gads (1)
- Gait analysis (1)
- Gallbladder percutaneous drainage (1)
- Galleria mellonella (1)
- Games (1)
- Gamma-Band Activity (1)
- Gamma-aminobutyric acid (1)
- Gap junctions (1)
- Gas gangrene (1)
- Gastritis (1)
- Gastroesophageal reflux disease (1)
- Gastroesophageal reflux disease symptoms (1)
- Gastrointestinal bleeding (1)
- Gastrointestinal cancer (1)
- Gastrointestinal neoplasm (1)
- Gastrointestinal tract (1)
- Gaucher disease type III (1)
- Gaucher’s disease (1)
- Gebärmutterhalskrebs (1)
- Gemcitabine (1)
- Gender analysis (1)
- Gender equality (1)
- Gender gap (1)
- Gender reassigning surgery (1)
- Gene Regulation (1)
- Gene engineering (1)
- Gene expression prediction (1)
- Gene fusion (1)
- Gene microarray analysis (1)
- Gene ontology (1)
- Gene polymorphism (1)
- Gene prediction (1)
- Gene set analysis (1)
- Gene-protein assay (1)
- GeneMANIA (1)
- General clinical cardiology (1)
- General dental practice (1)
- General practice/family medicine (1)
- General practitioner (1)
- Generation Y (1)
- Generation time (1)
- Generic drugs (1)
- Genetic causes of cancer (1)
- Genome annotation (1)
- Genomic instability (1)
- Geographically weighted regression (GWR) (1)
- German (1)
- German PID-NET registry (1)
- Gesprächsführung (1)
- Gestational age (1)
- Gestational diabetes (1)
- Gesundheitsamt (1)
- Gezielte Therapie (1)
- Giant lymph node hyperplasia (1)
- Gift (1)
- Gimbaled tracking (1)
- Glaucoma (1)
- Gleason Score (1)
- Gleason upgrading (1)
- Glioma (1)
- Glivec® (1)
- Global protein synthesis rates (1)
- Glomerular Filtration Rate (1)
- Glomerular diseases (1)
- Glomerulonephritis (1)
- Glucocorticoids (1)
- Glucose Transporter Type 1 (1)
- Glycogen synthase kinase 3 beta (1)
- Glycolysis (1)
- Glycosphingolipids (1)
- Glyoxalase I (1)
- Goal-oriented care (1)
- Gold (1)
- Goserelin (1)
- Grado en medicina (1)
- Graft function (1)
- Graft survival (1)
- Gram negative bacteria (1)
- Gram-positive infection (1)
- Granule cell (1)
- Grass pollen (1)
- Greater tuberosity fractures (1)
- Gross tumor volume optimization (1)
- Growth cone (1)
- Growth factor (1)
- Growth factor signalling (1)
- Guided surgery (1)
- Guided tissue regeneration (1)
- Guideline (1)
- Guideline adherence (1)
- Gut-liver-axis (1)
- GvHD (1)
- Gαq/11 (1)
- H-Index (1)
- H1N1 (1)
- H3 receptor (1)
- H5N1 (1)
- HACA (1)
- HAEGARDA (1)
- HAI‐1 (1)
- HBV filaments (1)
- HBV genotypes (1)
- HBV reactivation (1)
- HBV surface protein (1)
- HCC recurrence (1)
- HCMV (1)
- HCV treatment (1)
- HDAC-inhibition (1)
- HER2 c-erbB2 (1)
- HER2-positive (1)
- HER2/neu (ERBB2) (1)
- HEV (1)
- HFrEF (1)
- HGF (1)
- HH (1)
- HIBCPP cells (1)
- HIF (1)
- HIF1α (1)
- HIFU (1)
- HILI (1)
- HIV protease inhibitors (1)
- HIV serodiagnosis (1)
- HIV therapy (1)
- HIV-1 escape restriction (1)
- HIV-RNA (1)
- HLA DQ haplotypes (1)
- HLA class I loss (1)
- HLA class II (1)
- HLA peptidome (1)
- HMA (1)
- HMGB1 (1)
- HODE (1)
- HRM (1)
- HRas (1)
- HSPC (1)
- HSV-1 (1)
- HSV-2 (1)
- HUVEC (1)
- Haematoma expansion (1)
- Haematopoietic stem cells (1)
- Haemodynamic monitoring (1)
- Haemostatics (1)
- Hand-foot syndrome (1)
- Haploidentical stem cell transplantation (1)
- Haplotypes (1)
- Hard-to-reach population (1)
- Hashimoto’s thyroiditis (1)
- Hausarztmangel (1)
- HbA1c (1)
- Head and neck Cancer (1)
- Head injury (1)
- Health Policy (1)
- Health Systems (1)
- Health care (1)
- Health care access (1)
- Health care resource utilization (1)
- Health care sector (1)
- Health care workers (1)
- Health education and awareness (1)
- Health information (1)
- Health literacy (1)
- Health policy (1)
- Health risk analysis (1)
- Health services (1)
- Health services research [MeSH] (1)
- Health-related quality of life (1)
- Health-seeking behaviour (1)
- Health‐related quality of life (1)
- Heart regeneration (1)
- Heat dissipation (1)
- Heat pain (1)
- Hebbian plasticity (1)
- Hedgehog (1)
- Hedgehog pathway (1)
- Helpline (1)
- Hemagglutination inhibition assay (1)
- Hematocrit value (1)
- Hematopoietic stem and progenitor cells (HSPCs) (1)
- Hematopoietic stem cell transplantation (1)
- Hematopoietic stem cells (1)
- Hematoxylin staining (1)
- Hemodilution (1)
- Hemodynamic management (1)
- Hemodynamics (1)
- Hemoglobin (1)
- Hemophilia A (1)
- Hemorrhagic shock (1)
- Hemostasis (1)
- Hemostatics (1)
- HepaRG cells (1)
- Hepatic encephalopathy (1)
- Hepatitis (1)
- Hepatitis B (1)
- Hepatitis B infection (1)
- Hepatitis B vaccination (1)
- Hepatitis B virus (1)
- Hepatitis C (1)
- Hepatitis C, Chronic (1)
- Hepatitis c (1)
- Hepatotoxicity (1)
- Herbal hepatotoxicity (1)
- Herbalife (1)
- Herbs (1)
- Herd immunity (1)
- Hereditary breast and ovarian cancer (1)
- Hereditary breast cancer (1)
- Hereditary ovarian cancer (1)
- Heregulin (1)
- Hernia recurrence (1)
- Hernia surgery (1)
- Heterogeneity (1)
- Hexavalent vaccine (1)
- HhAntag (1)
- HiC (1)
- HiChIP (1)
- Hif-1 alpha (1)
- Hif1α (1)
- High-dose chemotherapy (1)
- High-income countries (1)
- High-intensity interval endurance training (1)
- High-risk cardiac surgery (1)
- High-risk patient (1)
- High-throughput screening (1)
- Highly infectious diseases (1)
- Hindu Kush Himalayas (1)
- Hip (1)
- Hippo signaling (1)
- Hippocampal volume (1)
- Hirnverletzung (1)
- Hispanic people (1)
- Histone post-translational modifications (1)
- Histoplasma qPCR (1)
- Hmox1 (1)
- Hochansteckende Krankheiten (1)
- Hochschuldidaktik (1)
- Hodgkin’s lymphoma (1)
- Homeostatic plasticity (1)
- Homicide (1)
- Homocysteine (1)
- Hormone de régression müllérienne (1)
- Horner's syndrome (1)
- Horses (1)
- Hospital (1)
- Hospitalization (1)
- Hospitalizations (1)
- Host-directed therapies (1)
- Host-targeting agents (HTAs) (1)
- House dust mite allergy (1)
- Household contacts (1)
- Hrvaška (1)
- Hsp70 (1)
- Hsp90 inhibitor (1)
- HuR (1)
- Huh7 (1)
- Human (1)
- Human experimental pain models (1)
- Human immunodeficiency virus (HIV) (1)
- Human olfaction (1)
- Human physiology (1)
- Human prostate (1)
- Humangenetik (1)
- Humans (1)
- Humeral fractures (1)
- Humerus (1)
- Hungary (1)
- Hydrocephalus (1)
- Hydroxyapatite (1)
- Hydroxychloroquine (1)
- Hydroxycut (1)
- Hydroxyurea (1)
- Hymenoptera venom immunotherapy (1)
- Hyperammonemic encephalopathy (1)
- Hypofractionated radiotherapy (1)
- Hyponatremia (1)
- Hypoxia inducible factor (1)
- Hypoxic responses (1)
- Hysterektomie-Prävalenz (1)
- I-FABP (1)
- I-PRF (1)
- ICSI (1)
- IDH mutation (1)
- IDH1 inhibitor (1)
- IDO1 (1)
- IFA (1)
- IFN (1)
- IFN-γ expression (1)
- IGF (1)
- IGRA (1)
- IKKε (1)
- IKZF1 (1)
- IL -17 (1)
- IL -23 (1)
- IL 23p19 knockout mouse (1)
- IL-11 (1)
- IL-12 (1)
- IL-13 (1)
- IL-15 (1)
- IL-18 binding protein (1)
- IL-18BP (1)
- IL-21 (1)
- IL-22 (1)
- IL-27 cytokine (1)
- IL-33 (1)
- IL10R (1)
- ILUVIEN (1)
- IMiD® (1)
- IPEX (1)
- IPS e.max system (1)
- IRES translation (1)
- ISS (1)
- ITGA7 (1)
- IUIS classification 2017 (1)
- IV iron (1)
- IVA interference tandem mass spectrometry (1)
- IVD degeneration (IVDD) (1)
- IVDU (1)
- IVF (1)
- Iceland (1)
- Idarucizumab (1)
- Identity (1)
- Idiopathic pulmonary fibrosis (IPF) (1)
- IgE (1)
- IgG (1)
- IgG substitution therapy (1)
- IgG4-related disease (1)
- IgGAM (1)
- Illumina (1)
- Image processing (1)
- Image processing (computer-assisted) (1)
- Imaging (1)
- Imaging genetics (1)
- Imaging in LGG (1)
- Imaging, three-dimensional (1)
- Immediate loading (1)
- Immediate placement (1)
- Immobilization (1)
- Immune Response (1)
- Immune cells (1)
- Immune receptor signaling (1)
- Immune response (1)
- Immune system (1)
- Immunity (1)
- Immunmodulation (1)
- Immunoassays (1)
- Immunocompromised (1)
- Immunoglobulin Therapy (1)
- Immunohistochemistry techniques (1)
- Immunological techniques (1)
- Immunologie (1)
- Immunology and Microbiology Section (1)
- Immunomodulation (1)
- Immunomonitoring (1)
- Immunosenescence (1)
- Immunostaining (1)
- Immunosuppression (1)
- Immunosuppressive Agents (1)
- Immunosuppressive agents (1)
- Immunosuppressive therapy (1)
- Impfung (1)
- Implant-supported bars (1)
- Implementación (1)
- Impulse control (1)
- In vivo (1)
- In-hospital cardiac arrest (1)
- In-line filtration (1)
- In-vivo (1)
- IncL (1)
- Incidence rate (1)
- Incomplete colonoscopy (1)
- Independent component analysis (1)
- Independent laboratories (1)
- Indeterminate biliary stricture (1)
- Index (1)
- Indication (1)
- Individualisierung des Studiums (1)
- Individualized intervention (1)
- Individuelle Studienbegleitung (1)
- Indonesia (1)
- Indoor air pollution (1)
- Induced membrane technique (1)
- Induced pluripotent stem cells (1)
- Induced sputum (1)
- Inertial motion capture (1)
- Infant (1)
- Infant leukemia (1)
- Infants (1)
- Infarction (1)
- Infections (1)
- Infectious disease (1)
- Infectious disease epidemiology (1)
- Infektionsabwehr (1)
- Infektionsprophylaxe (1)
- Infliximab (1)
- Inflow obstruction (1)
- Influenza (1)
- Information theory (1)
- Information transfer (1)
- Infusion management (1)
- Injuries (1)
- Injury (1)
- Inner ear therapy (1)
- Inpatients (1)
- Inside-out Signaling (1)
- Insula (1)
- Insulin (1)
- Insulin secretion (1)
- Insulin therapy (1)
- Integrated multimodal training (1)
- Integration (1)
- Integrin (1)
- Integrins (1)
- Intelligence (1)
- Intelligence tests (1)
- Intensive care outcome (1)
- Intensive care unit (1)
- Inter-study reproducibility (1)
- Interdisziplinarität (1)
- Interferon-free HCV treatment (1)
- Interferons (1)
- Interleukin-17A (1)
- Interleukin-18 (1)
- Interleukin-18 binding protein (1)
- Interleukin-22 binding protein (1)
- Intermediate filaments (1)
- International body passport (1)
- Internet citation (1)
- Interspecific competition (1)
- Interstitial lung diseases (ILD) (1)
- Interventional Trials (1)
- Interventional cardiology (1)
- Intervertebral disc degeneration (1)
- Intestinal failure-associated liver disease (1)
- Intestinal neoplasms (1)
- Intolerance (1)
- Intra-abdominal infection (1)
- Intracellular pathogens (1)
- Intracerebral haemorrhage (1)
- Intracranial embolism (1)
- Intracranial haemorrhage (1)
- Intracranial hemorrhage (1)
- Intragastric balloon (1)
- Intraoral scanners (1)
- Intraosseous access (1)
- Intratumoral (1)
- Intratympanic drug delivery (1)
- Intravenous Drug User (1)
- Intravenous injections (1)
- Invasive candidiasis (1)
- Invasive fungal infection (1)
- Invasive fungal infections (1)
- Inzidenzkorrektur (1)
- Ionenkanal (1)
- Ipilimumab (1)
- Ireb2 (1)
- Ireland (1)
- Iron Overload (1)
- Iron chelation (1)
- Iron deficiency (1)
- Irregular vaccination (1)
- Ischemia-reperfusion injury (1)
- Ischemia–reperfusion injury (1)
- Isolierung <Medizin> (1)
- Isoproterenol (1)
- Issue 96 (1)
- Italy (1)
- Itpr1 (1)
- Ivor Lewis esophagectomy (1)
- Ixodes ricinus (1)
- JAK inhibition (1)
- JNK3 (1)
- Jak2(V617F) (1)
- Joint destruction (1)
- Joint loading (1)
- Joubert syndrome (1)
- Jumping (1)
- Juvenile myoclonic epilepsy (1)
- KAP (1)
- KCGS (1)
- KCNJ2 mutation (1)
- KCNQ4 (1)
- KDIGO (1)
- KIF (1)
- KIF11 (1)
- KIR (1)
- KLK5 (1)
- KOOS IV (1)
- KRAS (1)
- Kaisidis plate (1)
- Karyotypes (1)
- Kegelschnecke (1)
- Keratinocytes (1)
- Ketogenic Diet (1)
- Ki-67 (1)
- Ki-67/MIB1 (1)
- Ki67 transgenic c‐myc/TGFα mice (1)
- Kidney Transplantation (1)
- Kidney disease (1)
- Kidney neoplasm (1)
- Kidney transplant recipients (1)
- Kiefer (1)
- Kim-1 (1)
- Kinases (1)
- Kinder (1)
- Kindheit (1)
- Kinematic posture analysis (1)
- Kinematics (1)
- Kinetochore (1)
- Klinische Ergebnisse (1)
- Klinische Fertigkeiten (1)
- Knee joint (1)
- Knockout (1)
- Kongress (1)
- Konsensus Methode (1)
- Konzeption (1)
- Konzeptpapier (1)
- Krait (1)
- Kraniomandibuläre Dysfunktion (1)
- Krebs (1)
- Krebsforschung (1)
- Kupffer cells (1)
- Kynurenine (1)
- Körperbild (1)
- Körpermodifikation (1)
- L1 cell-adhesion molecule (L1-CAM) (1)
- LABAs (1)
- LAMP3 (1)
- LAMTOR2 (1)
- LAT (1)
- LC-NE system (1)
- LC3 I/II (1)
- LC3B (1)
- LCH (1)
- LC–MS/MS (1)
- LDL (1)
- LDL-cholesterol (1)
- LFA-1 (1)
- LFP (1)
- LHRH receptor (1)
- LIR interaction, (1)
- LIVIN (1)
- LM11A 31 (1)
- LN229 (1)
- LNS (1)
- LOS (1)
- LPP (1)
- LRBA (1)
- LSCC (1)
- LTB4 (1)
- LTBI (1)
- LUBAC (1)
- LUT (1)
- Laboratory techniques and procedures (1)
- Lack of immunity (1)
- Lactation (1)
- Lactic acidosis (1)
- Lactobacillus (1)
- Lafora disease (1)
- Lamivudine (1)
- Landarztprogramm (1)
- Langzeitpflege (1)
- Laparoscopic fundoplication (1)
- Laparostomy (1)
- Laparotomy. Joel-Cohen (1)
- Laser navigation system (1)
- Late Gadolinium Enhancement (LGE) (1)
- Late gadolinium enhancement (1)
- Late presentation (1)
- Latent transforming growth factor β-binding protein 4 (1)
- Lateral recess stenosis (1)
- Laterality (1)
- Le carcinome épidermoïde oral (1)
- Leadership (1)
- Learning algorithms (1)
- Learning and memory (1)
- Learning outcomes (1)
- Leber congenital amaurosis (1)
- Lectin affinity plasmapheresis (1)
- Lecture (1)
- Leflunomide (1)
- Left Ventricular Mass (1)
- Left ventricular assist device (1)
- Left ventricular function (1)
- Left ventricular mass (1)
- Left ventricular non-compaction, (1)
- Leg alignment (1)
- Lehre (1)
- Lehrerausbildung (1)
- Leistungsorientierte Mittelvergabe (1)
- Leitlinie (1)
- Lenalidomide (1)
- Length of stay (1)
- Lentiviral vectors (1)
- Lernerfolgsmessung (1)
- Lernziele (1)
- Les macrophages associés aux tumeurs (1)
- Lesion (1)
- Leukemia (1)
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)
- Leukocyte elastase (1)
- Leukocytes (1)
- Leukodystrophy (1)
- Leukotriene (1)
- Lice (1)
- Light sheet fluorescence microscopy (1)
- Lineage (1)
- Lineage tracing (1)
- Linkage (1)
- Lipid metabolism (1)
- Lipid signaling (1)
- Lipid trafficking (1)
- Lipidol (1)
- Lipiodol (1)
- Lipodystrophy (1)
- Lipopolysaccharide-binding protein (1)
- Liquid filled MicroLion ion chamber array (1)
- Lithium (1)
- Liver (1)
- Liver cancer (1)
- Liver enzymes (1)
- Liver injury (1)
- Liver metastases (1)
- Liver resection (1)
- Liver transplant (1)
- Liver-Related Complications (1)
- Liver-related complications (1)
- LiverTox (1)
- Livestock (1)
- LncRNA (1)
- LncRNA - long noncoding RNA (1)
- Local IgE (1)
- Local allergic rhinitis (1)
- Local climate (1)
- Local control (1)
- Localized prostate cancer (1)
- Locally advanced (1)
- Loco-regional control (1)
- Locomotor circuit (1)
- Lomentospora prolificans (1)
- Long term output (1)
- Long term result (1)
- Long-term (1)
- Long-term follow up (1)
- Longitudinal analysis (1)
- Low birth weight infant (1)
- Low volume prep (1)
- Low-dose X-irradiation (1)
- Low-dose ionizing radiation (1)
- Low-grade glioma (1)
- Low-virulent infection (1)
- Lower back pain (1)
- Lpar2 (1)
- Ltbp-4 (1)
- Ltbp-4L (1)
- Ltbp-4S (1)
- Ltbp4 (1)
- Lucigenin (1)
- Luftverkehr (1)
- Lumbar spinal canal stenosis (1)
- Lumbar stenosis (1)
- Lumican (1)
- Lung (1)
- Lung Cancer (1)
- Lung adenocarcinoma (1)
- Lung cancer (1)
- Lung failure (1)
- Lungenerkrankungen (1)
- Lyme Borreliosis (1)
- Lyme borreliosis (1)
- Lyme disease - Borreliosis (1)
- Lymph node (1)
- Lymphadenopathy (1)
- Lymphangiogenesis (1)
- Lymphangioleiomyomatosis (1)
- Lymphedema (1)
- Lymphocyte (1)
- Lymphoepithelioma (1)
- Lymphoid Neoplasia (1)
- Lymphoid tissues (1)
- Lymphoma (1)
- Lymphomas (1)
- Lysophosphatidic acids (1)
- Lysosomal storage disease (1)
- MACE (1)
- MAGGIC score (1)
- MAIT cell (1)
- MC-Fragen (1)
- MCP (1)
- MCP-1 (1)
- MDM2 (1)
- MDR1 (1)
- MEDIC (1)
- MEIS2 (1)
- MELD (1)
- MET (1)
- MK-0457 (1)
- MKP1 (1)
- MLC tracking (1)
- MLH1 (1)
- MLKL (1)
- MLL-rearranged leukemia (1)
- MLN8237 (1)
- MLV (1)
- MM-121 (1)
- MMF (1)
- MMP14 (1)
- MMP2 (1)
- MOLLI (1)
- MPA (1)
- MPM (1)
- MPN (1)
- MPN-U (1)
- MR spectroscopy (1)
- MR-based histology (1)
- MR-proADM (1)
- MR-spectroscopy (1)
- MRI patterns of gliomas (1)
- MRP4 (1)
- MSC-subsets (1)
- MSM (1)
- MTCL (1)
- MTRNR1 (1)
- MTT (1)
- MTT assay (1)
- Machine learning algorithms (1)
- Machine teaching (1)
- Macrophage Transdifferentiation (1)
- Macrophage polarization (1)
- Macular neovascularization (1)
- Magnetic resonance (1)
- Magnetic resonance imaging (MRI) (1)
- Magnetoencephalography (1)
- Magnetresonanztomografie (1)
- Maintenance treatment (1)
- Major bleeding (1)
- Major infection after cardiac surgery (1)
- Malaria prevalence (1)
- Malariae (1)
- Male (1)
- Male Population (1)
- MammaPrint (1)
- Mammalian target of rapamycin (1)
- Mammaplasty (1)
- Mammary gland (1)
- Manatee invariant (1)
- Mandible (1)
- Mania (1)
- Manner of death (1)
- Manufacturing (1)
- Maple bark disease (1)
- Maple bark strippers’ lung (1)
- Mapping (1)
- Marburg virus (1)
- Marginal grafts (1)
- Marker genes (1)
- Markov model (1)
- Massive Online Open Course (1)
- Mastectomy (1)
- Maternal morbidity (1)
- Mathematical methods (1)
- Mathematical model (1)
- Mathematical models (1)
- Mathematische Biologie (1)
- Mcl-1 (1)
- MdM2 (1)
- Measles (1)
- Measurement equipment (1)
- Mechanical ankle instability (1)
- Meckel’s diverticulum (1)
- Medical (1)
- Medical Education (1)
- Medical communication (1)
- Medical ethics (1)
- Medical hypoxia (1)
- Medical imaging (1)
- Medical implants (1)
- Medical management (1)
- Medical research (1)
- Medical school (1)
- Medical staff (1)
- Medical student (1)
- Medical traineeship (1)
- Medication changes (1)
- Medicine and health sciences (1)
- Medizin (1)
- Medizinische Abbildung (1)
- Medizinische Ausbildung (1)
- Medizinische Ethik (1)
- Medizinische Lehre (1)
- Medizinische Psychologie (1)
- Medizinstudierende (1)
- Melanoma (1)
- Membrane Attack Complex (1)
- Membrane Trafficking (1)
- Membrane assays (1)
- Membrane proteins (1)
- Membrane staining (1)
- Memory (1)
- Mena/VASP (1)
- Mental health (1)
- Mental health disorders (1)
- Mental health problems (1)
- Menthol (1)
- Mentor (1)
- Mesangial cells (1)
- Mesenchymal stem cell (1)
- Mesenchymal stem/stromal cells (1)
- Mesenchymal stromal cells (1)
- Mesenchymal stromal cells (MSC) (1)
- Mesh repair (1)
- Meta-analysis (1)
- Metaanalysis (1)
- Metabolic diseases (1)
- Metabolic syndrome (1)
- Metabolism (1)
- Metabolism, Inborn Errors (1)
- Metalloproteases (1)
- Metastasis (1)
- Metastatic (1)
- Metastatic castration-resistant prostate cancer (1)
- Metastatic tumors (1)
- Methacholine challenge test (1)
- Methicillin resistance (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Methionine (1)
- Methoden (1)
- Methotrexate (1)
- Mgm1p (1)
- MiSpEx Network (1)
- Mice (1)
- Micro RNAs (1)
- Micro-CT (1)
- MicroRNA-181a (1)
- MicroRNAs (miRNAs) (1)
- Microalgae (1)
- Microarray (1)
- Microbial mutation (1)
- Microfluidics (1)
- Microglia (1)
- Microglial cells (1)
- Micrognathia (1)
- Microphones (1)
- Microphysiological models (1)
- Microsatellite instability (1)
- Microstates (1)
- Microtubule (1)
- Midbrain/brainstem expression changes (1)
- Middle East respiratory syndrome coronavirus (1)
- Midkine (1)
- Midline laparotomy (1)
- Midwifery (1)
- Migration (1)
- Mild cognitive impairment (1)
- Minimal Residual Disease (MRD) (1)
- Minimal core of imaging (1)
- Minimal invasive (1)
- Minimally invasive surgical procedures (1)
- Minimally invasive transforaminal interbody fusion (1)
- Mislocalised proteins (1)
- Mitochondrial ROS (1)
- Mitochondrial amino acid tRNA synthetases (1)
- Mitochondrial complex I (1)
- Mitochondrial disease (1)
- Mitochondrial disorder (1)
- Mitochondrial dysfunction (1)
- Mitochondrial function (1)
- Mitochondrial proteins (1)
- Mitochondrial respiration (1)
- Mitochondrial shuttles (1)
- Mitochondrien (1)
- Mitomycin C (1)
- Mitoxantrone (1)
- Mobilization (1)
- Model Organism (1)
- Modell-Curriculum (1)
- Modellprojekt, (1)
- Moderating factors (1)
- Modified FDI criteria (1)
- Molar tooth sign (1)
- Mole-rat (1)
- Molecular diagnostic testing (1)
- Molecular genetics (1)
- Molecular imaging (1)
- Molecular marker (1)
- Molecular matched therapy (1)
- Molecular signatures (1)
- Molecular subtype (1)
- Molecular subtypes (1)
- Molecular therapy (1)
- Molecularly targeted therapy (1)
- Molekulare Therapie (1)
- Monacolin K (1)
- Monitoring (1)
- Monoclonal antibodies (1)
- Monocytes and macrophages (1)
- Monolithic crown (1)
- Monosaccharide Transport Proteins (1)
- Monte Carlo method (1)
- Monte Carlo simulation (1)
- Morbus Crohn (1)
- Morphological modeling (1)
- Mortalitätskorrektur (1)
- Motility disorder (1)
- Motivating factor (1)
- Motor neuron disease (1)
- Motor skills (1)
- Mountain (1)
- Mouse model (1)
- Moviprep (1)
- Mucomaix® matrix (1)
- Mucopolysaccharidoses (1)
- Multi-center (1)
- Multi-modal feedback (1)
- Multi-nucleated cardiomyocytes (1)
- Multi-resistant pathogens (1)
- Multidetector Computed Tomography (1)
- Multidetector computed tomography (1)
- Multidisciplinary management (1)
- Multidrug-resistant bacteria (1)
- Multidrug-resistant tuberculosis (1)
- Multilevel two-part modelling (1)
- Multimedia (1)
- Multimodal imaging (1)
- Multimorbid patients (1)
- Multimorbilidad (1)
- Multinomial logistic regression (1)
- Multinucleated giant cells (1)
- Multiomics (1)
- Multiple Sclerosis (1)
- Multiple choice Fragen (1)
- Multiple myeloma (1)
- Multiple trauma (1)
- Multisensory (1)
- Multivariable analysis (1)
- Muscarinic acetylcholine receptor (1)
- Muscle atrophy (1)
- Muscle tissue (1)
- Muscular diseases (1)
- Musculoskeletal (1)
- Musculoskeletal ultrasound (1)
- Music chair concepts (1)
- Musical rhythm (1)
- Musician (1)
- Musician-specific seating position (1)
- Muskuloskeletales System (1)
- Muskuloskelettale Erkrankungen (1)
- Mutation databases (1)
- Mutations (1)
- Myalgia (1)
- Mycoses (1)
- Myelin or myeloarchitecture (1)
- Myelodysplastic syndrome (1)
- Myelofibrosis (1)
- Myeloperoxidase (1)
- Myeloproliferative disease (1)
- Myocardial perfusion (1)
- Myocardial revascularization (1)
- Myocardial segmentation (1)
- Myonecrosis (1)
- Myotonic dystrophy (1)
- Mφs (1)
- N-Acetylaspartate (1)
- N-acetyl-L-cysteine (1)
- N-acetylcysteine (1)
- N-cadherin (1)
- N-cadhérine (1)
- N-hydroxysuccinimide (1)
- N-methyl-D-aspartate receptor (1)
- N-myc (1)
- N2 (1)
- NADH dehydrogenase (1)
- NADPH oxidase 4 (1)
- NAFL (1)
- NCAM (1)
- NCH93 (1)
- NDBI (1)
- NDNF interneurons (1)
- NDR1 (1)
- NDUFA6 (1)
- NDUFAF8 (1)
- NEAT1 (1)
- NEAT2 (1)
- NETs (1)
- NF-ĸB (1)
- NF-κB pathway (1)
- NF-кB (1)
- NFAT (1)
- NFκB (1)
- NGS (1)
- NHE (1)
- NHEJ (1)
- NIRS (1)
- NK cell subset (1)
- NK receptors (1)
- NKG2A blocking (1)
- NKT cell (1)
- NMDA IgA/IgM antibodies (1)
- NMDA antibody (1)
- NMDAR subunit GluN2B (1)
- NMO-IgG (1)
- NO (1)
- NOD2 (1)
- NOXA (1)
- NPC disease (1)
- NPH insulin (1)
- NPSR1 (1)
- NRAS (1)
- NS1608 (1)
- NS3 protease inhibitor (1)
- NS3-4A protease inhibitor (1)
- NS3/4A protease inhibitors (PI) (1)
- NS5A inhibitors (1)
- NS5B polymerase inhibitor (1)
- NSAIDs (1)
- NSC350625 (1)
- NSE (1)
- NSF (1)
- NSG mice (1)
- NSTEMI (1)
- NXF1 (1)
- Nackenmuskulatur (1)
- NanoBone (1)
- Nanocrystalline (1)
- Nanoparticles (1)
- Nanopore (1)
- National catalogue of competence-based learning objectives in dentistry (1)
- Native T1 (1)
- Native T1 mapping (1)
- Natriuretic peptide (1)
- Naturwissenschaften (1)
- Nav channel activity (1)
- Nav1.7 (1)
- Neck muscles (1)
- Necrosis (1)
- Necrotic area (1)
- Necrotizing enterocolitis (1)
- Necrotizing fasciitis (1)
- Needs assessment [MeSH] (1)
- Negative staining (1)
- Negative-pressure wound therapy (1)
- Neoadjuvant radiochemotherapy (1)
- Neoadjuvant therapy (1)
- Neonatal (1)
- Neonatal brain damage (1)
- Neonatal intensive care unit (1)
- Neonatal morbidity (1)
- Neonatal outcome (1)
- Neonatal urea cycle disorders (1)
- Neosexualitäten (1)
- Nephrectomy (1)
- Nephrons (1)
- Nerves (1)
- Nervous system diseases (1)
- Nesplora Aquarium (1)
- Network analysis (1)
- Network model (1)
- Neugeborenes (1)
- Neural function (1)
- Neural networks (1)
- Neural stem cells (1)
- Neuro-ophthalmology (1)
- Neurobiology of disease and regeneration (1)
- Neuroblastoma (1)
- Neurochemistry (1)
- Neurodegeneration (1)
- Neurodegenerative diseases (1)
- Neurodevelopment (1)
- Neurodevelopmental disorders (1)
- Neuroendocrine cancer (1)
- Neurogenese (1)
- Neurogenesis (1)
- Neuromyelitis optica (1)
- Neuronal dendrites (1)
- Neuronal homeostasis (1)
- Neuronal networks (1)
- Neuronal nitric oxide synthase (1)
- Neuronal plasticity (1)
- Neuropathic pain (1)
- Neurophysiology (1)
- Neuropsychological testing (1)
- Neuropsychology (1)
- Neurotoxicity (1)
- Neurotransmitter (1)
- Neurowissenschaften (1)
- Neutrophils (1)
- New Developments (1)
- Next generation sequencing (1)
- Nfe2l2 (1)
- Niche differentiation (1)
- Nicolaides-Baraitser syndrome (1)
- Nicotine (1)
- Nimotuzumab (1)
- Nociception (1)
- Nodular lymphocyte predominant Hodgkin lymphoma (1)
- Non-RCT (1)
- Non-alcoholic fatty liver disease (1)
- Non-allergic-rhinitis (1)
- Non-aneurysmal (1)
- Non-clear cell renal cell cancer (1)
- Non-coding RNAs (1)
- Non-falciparum (1)
- Non-invasive brain stimulation (1)
- Non-neuronal cholinergic system (1)
- Non-nucleoside polymerase inhibitors (NNI) (1)
- Non-operative (1)
- Non-perimesencephalic (1)
- Non-responder (1)
- Non-small-cell lung cancer (1)
- Non-steroidal anti-inflammatory drugs (1)
- Non-trauma (1)
- Non-urothelial (1)
- Noncoding RNA (1)
- Noninferiority (1)
- Nonsteroidal anti-inflammatory drugs (1)
- Nonunion (1)
- Non–small-cell lung cancer (1)
- Nordic questionnaire (1)
- Notch (1)
- Novel treatment target (1)
- NoxA1 (1)
- Nucleolus (1)
- Nucleophosmin-1 (1)
- Nucleus pulposus cells (1)
- Numerical simulation (1)
- Nurses (1)
- Nursing (1)
- Nutrition (1)
- Nutrition risk stratification (1)
- Nymphs (1)
- O-GlcNAcylation (1)
- OCT (1)
- OECD performance standards (1)
- OGTT (1)
- ONC201 (1)
- OPRM1 methylation (1)
- OPS (1)
- OR time (1)
- OXA-48 (1)
- Object perception (1)
- Object vision (1)
- Objectives (1)
- Objektivität (1)
- Observational (1)
- Observational studies (1)
- Obstetric care (1)
- Obstetrics (1)
- Obstetrics and gynecology (1)
- Occupational Accidents (1)
- Occupational disease (1)
- Occupational exposure (1)
- Occupational health (1)
- Occupational medicine (1)
- Ocular findings (1)
- Oesophageal cancer (1)
- Oesophagogastric cancer oxaliplatin (1)
- Off-pump surgery (1)
- Offene Versorgung (1)
- Okinawa (1)
- Okinawa diet (1)
- Older adults (1)
- Oldest-old (1)
- Olfactory diagnostics (1)
- Olfactory system (1)
- Omics (1)
- Oncologic surgery (1)
- Oncolytic adenovirus (1)
- Oncolytic virus (1)
- Oncotargets (1)
- One health (1)
- Online-Lehre (1)
- Online-Lernen (1)
- Online-Magazine (1)
- Opacity (1)
- Open abdomen (1)
- Open repair (1)
- Open source concept (1)
- Opioids (1)
- Oposterior urethral valve (1)
- Opportunistic infections (1)
- Oppositional defant disorder (1)
- Oppositional defiant disorder (1)
- Optic nerve atrophy (1)
- Optical coherence tomography angiography (1)
- Optical lenses (1)
- Oral Health Impact Profile (OHIP) (1)
- Oral and maxillofacial trauma (1)
- Oral implantology (1)
- Ordinary least squares (OLS) (1)
- Organ allocation (1)
- Organ motion (1)
- Organ preservation (1)
- Organ rinse (1)
- Organ shortage (1)
- Organ support (1)
- Organoids (1)
- Organs at Risk (1)
- Oroantral communication (1)
- Orphan disease (1)
- Orthodontist (1)
- Oryctolagus cuniculus (1)
- Osimertinib (1)
- Osmosensing (1)
- OspE (1)
- Osteoinduction (1)
- Osteonecrosis (1)
- Osteoporosis diagnosis (1)
- Oswestry Disability Score (1)
- Outcome assessment [MeSH] (1)
- Outcomes research (1)
- Outpatients (1)
- Ovale (1)
- Ovarian carcinoma (1)
- Overall survival (1)
- Oxaliplatin (1)
- Oxidativer Stress (1)
- OxyELITE Pro (1)
- Oxygen (1)
- Oxygen consumption (1)
- Oxygen uptake (1)
- Oxygen-derived free radicals (1)
- P-gp (1)
- P1NP (1)
- P2X7 receptor (1)
- PAH (1)
- PAI-1 (1)
- PAR (1)
- PARK4 (1)
- PARK6 (1)
- PARK7 (1)
- PAX3/FOXO1 (1)
- PBMC (peripheral blood mononuclear cells) (1)
- PBPK simulation (1)
- PBX1 (1)
- PC12 cells (1)
- PC12 neuronal differentiation (1)
- PCP (1)
- PCSK9 protein (1)
- PCV (1)
- PD-1 (1)
- PD-1 inhibitor (1)
- PDCD4 (1)
- PDD - Assessment - Screening (1)
- PDE inhibition (1)
- PDE‐5‐inhibitor (1)
- PDI (1)
- PDK1 (1)
- PEA-15 (1)
- PEGylated PLGA (PLGA-PEG) (1)
- PEI (1)
- PELICAN (1)
- PEM-technology (1)
- PF-06273340 (1)
- PFL (1)
- PGE2 (1)
- PID prevalence (1)
- PIF pocket (1)
- PKA (1)
- PKCε (1)
- PKD (1)
- PKD/IC (1)
- PLK1 (1)
- PLK1 inhibitors (1)
- PLX4032 (1)
- PLX4720 (1)
- PM (1)
- PMF (1)
- PML (1)
- POLG (1)
- PPAR (Peroxisome proliferator-activated receptors) (1)
- PPARγ (1)
- PRG-1 (1)
- PRLTS3 (1)
- PRNT (1)
- PROM (1)
- PROMISE (1)
- PROTAC (1)
- PRRT2 (1)
- PRoMPT (1)
- PSA (1)
- PTCH (1)
- PTCH-1 (1)
- PTDM (1)
- PTEN (1)
- PTK2B (1)
- PUMA (1)
- PV (1)
- PXA (1)
- PYGL (1)
- Pacemaker (1)
- Paediatric Investigation Plan (1)
- Paediatric oncology (1)
- Paediatric research (1)
- Paediatrics (1)
- Pain management (1)
- Pain sensation (1)
- Pancreas transplantation (1)
- Pancreatic islet (1)
- Pancreatic surgery (1)
- Pancreatitis (1)
- Pancreatoduodenectomy (1)
- Panel testing (1)
- Panic disorder (1)
- Par-4 (1)
- Paracetamol (1)
- Parainfluenza (1)
- Paraneoplastic syndrome (1)
- Parapneumonic pleural effusion (1)
- Parent support (1)
- Parenteral nutrition (1)
- Parkinson (1)
- Parkinsonerkrankung (1)
- Parkinsons disease (1)
- Particles (1)
- Particulate matter (1)
- Patellofemoral Joint (1)
- Pathogen reduction (1)
- Pathogenesis (1)
- Pathologic changes (1)
- Pathological complete response (1)
- Pathologists (1)
- Pathology (1)
- Pathology Section (1)
- Patient Blood Management (1)
- Patient Outcome Assessment (1)
- Patient care planning (1)
- Patient education (1)
- Patient information materials (1)
- Patient isolation (1)
- Patient knowledge (1)
- Patient manikins (1)
- Patient preference (1)
- Patient preferences (1)
- Patient reported outcomes (1)
- Patient safety (1)
- Patient satisfaction (1)
- Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (1)
- Patient-centered care (1)
- Patient-reported outcomes (1)
- Pattern recognition receptors (1)
- Pause (1)
- Pdgfrβ (1)
- Pediatric burn injury (1)
- Pediatric neuroimaging (1)
- Pediatric sarcoma (1)
- Pediatrics (1)
- Pediatrics [MeSH] (1)
- Peer Teaching (1)
- Peer teaching (1)
- Peer-feedback (1)
- Peer-teaching (1)
- Peg3 (1)
- Pegylated liposomal doxorubicin (1)
- Penile carcinomas (1)
- Pentaglobin (1)
- Peptides and proteins (1)
- Percutaneous (1)
- Performing Artists (1)
- Pericardial effusion (1)
- Pericarditis (1)
- Perilymph (1)
- Perimesencephalic (1)
- Periodontal disease (1)
- Periodontal diseases (1)
- Periodontal therapy (1)
- Peripheral vascular disease (1)
- Personalised medicine (1)
- Personalisierte translationale Therapie (1)
- Personality (1)
- Personality disorder (1)
- Pessar (1)
- Petri net (1)
- Pfannenstiel (1)
- Pflege (1)
- Pflegeeinrichtungen (1)
- Pgrmc1 (1)
- Phagocytosis (1)
- Phantom study (1)
- Pharm-fMRI (1)
- Pharmaco-nutrition (1)
- Pharmacodynamic (1)
- Pharmacological treatment (1)
- Pharmacology (1)
- Pharmacometrics (1)
- Pharmacy setting (1)
- Pharmakoepidemiologie (1)
- Pharyngeal reflex (1)
- Phase 2 (1)
- Phase I trials (1)
- Phase II trial (1)
- Phase rotors (1)
- Phase-IV research (1)
- Philadelphia Chromosome (1)
- Philadelphia Chromosome-positive leukemia (1)
- Phospho-soda (1)
- Phospho-tau (1)
- Phospholipids (1)
- Physical activity (1)
- Physical environment (1)
- Physical fitness (1)
- Physical therapist (1)
- Physician report (1)
- Physician-assisted suicide (1)
- Phytochemicals (1)
- Piercing (1)
- Pierre Robin sequence (1)
- Pill Count (1)
- PillCamColon2 (1)
- Pilocytic astrocytoma (1)
- Pim-1 (1)
- Pink esthetic score (1)
- Placental growth factor (1)
- Planning target volume (1)
- Plasma (1)
- Plasma fibronectin (1)
- Plasma transfusion (1)
- Plasma usage (1)
- Plasmacytoid dendritic cell (1)
- Plasminogen (1)
- Plastic endoprosthesis (1)
- Platelet (1)
- Platelet dysfunction (1)
- Platelet lysate (1)
- Platelet releasate (1)
- Platzierung (1)
- Plectin (1)
- Pleural empyema (1)
- Plk1 (1)
- Plus-end (1)
- Pneumococcal conjugate vaccine (1)
- Pneumocystis jirovecii (1)
- Polarity index (1)
- Police (1)
- Poliomyelitis (1)
- Polo-like kinase 3 (1)
- PolySUMOylation (1)
- Polyhexanide (1)
- Polymerase Chain Reaction (PCR) (1)
- Polyphenole (1)
- Polyps (1)
- Polysomnography (1)
- Polyzystisches Ovarsyndrom (1)
- Política de Saúde (1)
- Pooling (1)
- Poor solubility (1)
- Population-based screening (1)
- Porin regulation (1)
- Portal (1)
- Portugal (1)
- Posaconazole serum level (1)
- Position paper (1)
- Positron-emission tomography (1)
- Post surgery pain (1)
- Post treatment (1)
- Post-transplant (1)
- Posterior Cerebral (1)
- Postoperative infections (1)
- Postoperative nutritional management (1)
- Posttranslational modification (1)
- Posttraumatic stress disorder (1)
- Posttraumatische Belastungsstörung (1)
- Posture (1)
- Posture analysis (1)
- Potassium channel Kir2.1 (1)
- Poverty (1)
- Practical training (1)
- Practice (1)
- Practice-based research network (1)
- Praktikum (1)
- Praktische Fertigkeiten (1)
- Pre-economic effects (1)
- Pre-emptive immunotherapy (1)
- Pre-treatment drug resistance mutations (1)
- PreS1 deletion (1)
- Precision (1)
- Precision oncology (1)
- Preclinical (1)
- Preclinical drug development (1)
- Preclinical research (1)
- Precompetitive development (1)
- Predictive medicine (1)
- Predominant polarity (1)
- Preeclampsia (1)
- Prenatal ultrasonographic detection rate (1)
- Preoperative diagnostics (1)
- Preoperative radiochemotherapy (1)
- Prepontine (1)
- Pressure pain (1)
- Presynaptic vesicles (1)
- Preterm birth (1)
- Preventive medicine (1)
- Pre‐Ligand Assembly Domain (PLAD) (1)
- Primary Care Health Centre (1)
- Primary breast lymphoma (1)
- Primary cilium (1)
- Primary health care (1)
- Primary health care [MeSH] (1)
- Primary prophylaxis (1)
- Primary sclerosing cholangitis (1)
- Primärversorgung (1)
- Prisoners (1)
- Prisons (1)
- Probability density (1)
- Probability distribution (1)
- Produkte zur Desinfektion (1)
- Professions (1)
- Profiling Transthiolation Activity (1)
- Profilometry (1)
- Progesteron (1)
- Progesterone (1)
- Prognostic biomarker (1)
- Programming languages (1)
- Prospective randomized Analysis (1)
- Prostaglandin (1)
- Prostate Cancer (1)
- Prostate cancer cell lines (1)
- Prostate-specific membrane antigen (1)
- Prosthetic rehabilitation (1)
- Protease activity (1)
- Proteasomes (1)
- Protective factors (1)
- Protein Kinase Inhibitors (1)
- Protein Structure (1)
- Protein Translocation (1)
- Protein aggregates (1)
- Protein complex (1)
- Protein degradation (1)
- Protein domains (1)
- Protein kinase (1)
- Protein purify derivative (1)
- Protein tyrosine modification (1)
- Protein-Kinasen (1)
- Protein-Protein Interactions (1)
- Proteinkinase (1)
- Proteins (1)
- Proteostasis (1)
- Protestantism (1)
- Prothrombin complex concentrate (1)
- Protokoll-Compliance (1)
- Prototypes (1)
- Proximal humeral fracture (1)
- Präanalytik (1)
- Prädiktive Validität (1)
- Prävalenz (1)
- Prüfung (1)
- Prüfungen (1)
- Prüfungserfolg (1)
- Prüfungsfragen (1)
- Pseudo HE-images (1)
- Psoriasis (1)
- Psoriasis vulgaris (1)
- Psycho-oncology (1)
- Psychodynamic psychotherapy (1)
- Psychological stress (1)
- Psychometric evaluation (1)
- Psychometrics (1)
- Psychopathology (1)
- Psychophysiologie (1)
- Psychosocial (1)
- Public and occupational health (1)
- Publication (1)
- Publication output (1)
- Pulmonary artery pressure (1)
- Pulmonary disease, chronic obstructive (1)
- Pulmonary embolism (1)
- Pulmonary failure (1)
- Pulse contour analysis (1)
- Pulse pressure variation (1)
- Pulsed SILAC (1)
- Pupillometry (1)
- Pustulosis (1)
- Pyruvate (1)
- Pädiatrische Brandverletzung (1)
- QA/QC (1)
- QOL (1)
- Qb-Test (1)
- QbTest® (1)
- Qualitative research (1)
- Qualitative research [MeSH] (1)
- Quality indicators (1)
- Quality management (1)
- Quality of Teaching and Learning (1)
- Quality of health care [MeSH] (1)
- Quality, performance, safety and outcomes (1)
- Qualität (1)
- Qualitätsmanagement (1)
- Qualitätssicherung (1)
- Qualitätssicherung der Lehre (1)
- Quantitative research (1)
- Quantitative sensory testing (1)
- Quantitative trait (1)
- Quantitative trait loci (1)
- Questionnaire (1)
- Questionnaire - Psychometrics - Diagnostics (1)
- Quinine (1)
- Quinolinate phosphoribosyltransferase (1)
- Quinolinic acid (1)
- R (1)
- R programming language (1)
- R software (1)
- RAD001 (1)
- RBC (1)
- RBC-depletion (1)
- RBFOX1 (1)
- RCT (1)
- RD cells (1)
- RDoC (1)
- REM sleep (1)
- REMS (1)
- RH30 cells (1)
- RIP1 (1)
- RMS (1)
- RNA Biology (1)
- RNA extraction (1)
- RNA polymerase (1)
- RNA polymerase inhibitors (1)
- RNA processing (1)
- RNA processing machinery (1)
- RNA therapeutics (1)
- RNA therapy (1)
- RNA viruses (1)
- RNA, long noncoding (1)
- RNA-Interferenz (1)
- RNA-sequencing (1)
- RNA-templated DNA repair (1)
- RNActive (1)
- RNAi (1)
- RNAi and CRISPR screens (1)
- RNAseq analysis (1)
- RNF4 (1)
- ROS generation (1)
- ROS/RNS (1)
- ROS1 (1)
- RPE65 (1)
- RT-qPCR (1)
- RTS (1)
- RUFY (1)
- RULA (1)
- RUNX1/ETO (1)
- Rab proteins (1)
- Rab7 (1)
- Rac1 (1)
- Radial artery (1)
- Radiation exposure (1)
- Radiation induced diarrhoea (1)
- Radical cystectomy (1)
- Radical nephrectomy (1)
- Radiochemotherapy (1)
- Radiofrequency (1)
- Radiology and imaging (1)
- Radiyal arter (1)
- Rahmenbedingungen der Lehre (1)
- Rainfall (1)
- Raman spectroscopy (1)
- Ramón y Cajal (1)
- Random forest (1)
- Randomised controlled trial (1)
- Randomised trial (1)
- Randomized (1)
- Randomized controlled trials (1)
- Randomized trial (1)
- RapL (1)
- Rapamycin (1)
- Rapid diagnostic test (1)
- Rapid eye movement sleep behavior disorder (1)
- Rare Diseases (1)
- Rare disease (1)
- Ratewahrscheinlichkeit (1)
- Rational use (1)
- Re-exploration (1)
- Re-exposure (1)
- Re-injury (1)
- Readmission (1)
- Real-time phase contrast (1)
- Real-world data (1)
- Real-world evidence (1)
- RealTime (1)
- Rearing temperature (1)
- Recall rate (1)
- Receptor physiology (1)
- Reconstructed human epidermis (1)
- Reconstruction (1)
- Reconstructive surgical procedures (1)
- Recurrence (1)
- Recurrence rate (1)
- Red blood cells (1)
- Red yeast rice (1)
- Redox (1)
- Redox modification (1)
- Redox-sensitive GFP (1)
- Reference (1)
- Refractory ALL (1)
- Regenerative medicine (1)
- Regulatory T cells (1)
- Regulatory framework (1)
- Regulatory networks (1)
- Rehabilitation (1)
- Rehospitalization (1)
- Reintervention (1)
- Reisefieber (1)
- Rejection (1)
- Rekonstruktive chirurgische Verfahren (1)
- Relapse (1)
- Relapsed ALL (1)
- Relaxometry (1)
- Release of mtDNA and mtRNA (1)
- Remission (1)
- Remote ischemic conditioning (1)
- Remote monitoring (1)
- Renal cancer (1)
- Renal function (1)
- Renal lesions (1)
- Renal replacement therapy (1)
- Repatriation of corpses (1)
- Reperfusion (1)
- Replication study (1)
- Repositioning drugs (1)
- Reproducibility (1)
- Reproduktionsmedizin (1)
- Research Article (1)
- Research trends (1)
- Reservoir function (1)
- Residential care (1)
- Residential facilities (1)
- Resin composites (1)
- Resource competition (1)
- Respimat® Soft Mist™ Inhaler (1)
- Respiratory Syncytial Virus (1)
- Respiratory infections (1)
- Respiratory signs and symptoms (1)
- Respiratory syncytial virus (1)
- Respiratory tract diseases (1)
- Response (1)
- Response criteria (1)
- Ressourcen (1)
- Restenosis (1)
- Resting state (1)
- Resting-state (1)
- Restricted posture (1)
- Resuscitation (1)
- Reticulon (1)
- Retina (1)
- Retinal degeneration (1)
- Retro-IDEAL (1)
- Retrospective studies (1)
- Return to play (1)
- Return to sports (1)
- Reverse transcription polymerase chain reaction (1)
- Review (1)
- Rezidivrate (1)
- Rheumatology (1)
- Rho GTPases (1)
- Rho/Rho-kinase (1)
- RhoA (1)
- RhoGTPases (1)
- Ribosomal S6 phosphorylation (1)
- Ribosomal translation (1)
- Ribosomes (1)
- Right hemisphere (1)
- Risk assessment (1)
- Risk factor (1)
- Risk factors (1)
- Risk prediction (1)
- Risk reduction (1)
- Risk stratification (1)
- Rivaroxaban (1)
- Robotic Radiosurgery (1)
- Robotic tracking (1)
- Roe deer (1)
- Rolandic Spikes (1)
- Roma women (1)
- Rora (1)
- Roughness (1)
- Round window membrane (1)
- Routinedaten (1)
- Roux-en-Y gastric bypass (1)
- Rtn3 (1)
- Ruijs-Aalfs syndrome (1)
- Rural area (1)
- Rush (1)
- Rush protocol (1)
- Rush-SIT (1)
- Ruxolitinib (1)
- Ryanodine (1)
- S. cerevisiae (1)
- S100 calcium‑binding protein B (1)
- S100b (1)
- S1P lyase (1)
- S1P1 receptor (1)
- S1P1–5 (1)
- S1PR1 (1)
- S1PR4 (1)
- SAGE (1)
- SAH close (1)
- SAMHD1 (1)
- SAMHD1 knockout mouse (1)
- SAMHD1 phosphorylation (1)
- SAP (1)
- SARS coronavirus (1)
- SARS-CoV (1)
- SAVI (1)
- SCA34 (1)
- SCA38 (1)
- SCCHN (1)
- SCMR (1)
- SCT (1)
- SDF-1 (1)
- SDH (1)
- SDS (1)
- SENP (1)
- SENP6 (1)
- SERS (1)
- SF-36 (1)
- SHH (1)
- SIADH (1)
- SILAC (1)
- SIRT1 (1)
- SKI II (1)
- SLC20A1 (1)
- SLP-76 (1)
- SMAD (1)
- SMAD signaling (1)
- SNP (1)
- SOCS (1)
- SOD (1)
- SOFA (1)
- SPARTAN (1)
- SPRTN (1)
- SPSS (1)
- SR protein (1)
- SR-BI (1)
- SRSF3 (1)
- SRSF7 (1)
- ST2L (1)
- STAMPE2 (1)
- STAT1 (1)
- STAT5 (1)
- STDP (1)
- STIR (1)
- SUMO (1)
- SUMO chains (1)
- SUMO1-3 (1)
- SUMOylation (1)
- SUN1 (1)
- SUN2 (1)
- SUV (1)
- SVR (1)
- SW480 Cell (1)
- SW480 cells (1)
- SWATH (1)
- Saccades (1)
- Saccadometry (1)
- Safety equipment (1)
- Safety learning (1)
- Salivary gland diseases (1)
- Salmonella choleraesuis (1)
- Salmonella infection (1)
- Salt inducible kinase 2 (SIK2) (1)
- Salvage therapy (1)
- Sarcomas (1)
- Sarcopenia (1)
- Sarkoidose (1)
- Sauerstoffpartialdruck (1)
- Scedosporium spp. (1)
- Scheimpflug imaging (1)
- School support (1)
- Science structure (1)
- Scientifi c competence (1)
- Scientific community (1)
- Scientific publishing (1)
- Scientometria (1)
- Scientometric analysis (1)
- Scientometrics (1)
- Scientometry (1)
- Sclerostin (1)
- Screening guidelines (1)
- Seattle heart failure model (1)
- Second stage of labor (1)
- Second-line treatment (1)
- Secondary injury cascades (1)
- Secondary prevention (1)
- Secretion (1)
- Seizure (1)
- Seizures (1)
- Selection bias (1)
- Selective autophagy (1)
- Selenium (1)
- Selenium administration in gynecologic radiation oncology (1)
- Selenoproteins (1)
- Self-assessment (1)
- Self-efficacy (1)
- Self-expandable metal stent (SEMS) (1)
- Self-expandable metal stents (1)
- Self-expandable metal stents complications (1)
- Self-management support (1)
- Self-myofascial release (1)
- Self-renewal (1)
- Self-report (1)
- Seltene Erkrankungen (1)
- Semicontinuous (1)
- Semitendinosus tendon autograft (1)
- Sensitivity (1)
- Sensorimotor processing (1)
- Sensorimotor training (1)
- Sensory Neuroscience (1)
- Sensory neuron (1)
- Sensory perception (1)
- Sensory systems (1)
- Sepsis-bundle (1)
- Septic shock (1)
- Sequence (1)
- Sequence alignment (1)
- Sequence motif analysis (1)
- Sequential (1)
- Seribantumab (1)
- Serine proteases (1)
- Seroconverter (1)
- Seroepidemiology (1)
- Seroprevalence (1)
- Serotype 3 (1)
- Serum (1)
- Serum Susceptibility (1)
- Severe Acute Respiratory Syndrome (1)
- Severe bacterial infection (1)
- Severe blood loss (1)
- Severe malaria (1)
- Severity of illness index (1)
- Sex (1)
- Sexual Dysfunctions (1)
- Sexual child abuse (1)
- Sexual violence (1)
- Sexualmedizin (1)
- Sexuelle Dysfunktionen (1)
- Sexuelle Gewalt (1)
- Sexuelle Revolution (1)
- Sexueller Kindesmissbrauch (1)
- Shannon index (1)
- Sharpin (1)
- Sholl analysis (1)
- Shone’s complex (1)
- Short bowel syndrome (1)
- Shoulder joint (1)
- Shunt (1)
- Sickle Cell Disease (1)
- Signal Transduction (1)
- Signal transduction (1)
- Signaling ROS (1)
- Signaling pathway (1)
- Silicosis (1)
- Silver in situ hybridization (1)
- Simulation and modeling (1)
- Simulation komplexer Systeme (1)
- Simulation training (1)
- Simultaneous (1)
- Single-Molecule Localization Microscopy (SMLM) (1)
- Single-cell RNA-seq (1)
- Single-cell RNA-sequencing (1)
- Sistemas de Saúde (1)
- Skeletal muscle (1)
- Skills training (1)
- Skin fibroblast (1)
- Skin irritation test (1)
- Skin manifestation (1)
- Skin morphology (1)
- Skp (1)
- Slc11a2 (1)
- Slc25a37 (1)
- Sleep deprivation (1)
- Smac mimetic (1)
- Small bowel (1)
- Small bowel atresia (1)
- Small bowel endoscopy (1)
- Small molecules (1)
- Small- and medium-sized enterprises (1)
- Small-cell lung cancer (1)
- Smart nebulizer (1)
- Smoking habits (1)
- Smooth muscle (1)
- Smooth muscle cell (1)
- Snakebite (1)
- Social Media (1)
- Social communication (1)
- Social epidemiology (1)
- Social health determinants (1)
- Social information processing (1)
- Social phobia (1)
- Social research (1)
- Social sciences (1)
- Social skills training (1)
- Social support (1)
- Socio-economic analysis (1)
- Soft skills (1)
- Soft tissue infection (1)
- Soft-tissue sarcoma (1)
- Software tool (1)
- Software tools (1)
- Solidworks 2015 (1)
- SoloSTAR (1)
- Somatization (1)
- Sonication (1)
- Source reconstruction (1)
- Sozialpsychiatrischer Dienst (1)
- Spa water (1)
- Spanish National Health System (1)
- Species identification (1)
- Speciesidentification (1)
- Specimen preparation and treatment (1)
- Spectral library (1)
- Spectraldomain OCTA (1)
- Spectrin (1)
- Speech (1)
- Speech signal processing (1)
- Sphere Formation Assay (1)
- Sphingolipid (1)
- Sphingosine 1-phosphate (1)
- Sphingosine-1-phosphate (1)
- Spinal cord (1)
- Spine Register (1)
- Spine density (1)
- Spinocerebellar ataxia (1)
- Spirochetes (1)
- Splanchnic Hemodynamics (1)
- Spleen (1)
- Splenic dendritic cell (1)
- Splice variants (1)
- Spondyloarthritis (1)
- Spondylolisthesis (1)
- Spontaneous bacterial peritonitis (1)
- Sports (1)
- Spot sign (1)
- Squamous cell carcinoma (1)
- StUbL (1)
- Staatsexamen (1)
- Standard risk (1)
- Standardized operating procedures (1)
- Standards of care (1)
- Standardverfahren (1)
- Staphylococcus aureus (1)
- Starvation (1)
- Statistical methods (1)
- Status epilepticus (1)
- Stavudine (1)
- Steatosis (1)
- Stenosis (1)
- Stenotrophomonas maltophilia (1)
- Stentoplasty (1)
- Sterblichkeit (1)
- Stereotactic radiosurgery (1)
- Steroid (1)
- Stilbene (1)
- Stimulation experiments (1)
- Stimulus-secretion coupling (1)
- Stoma (1)
- Stress (1)
- Stress and resilience (1)
- Stress resilience (1)
- Striatum (1)
- Stringed bow player (1)
- Stroke prevention (1)
- Stroke volume variation (1)
- Stromal cell (1)
- Structural MRI (1)
- Structural genomics (1)
- Structured reporting (1)
- Strukturwandel der Sexualität (1)
- Students (1)
- Studiendauer (1)
- Studium mit Kind (1)
- Störfaktoren (1)
- Sub-segmentation (1)
- Subacute cerebellar degeneration (1)
- Subarachnoid Hemorrhage (1)
- Subcutaneous (1)
- Subgroup identification (1)
- Subpopulation (1)
- Substances for disinfection (1)
- Subterranean (1)
- Sudden cardiac death (1)
- Suicidal behavior (1)
- Suicidal ideation (1)
- Suicidal thoughts (1)
- Sulfasalazine (1)
- Sulfhydryl-reactivity (1)
- Sulfur metabolism (1)
- Sumatra (1)
- Superimposition (1)
- Superinfection (1)
- Supplemental parenteral nutrition (1)
- Supplementation (1)
- Supraspinatus tendon (1)
- Supraventricular arrhythmias (1)
- Surface (1)
- Surgical ICU (1)
- Surgical risk (1)
- Surgical site occurrence (1)
- Surveillance (1)
- Surveys (1)
- Survival data (1)
- Sustainable Development (1)
- Sustained virological response (SVR) (1)
- Sweat osmolality (1)
- Sweat secretion rate (1)
- Swept-source OCTA (1)
- Switzerland (1)
- Sycamore (1)
- Syllables (1)
- Sympathicolysis (1)
- Symptome (1)
- Symptoms (1)
- Synapses (1)
- Synaptic dysfunction (1)
- Synaptopodin (1)
- Syncope (1)
- Syndrome des ovaires polykystiques (1)
- Synovial inflammation (1)
- Synovial sarcoma (1)
- Synthetic (1)
- Systematic review (1)
- Systemic inflammatory response (1)
- Systemic lupus erythematosus (1)
- Systemic treatment (1)
- Systems biology (1)
- Systems medicine (1)
- T Cells (1)
- T cell receptors (1)
- T cell/histiocyte rich large B cell lymphoma (1)
- T helper 17 cells (1)
- T-ALL (1)
- T-DM1 (1)
- T-cell homeostasis (1)
- T-cell homing (1)
- T-cell niche (1)
- T-cell receptor (1)
- T-cell targeting (1)
- T-cells (1)
- T-lymphocytes (1)
- T-tubule system (1)
- T1 (1)
- T1 and T2 mapping (1)
- T1 mapping (1)
- T84 colon carcinoma cells (1)
- TACE (1)
- TALE-homdomain protein (1)
- TAPSE (1)
- TAVI (1)
- TAVR (1)
- TAX1BP1 (1)
- TBK1 (1)
- TC stenosis (1)
- TCR signaling cascade (1)
- TEER (1)
- TEM (1)
- TEVAR (1)
- TG-186 (1)
- TG-43 (1)
- TGF-beta (1)
- TGF-β (1)
- TGF-β1 (1)
- THV (1)
- TIA-1 (1)
- TIC10 (1)
- TILs (1)
- TIM23 (1)
- TIMP2 (1)
- TL AOSIS (1)
- TLR (1)
- TLR2/6 (1)
- TLR7 (1)
- TLR8 (1)
- TMC435 (1)
- TMEM126B (1)
- TMS (1)
- TMS-EEG (1)
- TMT (1)
- TNF (1)
- TNF inhibitors (1)
- TNF-α (1)
- TNFR1 (1)
- TOR inhibitor (1)
- TOR1A (1)
- TP53 (1)
- TP53 mutation status (1)
- TP53-induced glycolysis and apoptosis regulator (1)
- TPR (1)
- TRAPP (1)
- TRIM25 (1)
- TRPA1 (1)
- TSC (1)
- TSC-associated neuropsychiatric disorders (1)
- TSC22D3 (1)
- TVT (1)
- TWINKLE (1)
- Tabakkonsum (1)
- Tagging (1)
- Tailored medicine (1)
- Tailored therapy (1)
- Tamponade (1)
- Targeted therapies (1)
- Targeted tumor therapy (1)
- Tas2r126 (1)
- Tas2r135 (1)
- Tas2r143 (1)
- Tattoo (1)
- Tau (1)
- Tau acetylation (1)
- Tax effect (1)
- Taxane (1)
- Taxonomy (1)
- Tea (1)
- Teaching and Learning conditions (1)
- Technicians (1)
- Technique (1)
- Telemedicine (1)
- Telomere length (1)
- Telomeres (1)
- Temozolomide (1)
- Temporal lobe epilepsy (1)
- Temsirolimus (1)
- Tendon incontinence repair (1)
- Tendon transplantation (1)
- Term birth (1)
- Testosterone (1)
- Tet-inducible system (1)
- Texture analysis (1)
- Tfrc (1)
- Tgfβ (1)
- Th1 polarization (1)
- Theft (1)
- Theorie der Sexualität (1)
- Therapeutics (1)
- Therapy response (1)
- Thermal injury (1)
- Thermal spring water (1)
- Thermische Verletzung (1)
- Thermodilution (1)
- Thermoplasma (1)
- Thiol redox modification (1)
- Three-dimensional back scan (1)
- Three-dimensional echocardiography (1)
- Thrombosis/hypercoagulable states (1)
- Thrombotic microangiopathy (1)
- Thrombotic thrombocytopenic purpura (1)
- Thromboxane (1)
- Thymocytes (1)
- Thymus (1)
- Thyroid (1)
- Thyroid disease (1)
- Tick (1)
- Tick-Borne diseases (1)
- Tick-borne encephalitis (1)
- Ticks (1)
- Time in therapeutic range (TTR) (1)
- Time optimization (1)
- Time series (1)
- Time to treatment failure (1)
- Timing (1)
- Tinnitus (1)
- Tissue microarray (TMA) (1)
- Tissue stiffness (1)
- Toll-like receptor (TLR) 6 (1)
- Toll-like receptors (1)
- Tomography (1)
- Tonsil (1)
- Tools and ressources (1)
- Tooth transplantation (1)
- Topoisomerase (1)
- Total colonoscopy (1)
- Total hip replacement (1)
- Total operating room time (1)
- Toxicology (1)
- Tozasertib (1)
- Tracheal Intubation (1)
- Tranexamic acid (1)
- Transcatheter Aortic Valve Implantation (1)
- Transcatheter based aortic valve implantation (1)
- Transcription (1)
- Transcriptional control (1)
- Transcriptome (1)
- Transcriptome analysis (1)
- Transcriptome microarray (1)
- Transduction (1)
- Transesophageal echocardiography (1)
- Transfer model (1)
- Transferases (1)
- Transformation (1)
- Transgender (1)
- Transgenic SK-2 mice (1)
- Transient (1)
- Transient elastography (1)
- Transient ischemic attack (1)
- Transition invariant (1)
- Transitional cell carcinoma (1)
- Translation initiation (1)
- Translational (1)
- Transmembrane communication (1)
- Transplantation (1)
- Transportation (1)
- Trastuzumab (1)
- Trauma surgery (1)
- Traumatic brain injury (1)
- Travellers (1)
- Treatment modification (1)
- Treatment protocol (1)
- Trees (1)
- Treg cell (1)
- Triamcinolone acetonide (1)
- Trichuris suis ova (1)
- Triple negative (1)
- Triple therapy (1)
- Triple-negative breast cancer (1)
- Trk (1)
- TrkC (1)
- Tropenmedizin (1)
- Troponin (1)
- Trousseau’s syndrome (1)
- Trueness (1)
- Tubers (1)
- Tularemia (1)
- Tumor growth (1)
- Tumor heterogeneity (1)
- Tumor infiltrating lymphocytes (1)
- Tumor interstitial fluid pressure (1)
- Tumor obstruction (1)
- Tumor suppressor protein (1)
- Tumor volume (1)
- Tumormarker (1)
- Tumorsphere Formation (1)
- Tumour biomarkers (1)
- Tumour immunology (1)
- Turkish (1)
- Tween20 (1)
- Twist (1)
- Two-hit hypothesis (1)
- Type 2 Diabetes mellitus (1)
- Type 2 diabetes (1)
- Tyrosine kinase inhibitor (1)
- Tyrosine kinase inhibitor mTOR inhibition (1)
- Tyrosine kinases (1)
- U-87MG (1)
- UDP-glucose ceramide glycosyltransferase (1)
- UGCG (1)
- ULBP4 (1)
- UPPS (1)
- USP9X (1)
- UVA (1)
- UWB diagnostics (1)
- Ubiquitin (1)
- Ubiquitin Ligase (1)
- Ubiquitin kinase PINK1 (1)
- Ubiquitylation (1)
- Ultra microscopy (1)
- Ultra-rush protocol (1)
- Ultrasonic nebulizer (1)
- Ultrasound imaging (1)
- Umbilical cord (1)
- Underfeeding (1)
- Undergraduate medical education (1)
- Undergraduate training (1)
- Undergraduates (1)
- Unilateral hip osteoarthritis (1)
- United States (1)
- União Européia (1)
- Unterdruckwundtherapie (1)
- Upper body posture (1)
- Upper respiratory tract infection (1)
- Urban (1)
- Ureter (1)
- Urethral cancer (1)
- Urothelial cancer (1)
- Urothelial carcinoma (1)
- Urothelial cells (1)
- Urticaria (1)
- Usutu virus (1)
- Uveal melanoma (1)
- V4 (1)
- VARGADO (1)
- VASP (1)
- VBM (1)
- VE-cadherin (1)
- VEGF receptors (1)
- VEGFA (1)
- VEGFR (1)
- VEGFR-2 (1)
- VEGFR-3 (1)
- VHH (1)
- VIP (1)
- VIP1 (1)
- VIS (1)
- VISTA (1)
- VLA4 (1)
- VPA-analogues (1)
- VPAC1 (1)
- VRE (1)
- VX680 (1)
- Vaccination breakthrough (1)
- Vaccine (1)
- Vaccine breakthrough (1)
- Vacuoles (1)
- Vaginal breech delivery (1)
- Vaginal delivery (1)
- Validierungsstudie (1)
- Validity (1)
- Value-added effect (1)
- Variant histology (1)
- Vascular biology (1)
- Vascular emergencies (1)
- Vascular endothelial growth factor A (1)
- Vascular endothelial growth factor receptor 2 (1)
- Vascular permeability (1)
- Vasculogenesis (1)
- Vector mosquito (1)
- Vector-borne infections (1)
- Vein (1)
- Veino-lymphatic separation (1)
- Vemurafenib (1)
- VeroE6‐eGFP cells (1)
- Versorgungsforschung (1)
- Versorgungsstrukturen (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Vertigo (1)
- Veränderungsmanagement (1)
- Vespid venom allergy (1)
- Victimization (1)
- Video-oculography (1)
- Videolaryngoscopy (1)
- Vincristine (1)
- VirB (1)
- Viral Load (1)
- Viral core (1)
- Viral infection (1)
- Viral replication (1)
- Virchow-Robin Spaces (1)
- Virological Failure (1)
- Virological Response (1)
- Virological failure (1)
- Virotherapy (1)
- Virtual implant planning (1)
- Visual impairments (1)
- Visual quality (1)
- Visual system (1)
- Vitamin (1)
- Vitamin K antagonists (1)
- Vitreous opacity (1)
- Vitreous samples (1)
- Voltage attenuation (1)
- Volume overload (1)
- Volumetric analysis (1)
- Volumetric indexes (1)
- Voriconazole (1)
- Vorkenntnisse (1)
- Vorklinik (1)
- Voxel-based morphometry (1)
- WNT (1)
- WRNIP1 (1)
- WT1 (1)
- WYE-354 (1)
- Wait and see (1)
- Wakefulness (1)
- Water chemistry (1)
- Weak bases (1)
- Wearable cardioverter‐defibrillator (1)
- Web 2.0 (1)
- Weight loss (1)
- West Nile fever (1)
- West Nile neuroinvasive disease (1)
- West Nile virus (1)
- Westphal-Paradigm (1)
- White blood cells (1)
- Whole genome association (1)
- Willensfreiheit (1)
- Wilms tumor (1)
- Wing morphometry (1)
- Wnt (1)
- WoMo score (1)
- Women in medicine (1)
- Women in science (1)
- Work shadowing (1)
- Workplace (1)
- Workplace ergonomics (1)
- Wound healing potential (1)
- X-ray Crystallography (1)
- X-ray crystallography (1)
- XL probe (1)
- Xenorhabdus (1)
- YB-1 (1)
- YK-4-279 (1)
- YM155 (1)
- YWHAE (1)
- YWHAZ (1)
- Yarrowia lipolytica (1)
- Yarrowia lipolytica mitochondrial genome complex I NADH: ubiquinoneoxidoreductase (1)
- Yellow fluorescent protein (1)
- Zebrafish (1)
- Zellbiologie (1)
- Zellulärer Transport (1)
- Zervixverkürzung (1)
- Zika (1)
- Zika fever (1)
- Zika vaccine (1)
- Zirconia (1)
- Zoopotentation (1)
- Zooprophylaxis (1)
- Zulassung zum Medizinstudium (1)
- Zulassungskriterien (1)
- Zwangseinweisungen (1)
- a disintegrin and metalloprotease 10 (ADAM10) (1)
- abdominal imaging (1)
- abemaciclib (1)
- ablation (1)
- ablation techniques (1)
- abnormal tumor vasculature (1)
- abuso (1)
- academic (1)
- academic medicine (1)
- acceptable change limit (1)
- accident (1)
- accidental falls [MeSH] (1)
- accidents (1)
- acetylation (1)
- acetylcholine binding protein (1)
- acetylcholine receptors (1)
- acetylcholinesterase (1)
- acetylcholinesterase (AChE) inhibition (1)
- acetylcholinesterase inhibition (1)
- acid dentine lysate (1)
- acid sphingomyelinase (ASMase; Smpd1) (1)
- acneiform skin toxicity (1)
- acoustic radiation force impulse imaging (1)
- acquired drug resistance (1)
- actin cytoskeleton (1)
- actin dynamics (1)
- action sounds (1)
- action-effect association (1)
- activation receptors (1)
- active/deactive transition (1)
- activities of daily life (1)
- activity-based benefits (1)
- actography (1)
- acupuncture (1)
- acute and chronic graft versus host disease (a/c GVHD) (1)
- acute attacks (1)
- acute cholecystitis (1)
- acute chronic inflammation (1)
- acute coronary syndromes (1)
- acute decompensation of cirrhosis (1)
- acute exacerbations of COPD (1)
- acute inflammation (1)
- acute leukemia (1)
- acute liver failure (1)
- acute liver injury (1)
- acute lung injury (ALI) (1)
- acute lymphatic leukemia (1)
- acute lymphoblastic leukaemia (1)
- acute myeloid leukemia (AML) (1)
- acute respiratory distress syndrome (1)
- acute-on-chronic liver failure (ACLF) (1)
- acute‐on‐chronic liver failure (1)
- adaptation plan (1)
- adaptive cardiac remodelling (1)
- adaptive immune escape (1)
- adaptive immunity (1)
- adeno-associated virus (1)
- adenocarcinoma (1)
- adenomatous polyposis (1)
- adenosine receptors (1)
- adeno‐associated virus (1)
- adipocytes (1)
- adiponectin (1)
- adipose tissue (1)
- adipose tissue-derived stem cell (1)
- adipose-derived stem cells (1)
- adipose-derived stem cells (ASCs) (1)
- adiposity (1)
- adjustment disorder (1)
- adjuvant chemotherapy (1)
- adjuvant radiotherapy (1)
- admission criteria (1)
- adolescence (1)
- adolescentes (1)
- adolescents’ health (1)
- adoptive cell therapy (1)
- adoptive immunotherapy (1)
- adrenal insuffciency (1)
- adrenoceptors (1)
- adult and elderly patients (1)
- adult attention deficit/hyperactivity disorder (adult ADHD) (1)
- adult congenital heart disease (1)
- adult neurogenesis (1)
- advance directive (1)
- advanced breast cancer (1)
- advanced glycation end products (1)
- adverse effects (1)
- adverse events (1)
- aerobic exercise (1)
- aerodynamics (1)
- aerosol (1)
- aesthetics (1)
- affective disorder (1)
- affective disorders (1)
- affinity purification (1)
- affordance (1)
- aftercare structures (1)
- aged [MesH] (1)
- aggressiveness (1)
- agonists (1)
- air pollution (1)
- air pouch (1)
- airborne bacteria (1)
- airway (1)
- airway remodeling (1)
- alcohol dehydrogenase (ADH) (1)
- alcohol metabolism (1)
- alcohol use disorder (1)
- alcoholic liver disease (1)
- alcoholic liver injury (1)
- aliphatic halogenated hydrocarbons (1)
- alkaloid (1)
- all-ceramic (1)
- alleles (1)
- allergen immunotherapy (1)
- allergic rhinitis (1)
- allergy (1)
- alloHSCT (1)
- allocation (1)
- allogeneic (1)
- allogeneic hematopoietic stem cell transplantation (1)
- allogeneic hematopoietic stem cell transplantation (aHSCT) (1)
- allogeneic transplantation (1)
- allosteric inhibition (1)
- allosteric regulation (1)
- alpha band (1)
- alpha peak (1)
- alpha-synuclein (1)
- alpharetroviral vector (1)
- alpinia zerumbet (1)
- alternative 3′ end processing (1)
- alternative oxidase (1)
- alveolar macrophages (1)
- alzheimer disease (1)
- ambiguity (1)
- amblyopia (1)
- ameloblastoma (1)
- amino acid PET (1)
- amino acids (1)
- amlexanox (1)
- amoeboid (1)
- amoxicillin/metronidazole (1)
- amphiregulin (1)
- amygdala (1)
- amyloid beta-peptides (1)
- amyotrophic lateral sclerosis (ALS) (1)
- anaesthesia in orthopaedics (1)
- anaesthetics (1)
- anal carcinoma (1)
- analgesia based sedation (1)
- anaphylactic reactions (1)
- anaplastic large cell lymphoma (1)
- anastomotic leakage (1)
- anatomy (1)
- anatomy and histology (1)
- anemia (1)
- anesthesiology (1)
- angio-immunogenic switch (1)
- angiography (1)
- angioplasty (1)
- angiopoietin-2 (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- angiopoietins (1)
- angiostasis (1)
- animal host (1)
- animal model (1)
- anisotropy (1)
- annual bleeding rate (1)
- anorexia nervosa (1)
- anoxygenic phototrophic sulfur bacteria (1)
- antenatal characteristics (1)
- antenatalne značilnosti (1)
- anterior chamber depth changes (1)
- anti-GD2 immunotherapy (1)
- anti-cancer therapy (1)
- anti-chronic myeloid leukemia (1)
- anti-citrullinated protein antibodies (1)
- anti-diabetes (1)
- anti-epileptic drug (1)
- anti-inflammatory (1)
- anti-inflammatory agents (1)
- anti-inflammatory effects (1)
- anti-retroviral agents (1)
- anti-skin aging (1)
- anti-tumor activity (1)
- antibiotic (1)
- antibiotic treatment (1)
- antibody (1)
- antibody tests (1)
- anticancer agents (1)
- anticholinergic burden (1)
- anticoagulants (1)
- anticoagulation (1)
- anticonvulsant (1)
- anticonvulsant activity (1)
- antidepressants (1)
- antiepileptic drug (1)
- antifibrotic therapy (1)
- antifungal activity (1)
- antifungal combination therapy (1)
- antifungal host response (1)
- antifungal management (1)
- antifungal prophylaxis (1)
- antifungal therapy (1)
- antigen (1)
- antigenic variation (1)
- antigens of infectious origin (1)
- antihormone therapy (1)
- antimicrobial activity (1)
- antioxidant (1)
- antioxidant activity (1)
- antioxidant defense (1)
- antiproliferative activity (1)
- antireflux surgery (1)
- antiresorptive agents (1)
- antiseizure (1)
- antisense oligonucleotides (1)
- antisynthetase antibodies (1)
- antisynthetase syndrome (1)
- antitumor immunity (1)
- antiviral drugs (1)
- antiviral peptide (1)
- anxiety (1)
- apical junction (1)
- apigenin (1)
- apixaban (1)
- apparent diffusion constant (1)
- apparent motion (1)
- apps (1)
- aprotinin (1)
- aptamer (1)
- aquaporin 1 (1)
- aquaporin-4 (AQP4) antibody (1)
- arachidonate 15-lipoxygenase (1)
- arachidonic acid (1)
- archaea (1)
- archaeosomes (1)
- architecture (1)
- arm (1)
- aromatics (1)
- arsenic trioxide (1)
- arterial hypertension (1)
- artery (1)
- artesunate (ART) (1)
- articulatory motor cortex (1)
- artificial neural networks (1)
- aspirin (1)
- assay development (1)
- assessment (1)
- associative memory (1)
- asthma phenotypes (1)
- astrocyte (1)
- astrocyte heterogeneity (1)
- astroglia (1)
- asymmetric hearing (1)
- asymptomatic (1)
- ataxia score (1)
- athletes (1)
- athletic training (1)
- atopy (1)
- atrial septostomy (1)
- atrophy (1)
- attachment loss (1)
- attention deficit hyperactivity disorder (1)
- attention modulation (1)
- attention-deficit/hyperactivity disorder (1)
- attention-deficit/hyperactivitydisorder (1)
- attractiveness (1)
- auditory cortex (1)
- auditory development (1)
- auditory language processing (1)
- auditory prediction (1)
- auditory system (1)
- augmentation materials (1)
- authentication (1)
- authorship (1)
- autism (1)
- autistic disorder (1)
- auto-structure (1)
- autoantibodies (1)
- autoantigen (1)
- autograft (1)
- autoimmune encephalomyelitis (1)
- autoimmune polyglandular syndrome type 2 (1)
- autoimmune thyroiditis (1)
- automated patch-clamp (1)
- automatic environmental tobacco smoke emitter (1)
- automation (1)
- autophagic cell death (1)
- autopsy (1)
- autoreactivity (1)
- autovaccine (1)
- avelumab (1)
- aviscumine (1)
- axon (1)
- azaindole (1)
- b-cell lymphomas (1)
- back pain (1)
- back scan (1)
- bacteria (1)
- bacterial translocation (1)
- bacterium (1)
- baicalein (1)
- balanced state (1)
- balloon pulmonary angioplasty (1)
- baroreflex (1)
- barriers to implementation (1)
- basal cell carcinoma (1)
- basal insulin (1)
- basic leucine zipper transcription factor ATF-like (1)
- basic mechanisms (1)
- basonuclin 2 (1)
- beads (1)
- beam quality correction factors (1)
- behavioral adverse events (1)
- behavioral performance (1)
- belimumab (1)
- bendamustine (1)
- berotralstat (1)
- beta band (1)
- beta blockade (1)
- betamethasone dipropionate (1)
- beta‐trace protein (1)
- bibliometric analysis (1)
- bicuspid aortic valve (1)
- biglycan (1)
- bile duct stenosis (1)
- biliary cirrhosis (1)
- binary search procedure (1)
- binaural cochlear implants (1)
- binding (1)
- bio imaging (1)
- bio-absorbable mesh (1)
- bioacoustics (1)
- bioactive phospholipids (1)
- bioactive phytochemicals (1)
- bioactivity (1)
- biobank (1)
- biochanin A (1)
- biochemical recurrence (1)
- biochemistry (1)
- bioenergetics (1)
- biofilm (1)
- biokompatibilni materijali (1)
- biological maturation (1)
- biological mesh (1)
- biological transport (1)
- biological treatments (1)
- biologically inspired computing (1)
- biologicals (1)
- bioluminescence (1)
- biomarker study (1)
- biomechanics (1)
- biopsy naïve (1)
- bipolar disorders (1)
- birch pollen allergoid (1)
- bistable (1)
- bladder cancer (1)
- bladder cancer (BCa) (1)
- bladder dose (1)
- bladder exstrophy-epispadias complex (1)
- blastic plasmacytoid dendritic cell neoplasm (1)
- blended learning (1)
- bleomycin (1)
- blood consumption (1)
- blood donor (1)
- blood flow recovery (1)
- blood hiv rna (1)
- blood loss (1)
- blood safety (1)
- blood transfusion (1)
- blood-brain barrier (1)
- blood-cerebrospinal fluid barrier (1)
- blow flies (1)
- blow fly (1)
- bmal1 (1)
- body dysmorphic disorder (1)
- body plethysmography (1)
- body posture (1)
- bone (1)
- bone chips (1)
- bone damage (1)
- bone loss (1)
- bone marrow (1)
- bone marrow derived mononuclear cells (1)
- bone marrow metastasis (1)
- bone marrow microenvironment (1)
- bone marrow mononuclear cells (1)
- bone metastasis (1)
- bone morphogenetic protein-2 (1)
- bone morphogenetic proteins (BMPs) (1)
- bone regeneration (1)
- bone substitute material (1)
- bone substitutes (1)
- bone tissue regeneration (1)
- bone-marrow (1)
- bone‐screw (1)
- bone–implant interface (1)
- borrelia mayonii (1)
- bortezomib (1)
- bottom-up (1)
- brachytherapy imaging methods (1)
- brain anatomy (1)
- brain function (1)
- brain injury (1)
- brain metastasis (1)
- brain networks (1)
- brain oscillations (1)
- brain phosphorylome (1)
- brain structure (1)
- brain tumor (1)
- brainmass (1)
- brainsize (1)
- branched-chain amino acids (BCAA) (1)
- breakpoint cluster region (1)
- breast cancer diagnosis (1)
- breast cancer systemic therapy (1)
- breast cancer treatment (1)
- breech (1)
- broad-range qPCR (1)
- broadly neutralizing antibodies (1)
- bronchial allergen challenge (1)
- bronchial allergen provocation (1)
- bronchiolitis obliterans syndrome (1)
- bronchodilator (1)
- buccal mucosa (1)
- buccal mucosal graft urethroplasty (1)
- bulimia nervosa (1)
- bullying (1)
- bundle (1)
- butyrylcholinesterase (1)
- c-kit (1)
- c1orf124 (1)
- cBioPortal (1)
- cFLIP (1)
- cGAS-STING (1)
- cHL (1)
- cIAP1 (1)
- cIAP1 BIR (1)
- cIAP1/2 (1)
- cadherin (1)
- calbindin (1)
- calcification score (1)
- calcipotriol (1)
- calcium handling (1)
- calcium-independent phospholipase A2β (1)
- calcium-sensor (1)
- callous-unemotional traits (1)
- caloric restriction (1)
- calprotectin (1)
- calretinin-knock out (1)
- cancer and drug vulnerabilities (1)
- cancer care (1)
- cancer care providers (1)
- cancer cell malignancy (1)
- cancer cell metabolism (1)
- cancer cells (1)
- cancer drug (1)
- cancer immunobiology (1)
- cancer patients (1)
- cancer screening (1)
- cancer therapy (1)
- cancer-associated fibroblasts (1)
- cancer-specific survival (1)
- candidate genes (1)
- candidemia (1)
- cannabidiol (1)
- cannabinoid receptor type 1 (1)
- cannabinoids (1)
- cannabis (1)
- canonical (1)
- canonical/non-canonical (1)
- cap-dependent translation (1)
- car indoor (1)
- carbapenem resistance (1)
- carbapenem-resistant Gram-negative bacteria (CRGN) (1)
- carbon oxides (COx) (1)
- carbon tetrachloride (1)
- carboxyfluorescein (1)
- carcinoma (1)
- cardiac I/R injury (1)
- cardiac arrest (1)
- cardiac events (1)
- cardiac ischaemia‐reperfusion (1)
- cardiac magnetic (1)
- cardiac myocytes (1)
- cardiac rehabilitation (1)
- cardiomegaly (1)
- cardiomyopathy (1)
- cardiovascular diseases (1)
- cardiovascular magnetic resonance (1)
- cardiovascular pharmacology (1)
- cardiovascular precision medicine (1)
- cardiovascular risk factors (1)
- career promotion (1)
- caregivers (1)
- carnitine supplementation (1)
- carotid (1)
- carpal tunnel syndrome (1)
- carrion (1)
- cartilage oligomeric matrix protein (1)
- cartilage trauma (1)
- case reports (1)
- case study (1)
- case-control study (1)
- caspase 8 (1)
- caspase-1 (1)
- cataract surgery (1)
- catheter (1)
- catheter removal (1)
- catheterization/diagnostic interventional (1)
- causality assessment (1)
- cd4 count determination procedure (1)
- cdk (1)
- cdk2/cyclin A (1)
- ceRNA (1)
- celery (1)
- celiac desease (1)
- cell adhesion (1)
- cell and focal adhesion (1)
- cell cycle (1)
- cell cycle arrest (1)
- cell cycling (1)
- cell fate (1)
- cell fusion (1)
- cell growth (1)
- cell identity (1)
- cell line (1)
- cell salvage (1)
- cell signaling (1)
- cell survival (1)
- cell survival mechanisms (1)
- cell transplantation (1)
- cellular immunology (1)
- cellular reaction (1)
- cellular response (1)
- cellular signalling (1)
- cellular therapy (1)
- centenarians (1)
- central nervous system (1)
- central nervous system infection (1)
- centrifugation (1)
- ceramide synthase (CERS2/CERS1) (1)
- cerclage (1)
- cerebellar mutism (1)
- cerebello-dentato-thalamo-cortical pathway (1)
- cerebral infarct (1)
- cerebral radiation necrosis (1)
- cerebrovascular disease (1)
- ceritinib (1)
- cervical shortening (1)
- cervical spine (1)
- cervico-thoracic junction (1)
- cetuximab-bevacizumab therapy sequence (1)
- ch14.18/CHO (1)
- chamomile (1)
- changes immune activation (1)
- chaperones (1)
- characterization (1)
- charged particles (1)
- checklist (1)
- checkpoint inhibition (1)
- checkpoint proteins (1)
- chelation therapy (1)
- chemical-induced proximity (1)
- chemoattractant (1)
- chemoconvulsant (1)
- chemoembolization (1)
- chemogenomic set (1)
- chemokine (1)
- chemokine receptor 4 (1)
- chemokine receptors (1)
- chemokines (1)
- chemokines: CYP2D6 model (1)
- chemoprevention (1)
- chemosensory cells (1)
- chemotaxis (1)
- chemotherapeutic drug resistance (1)
- chemotherapeutics (1)
- chemotherapeutics-treated (1)
- chemotherapy regimen (1)
- chemotherapy-resistance (1)
- chest injury (1)
- child abuse and neglect (1)
- child maltreatment (1)
- child psychiatry (1)
- childhood (1)
- childhood abuse (1)
- childhood cancer (1)
- children and adolescents (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- chinese medicine (1)
- chloroplasts (1)
- cholangiocarcinoma (1)
- cholecystectomy (1)
- cholestasis (1)
- cholinesterase (1)
- chondrocyte (1)
- chondrocytes (1)
- chromatin immunoprecipitation (1)
- chromosomal breaks (1)
- chromosomal instability (1)
- chromosomal integration (1)
- chromosomal translocations (1)
- chromosome alignment (1)
- chromosome instability (1)
- chromosome segregation (1)
- chronic care (1)
- chronic colitis (1)
- chronic coronary artery disease (1)
- chronic granulomatous disease (1)
- chronic hepatitis C (1)
- chronic illness (1)
- chronic infection (1)
- chronic inflammation (1)
- chronic kidney disease (CKD) (1)
- chronic liver disease (1)
- chronic liver disease (CLD) (1)
- chronic metabolic acidosis (1)
- chronic myeloid leukemia (CML) (1)
- chronic total occlusion (1)
- chronic viral hepatitis (1)
- chronische Niereninsuffizienz (1)
- chronische metabolische Azidose (1)
- chronobiology (1)
- chronotype (1)
- cigarette smoke (1)
- cigarette strength (1)
- cigarettes (1)
- cigarillos (1)
- cilia (1)
- circadian variation (1)
- circular RNA (1)
- circulating miRNA (1)
- circulation (1)
- cisplatin sensitivity (1)
- citizen science (1)
- claims data (1)
- classical conditioning (1)
- classification of bone defects (1)
- clean room (1)
- clear or almost clear skin (1)
- clinical (1)
- clinical cases (1)
- clinical competency (1)
- clinical features (1)
- clinical history (1)
- clinical immunology (1)
- clinical management (1)
- clinical pathways (1)
- clinical practice (1)
- clinical relevance (1)
- clinical tool (1)
- clinical trials (1)
- clinically important restrictions and symptoms (1)
- clinico-biological indices (1)
- cloacae (1)
- cloacal malformation (1)
- clonal dominance (1)
- clonal hematopoiesis (1)
- clopidogrel (1)
- cluster of differentiation 4 (CD4) (1)
- cluster-randomized controlled trial (1)
- clusteranalysis (1)
- co-crystallization (1)
- co-infection (1)
- coaching (1)
- coauthor ship (1)
- cocaine (1)
- coffee (1)
- cognitive control (1)
- cognitive decline (1)
- cognitive deficits (1)
- cognitive fluency (1)
- cognitive functions (1)
- cognitive models (1)
- cognitive states (1)
- cognitively stimulating leisure activities (1)
- cohlear implant (1)
- cohort study (1)
- cold induced pain (1)
- cold tolerance (1)
- colitis (1)
- collaborative feedback (1)
- collagen I (1)
- collagen VI (1)
- collagen adhesion (1)
- collagen degradation marker (1)
- collagen type I (1)
- collagen-based biomaterial (1)
- collagen-based matrix (1)
- collateral growth (1)
- collateral sprouting (1)
- collective dynamics (1)
- colloid (1)
- colon (1)
- colon cancer cells (1)
- colon carcinoma (1)
- colonization (1)
- colorectal cancer (CRC) (1)
- colorectal cancer liver metastases (CRLM) (1)
- column chromatography (1)
- combination (1)
- combination immunotherapy (1)
- combination therapies (1)
- combination treatment (1)
- combined immunodeficiency (1)
- common genetic variation (1)
- common neighbor (1)
- common variant (1)
- common variants (1)
- communication/social competencies (1)
- community violence exposure (1)
- comorbidities (1)
- comorbidity (1)
- compaction (1)
- comparative pathology (1)
- comparative study (1)
- competitive peptide (1)
- complement dependent cytotoxicity (1)
- complement; patients (1)
- complementary information (1)
- complementary psychosocial care (1)
- complex I deficiency (1)
- complex systems (1)
- complexity theory (1)
- complexome profiling (1)
- comprehensive care (1)
- computational biology (1)
- computational functional genomics (1)
- computational intelligence (1)
- computational modeling (1)
- computational models (1)
- computational neuroimaging (1)
- computational neuroscience (1)
- computational techniques (1)
- computer tomography (1)
- computer vision (1)
- computer-assisted (1)
- computer-assisted drug therapy (1)
- computerized programs (1)
- concentric (1)
- concordance (1)
- concurrent (1)
- concurrent TMS--fMRI (1)
- conditioning (1)
- conduit (1)
- cone-beam computed tomography (CBCT) (1)
- cone-beam computer tomography (1)
- confidence (1)
- confinement (1)
- congenic mice (1)
- congenital deafness (1)
- congruency (1)
- connectional fingerprint (1)
- connective tissue (1)
- connective tissue graft (1)
- conotoxin (1)
- consciousness (1)
- consensus (1)
- consolidation treatment (1)
- contact heat evoked potentials (CHEPS) (1)
- contact lens solution (1)
- continuing education (1)
- continuing medical education (1)
- continuous glucose monitoring (1)
- contralateral delay activity (1)
- controlled nuclear import (1)
- conventional laparoscopic (1)
- conventional/traditional transarterial chemoembolization (cTACE) (1)
- conversation skills (1)
- convolution neural network (1)
- convulsive seizures (1)
- cooling deactivation (1)
- cooling period (1)
- coordination (1)
- copeptin (1)
- coping (1)
- copy number polymorphism (1)
- cord clamping (1)
- corneas (1)
- corona virus (1)
- coronary (1)
- coronary artery bypass surgery (1)
- coronary calcium (1)
- coronary computed-tomography angiography (CCTA) (1)
- coronary disease (1)
- coronary plaques (1)
- coronavirus disease 2019 (1)
- corpus callosum (1)
- correction of incidence rate (1)
- correction of mortality rate (1)
- correlation (1)
- corrosion (1)
- cortex, gray matter (1)
- cortical folding (1)
- cortical layers and areas (1)
- cortical malformation (1)
- cortical network (1)
- cortical networks (1)
- cortical slices (1)
- cortical thickness (1)
- corticomuscular coherence (CMC) (1)
- cost-effective (1)
- cost-of-illness (1)
- costimulation (1)
- costs (1)
- coupling (1)
- courting behavior (1)
- cranberry (1)
- crestal bone loss (1)
- crime scene (1)
- crista junction (1)
- cristae (1)
- critical care unit (1)
- critical ill patients (1)
- critical periods (1)
- critical size defect (1)
- critically ill patients (1)
- cross-border (1)
- cross-communication (1)
- cross-modal (1)
- cross-modal plasticity (1)
- cross-sectional study (1)
- crowns (1)
- cryogenic electron microscopy (1)
- cryopreservation (1)
- cryotherapy (1)
- crystalloid (1)
- cultural and social transformation of sexuality (1)
- cumulative dose (1)
- curriculum (1)
- cutaneous T cell lymphoma (1)
- cuticular hydrocarbons (1)
- cyclic depsipeptide (1)
- cyclin D1 (1)
- cyclins (1)
- cyclooxygenase 1 (COX-1) (1)
- cyclooxygenase 2 (COX-2) (1)
- cyclophilin A (1)
- cyclophosphamide (1)
- cyclosporine (1)
- cys-loop receptor (1)
- cystatin C (1)
- cytarabin (1)
- cytarabine dose (1)
- cytokine (1)
- cytokine gene expression (1)
- cytokine release syndrome (1)
- cytokine, angiogenesis (1)
- cytoskeleton (1)
- cytotoxic immunotherapy (1)
- dNTP pools (1)
- dabigatran (1)
- daily activity protocols (1)
- damage associated molecular pattern (1)
- damage-associated molecular pattern (1)
- dapagliflozin (1)
- data modeling (1)
- data quality (1)
- data quality check (1)
- day clinic (1)
- deaf white cat (1)
- death (1)
- death receptor (1)
- debridement (1)
- decision aids (1)
- decision support systems (1)
- decision-making (1)
- declaration of tobacco ingredients (1)
- decomposition (1)
- deconvolution (1)
- decorin (1)
- decorrelation (1)
- dedifferentiation (1)
- deep mutational scanning (1)
- deep neural network (1)
- deep sedation (1)
- defect configuration (1)
- delay (1)
- delayed auditory feedback (1)
- delayed cholecystectomy (1)
- delayed wound healing (1)
- deletion 5q (1)
- delirium (1)
- delta-9-tetrahydrocannabinol (1)
- dendrite (1)
- dendritic cell–tumor cell fusion (1)
- dendritic inhibition (1)
- denervation (1)
- density equalizing mapping (1)
- dental abutment (1)
- dental assistant (1)
- dental emergency treatment (1)
- dental health professional (1)
- dentin adhesives (1)
- dentistry (1)
- dentoalveolar surgery (1)
- depolymerization (1)
- depressive symptoms (1)
- depressive symptoms clusters (1)
- deprivation (1)
- dermatology (1)
- dermatomes (1)
- desensitization (1)
- desmoplastic small round cell tumor (1)
- desmoplastic stroma (1)
- deswelling (1)
- deubiquitinating enzyme (1)
- deubiquitinating enzymes (1)
- devastated bladder outlet (1)
- device handling (1)
- dexamethasone (1)
- diabetes therapy (1)
- diabetic macular edema (1)
- diabetic nephropathy (1)
- diabetic neuropathy (1)
- diagnostic algorithm (1)
- diagnostic biomarkers (1)
- diagnostic method (1)
- diagnostic test (1)
- diagnostics (1)
- dialysis (1)
- diarrhoeal disease (1)
- diastolic function (1)
- diclofenac (1)
- diet (1)
- differentiated thyroid carcinoma (1)
- diffuse large B cell lymphoma (1)
- diffuse low-grade glioma (1)
- diffusion MRI (1)
- diffusion microstructure (1)
- diffusion tensor imaging (DTI) (1)
- digestive tract (1)
- digital age determination (1)
- digital didactics (1)
- digital pathology (1)
- digitale Didaktik (1)
- dihydroceramides (1)
- dimethylfumarate (1)
- dipeptide (1)
- diplopia (1)
- direct antiviral (1)
- direct antiviral agents (1)
- direct-acting antivirals (DAAs) (1)
- directed disulfide bond formation (1)
- directed forgetting (1)
- directly acting antiviral agents (1)
- disasters (1)
- discoidin domain-containing receptor (1)
- discomfort/pain (1)
- discontinuous dose dependency (1)
- disease modelling (1)
- disease progression (1)
- disease-free survival (1)
- disease-modifying antirheumatic drugs (1)
- disease-modifying therapy (1)
- dislocation (1)
- disposable insulin pens (1)
- disruptive behaviour disorder (1)
- dissemination (1)
- dissimilatory sulfite reductase (1)
- distal pronephric outlet obstruction (1)
- distance learning (1)
- distraction (1)
- distributed computation (1)
- diuretics (1)
- diurnal (1)
- docetaxel (1)
- docking studies (1)
- dog study (1)
- donor deferral (1)
- donor recruitment (1)
- donor retention (1)
- dopamine (1)
- doppler (1)
- dorsal auditory stream (1)
- dose response curve (1)
- dosimetry (1)
- dosing accuracy (1)
- double inversion recovery (DIR) (1)
- double orifice mitral valve (1)
- doublecortin (1)
- doxycycline (1)
- drilling tool design (1)
- drug delivery (1)
- drug hepatotoxicity (1)
- drug interaction (1)
- drug metabolism and distribution (1)
- drug resistance and invasiveness (1)
- drug screening (1)
- drug targets (1)
- drug therapy (1)
- drug-coated balloon (1)
- drug-eluting balloon (1)
- drug-eluting beads TACE (DEB-TACE) (1)
- drug-induced liver injury (DILI) (1)
- druggable genome (1)
- drugs (1)
- drug‐resistant epilepsy (1)
- dsr genes (1)
- dual antiplatelet therapy (1)
- dual bronchodilators (1)
- dynamic 18F-FDG PET/CT (1)
- dynamic connectivity (1)
- dynamic stimuli (1)
- dysbiosis (1)
- dysferlin (1)
- dysferlinopathy (1)
- dyssynchrony analysis (1)
- e-Health (1)
- e-scooter (1)
- eNOS (1)
- eNPP2 (1)
- ePTFE membrane (1)
- early cholecystectomy (1)
- early continence (1)
- early epilepsy (1)
- early infection (1)
- early loss (1)
- early myocardial damage (EMD) (1)
- early recognition (1)
- early tumor stages (1)
- eating disorders (1)
- eccentric (1)
- economic burden (1)
- economy (1)
- ectopic pregnancy (1)
- edema (1)
- editorials (1)
- edoxaban (1)
- educational cases (1)
- educational measurement (1)
- educational settings (1)
- educational technology (1)
- educational theory (1)
- effect mechanism (1)
- effective lens position (1)
- effectiveness (1)
- eight disorders (1)
- ejection fraction (EF) (1)
- electric and acustic stymulation (1)
- electric scooter (1)
- electrical stimulation (1)
- electroconvulsive therapy (1)
- electroencephalography (EEG), EEG reference choices, event-related potentials (ERP), independent component analysis (ICA), pain research, contact heat evoked potentials (CHEPS) (1)
- electromagnetic navigation bronchoscopy (EMN, ENB) (1)
- electrophiles (1)
- elite athlete (1)
- eltrombopag (1)
- embodiment (1)
- embolization (1)
- emergence (1)
- emergency care (1)
- emergent self-organizing maps (1)
- emotion (1)
- emotional climate (1)
- emotional information processing (1)
- empagliflozin (1)
- empowerment (1)
- emulsion diffusion (1)
- encoding strategies (1)
- end of life care (1)
- endocarditis (1)
- endogenous clock (1)
- endometrial cancer (1)
- endometriosis (1)
- endophytes (1)
- endoscopic retrograde cholangiopancreatography (1)
- endoscopy (1)
- endothelial activation (1)
- endothelial barrier (1)
- endothelial function (1)
- endothelial nitric-oxide synthase (1)
- endothelial receptor expression (1)
- endothelial to mesenchymal transition (1)
- endothelin (1)
- endothelin receptor type A antagonist (1)
- endothelium (1)
- endotoxemia (1)
- endotoxins (1)
- enforced viral replication (1)
- english (1)
- enterovirus (1)
- entomological evidence (1)
- envelope technique (1)
- environment (1)
- eosinophil cationic protein (1)
- eosinophilic cholangitis (1)
- eosinophils (1)
- epidemics (1)
- epidermal growth factor (1)
- epidermal growth factor receptor (1)
- epidermis (1)
- epididymitis (1)
- epigenetic memory (1)
- epigenome (1)
- epigenomics (1)
- epileptic encephalopathies (1)
- epileptic encephalopathy (1)
- epiregulin (1)
- epithelial cells (1)
- epithelial mesenchymal transition (1)
- epithelial‐mesenchymal transition (1)
- epitope mapping (1)
- erectile dysfunction (1)
- ergometry (1)
- ergonomics (1)
- erosions (1)
- erythropoietin (1)
- erythropoietin (EPO) (1)
- escape mutations (1)
- esterification (1)
- ethical trade-off (1)
- ethyl pyruvate (1)
- eutheria (1)
- euthymic (1)
- evaluation practice (1)
- event logs (1)
- event-based (1)
- event-related potential (1)
- event-related potentials (ERP) (1)
- evoked response (1)
- evolution (1)
- ex vivo expansion (1)
- ex vivo model (1)
- ex vivo stimulation (1)
- ex-Gaussian analysis (1)
- examination success (1)
- excess fluid volume (1)
- excitability (1)
- executive control (1)
- executive function (1)
- exercise on prescription (1)
- exercise physiology (1)
- exercise testing (1)
- exercise training (1)
- exome sequencing (1)
- experimental human pain models (1)
- expert review (1)
- explainable AI (1)
- exponential model (1)
- exposure (1)
- expressed emotion (1)
- expression studies (1)
- extensive surgery (1)
- extensively drug-resistant (1)
- external fixation (1)
- external joint moments (1)
- extracellular chromatin (1)
- extracellular vesicles (1)
- extracting solvents (1)
- extraction socket healing (1)
- extremity (1)
- eye movement (1)
- eye tracking (1)
- eye-tracking (1)
- face (1)
- face inversion effect (1)
- face-name association task (1)
- facial EMG (1)
- facial emotion recognition (1)
- facial expressions of emotion (1)
- facial muscle activity (1)
- facial nerve functional outcome (1)
- facial prosthesis (1)
- factor IX (1)
- factor VIII (1)
- factor VIII (FVIII) (1)
- falls (1)
- false memory (1)
- familial colorectal cancer (1)
- familial infantile epilepsy (1)
- familiengerechte Hochschule (1)
- family medicine (1)
- family-friendly universities (1)
- fat (1)
- fatty acid elongase (Elovl1/4/5) (1)
- fatty acids (1)
- fear conditioning (1)
- fear extinction (1)
- fear generalization (1)
- fear learning (1)
- feeder cells (1)
- feeding (1)
- female health (1)
- female subjects (1)
- femoropopliteal segment (1)
- ferret (1)
- ferric carboxymaltose (1)
- fetal weight estimation (1)
- fiber orientations (1)
- fibre tracking (1)
- fibrin (1)
- fibrinolysis (1)
- fibroblast (1)
- fibrocytes (1)
- fibrogenesis (1)
- fibromodulin (1)
- fibronectin (1)
- fibrosarcoma (1)
- fibrotest (1)
- fidaxomicin (1)
- finger tapping (1)
- fingolimod (1)
- first-line chemotherapy (1)
- fitness (1)
- fixation (1)
- fixed partial dentures (1)
- fizička aktivnost; (1)
- flavivirus entry factor (1)
- fluid (1)
- fluid shear stress (1)
- fluocinolone acetonide (1)
- fluorescent dye (1)
- fluorine (1)
- focal adhesion kinase (1)
- focal cortical dysplasia (FCD) (1)
- focal seizures (1)
- focal therapy (1)
- follow-up (1)
- forensics (1)
- formalin-fixed and paraffin-embedded tissue (FFPE) (1)
- formalin-fixed paraffin-embedded (FFPE) samples (1)
- fourth (1)
- fractional anisotropy (1)
- free gingival graft (1)
- free leptin index (FLI) (1)
- freeze avoidance (1)
- fresh frozen plasma (1)
- frontal cortex (1)
- frontotemporal lobar degeneration (1)
- full-contour crown restorations (1)
- full-contour zirconia (1)
- fully human (1)
- fumonisin B1 (1)
- function, sorting (1)
- functional MRI (1)
- functional imaging (1)
- functional magnetic resonance imaging (fMRI) (1)
- fundoplication (1)
- fungal pathogens (1)
- fungi (1)
- fungus (1)
- funktionelle Bildgebung (1)
- furcation involvement (1)
- further education (1)
- fusion (1)
- gRNA library (1)
- gadobutrol (1)
- gadolinium (1)
- gadolinium enhancing lesion (1)
- gadolinium‐based contrast agent (1)
- galactomannan (1)
- gallbladder cancer (1)
- gallbladder cancer xenografts (1)
- gallstone disease (1)
- galunisertib monohydrate (LY2157299) (1)
- gap junction protein alpha 4-genotype (1)
- gas chromatography-mass spectrometry (1)
- gastric (1)
- gastric surgery (1)
- gastro-oesophageal junction cancer (1)
- gastroesophageal reflux (1)
- gastrointestinal tract (1)
- gel spacer injection (1)
- gender difference (1)
- gender dysphoria (1)
- gender equality (1)
- gender equality plan (1)
- gender studies (1)
- gender-affirming hormone therapy (1)
- gene delivery (1)
- gene expression analysis (1)
- gene expression profiling (1)
- gene expression profiling (GEP) (1)
- gene signature (1)
- gene vectors (1)
- general anaesthesia (1)
- general practitioner (1)
- generic preparedness (1)
- genes (1)
- genetic diversity (1)
- genetic generalized epilepsy (1)
- genetic markers (1)
- genetic phenotypes (1)
- genetic polymorphisms (1)
- genetic predisposition (1)
- genetic rearrangements (1)
- genetics and genomics (1)
- gene×environment interactions (1)
- genome (1)
- genome editing (1)
- genome-wide (1)
- genome-wide association study (1)
- genomic classifiers (1)
- genotype (1)
- genotype determination (1)
- geriatric medicine (1)
- germ cell tumors (1)
- germinal center (1)
- gland extracts (1)
- glecaprevir (1)
- glial activation (1)
- glial fibrillary acidic protein (1)
- glioblastoma (GBM) (1)
- glioblastoma stem-like cells (1)
- glioma-associated oncogene homolog (1)
- gliomas (1)
- gliomatosis cerebri growth pattern (1)
- global diversity (1)
- global mapping (1)
- global warming (1)
- glucocorticoid (1)
- glucocorticoids (1)
- glucosamine (1)
- glucose (1)
- glutamate metabolism (1)
- glutamine (1)
- glycation (1)
- glycolysis (1)
- glycosaminoglycan (1)
- gold nanoparticles (1)
- good manufacturing practice (1)
- gossypol (1)
- governance (1)
- graft (1)
- graft perfusion (1)
- graft rejection (1)
- graft-versus host (1)
- graft-versus-host disease (1)
- graft-versus-tumor effect (1)
- gram-negative bacteria (1)
- granulocyte (1)
- granulocytecolony stimulating factor (1)
- granulocytemacrophage colony-stimulating factor (1)
- granuloma (1)
- granulomas (1)
- granulomatous inflammation (1)
- gray matter (1)
- gray matter changes (1)
- gray‐white matter blurring (1)
- green fluorescent protein (1)
- green tea extract (1)
- grey matter volume (1)
- grinding (1)
- grounded theory (1)
- growth hormone (1)
- guanidine alkaloid (1)
- guessing likelihood (1)
- guidance (1)
- guinea pig (1)
- gut microbiota (1)
- gyrification (1)
- h-index (1)
- hMOF/KAT8 (1)
- habituation (1)
- haematologic malignancies (1)
- haemophilia (1)
- haemophilia A (1)
- haemophilic arthropathy (1)
- haemostasis (1)
- hair cell (1)
- hand area (1)
- hanging donors (1)
- haplo-identical (1)
- haploidentical (1)
- harassment (1)
- harmine (1)
- head and neck neoplasms (1)
- head and neck squamous cell carcinoma (1)
- head to head (1)
- head zones (1)
- head-and-neck cancer (1)
- head-to-head (1)
- headache (1)
- health apps (1)
- health care (1)
- health care personnel (1)
- health economics (1)
- health insurance data (1)
- health literacy (1)
- health related quality of life (1)
- health services accessibility (1)
- health services research (1)
- healthcare (1)
- healthcare personnel (1)
- healthcare professional (1)
- healthcare systems (1)
- healthcare worker (1)
- healthcare workers (1)
- healthy subjects (1)
- health‐related quality of life (1)
- hearing loss (1)
- hearing nerve (1)
- heart (1)
- heart rate variability (1)
- heat (1)
- heat stress (1)
- hedgehog (1)
- hedgehog signaling pathway (1)
- helminths (1)
- hemadsorption (1)
- hemagglutination (1)
- hematoma (1)
- hematopoietic cell transplantation (1)
- hematopoietic cells (1)
- hematopoietic stem cell mobilization (1)
- hematopoietic stress (1)
- hemiplegic migraine (1)
- hemispherotomy (1)
- hemodynamic (1)
- hemodynamic instability (1)
- hemophilia A (1)
- hemorrhage (1)
- hemorrhagic transformation (1)
- hepatic fibrosis (1)
- hepatic osteodystrophy (1)
- hepatic phenotype (1)
- hepatic steatosis (1)
- hepatic tumor (1)
- hepatitis B virus (1)
- hepatitis E (1)
- hepatitis E virus (1)
- hepatitis c (1)
- hepatoblastoma (1)
- hepatocellular carcinoma (HCC) (1)
- hepatocyte transplantation (1)
- hepatocytes (1)
- hepatotoxicity (1)
- herb induced liver injury (HILI) (1)
- herbal drug (1)
- herbs (1)
- hereditary angioedema, (1)
- hereditary tumor syndromes (1)
- hernia to the cord (1)
- herpes simplex virus (1)
- heterogeneity of plasticity effects (1)
- hexosamine biosynthetic pathway (1)
- hiPSC (1)
- hierarchy (1)
- high molecular weight plasticizer (1)
- high surgical risk (1)
- high throughput (1)
- high-dimensional data sets (1)
- high-dose chemotherapy (1)
- high-dose-rate interstitial brachytherapy (1)
- high-energy photon and proton radiation (1)
- high-intensity focused ultrasound ablation (1)
- high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry (1)
- high-pitch (1)
- high-throughput nucleotide sequencing (1)
- high-throughput sequencing (1)
- higher education (1)
- higher education pedagogy (1)
- highly parallel recordings (1)
- high‐mobility group box‐1 (HMGB1) (1)
- hip joint (1)
- hippocampal neuronal cell line (1)
- hippocampal sclerosis (1)
- hippocampal volume (1)
- histamine (1)
- histological technic (1)
- histomorphometry (1)
- histone deacetylase (1)
- histone deacetylase 5 (1)
- histone deacetylases (HDACs) (1)
- histone modification (1)
- histoplasmosis (1)
- history (1)
- history of medicine (1)
- history taking (1)
- hiv (1)
- home care services (1)
- home visit (1)
- homeostatic synaptic scaling (1)
- homing (1)
- homoarginine (1)
- homologna transplantacija (1)
- hormonal therapy (1)
- hormone (1)
- hormones (1)
- hospital (1)
- hospital exemption (1)
- hospitalization (1)
- host cell interaction (1)
- host cell response (1)
- host immune response (1)
- host response (1)
- host-directed therapies (1)
- host-pathogen interaction (1)
- host-targeting antivirals (1)
- hostpathogen interaction (1)
- hotspot loci (1)
- house dust mite allergy (1)
- household chaos (1)
- huCAR19 (1)
- human Natural Killer cell (1)
- human antigen R (HuR) (1)
- human brain (1)
- human decellularized dermis (1)
- human erythroid leukemia (HEL) (1)
- human experimental pain (1)
- human genomics (1)
- human gingival fibroblasts (1)
- human immunodeficiency virus (1)
- human intracranial recordings (1)
- human knockout model (1)
- human lymph node (1)
- human natural killer cell (1)
- human papilloma virus (1)
- human renal proximal tubular epithelial cells (1)
- human resources (1)
- human sera (1)
- human skin graft (1)
- humanized mice (1)
- humanized mouse (1)
- humanized mouse model (1)
- humans (1)
- humectant agents (1)
- humoral factors (1)
- hybrid (1)
- hydrocephalus (1)
- hydroxyapatite crystals (1)
- hydroxyurea (1)
- hygienic hand disinfection (1)
- hygienische Händedesinfektion (1)
- hymenoptera (1)
- hyperalgesia (1)
- hyperammonemia (1)
- hyperarousal (1)
- hyperbaric oxygen treatment (1)
- hyperlipidemia (1)
- hypertension (1)
- hypertension and anti-hypertensive treatment (1)
- hypertension, pulmonary (1)
- hypertonic (1)
- hypoglycaemia (1)
- hyponatremia (1)
- hypoparathyroidism (1)
- hypophosphataemia (1)
- hypothalamus (1)
- hypothermia (1)
- hypoxia-induced cell death (1)
- hypoxia-inducible factor (1)
- hysteresis (1)
- i-AAA protease (1)
- iCBT (1)
- iCLIP (1)
- iDrug induced liver injury (1)
- idiopathic dystonia (1)
- idiopathic pulmonary fibrosis (1)
- idiosyncratic DILI (1)
- idiosyncratic drug-induced liver injury (1)
- ifenprodil (1)
- ignition (1)
- illness experiences (1)
- image analysis (1)
- image distortion (1)
- image-based risk modelling (1)
- imiquimod (1)
- imitation (1)
- immune (1)
- immune checkpoint inhibitors (1)
- immune deficiency (1)
- immune dysregulation (1)
- immune function (1)
- immune landscape (1)
- immune microenvironment (1)
- immune modulation (1)
- immune responses (1)
- immune surveillance of cancer (1)
- immune therapy (1)
- immune tolerance (1)
- immune-checkpoint inhibition (1)
- immune-mediated inflammatory diseases (1)
- immune-modulating therapy (1)
- immunization (1)
- immunocompromised patient (1)
- immunoglobulin superfamily (1)
- immunologic (1)
- immunological research (1)
- immunology and infectious diseases (1)
- immunomagnetic (1)
- immunoprecipitation (1)
- immunostaining (1)
- immunosuppressants (1)
- immunosuppression (1)
- immunosuppressive agent (1)
- immunosuppressive drug (1)
- impact factor (1)
- implant (1)
- implant movement (1)
- implant stability (1)
- implant survival (1)
- implanto-prosthetic therapy (1)
- imported malaria (1)
- improvement in quality of life (1)
- in silico simulation (1)
- in situ gene correction (1)
- in situ hybridization (1)
- in situ vaccine (1)
- in vivo micro‐CT (1)
- in vivo model of critical size defects (1)
- in-cabin exposure (1)
- incisional hernia (1)
- indacaterol/glycopyrronium (1)
- independent component analysis (ICA) (1)
- indication (1)
- individual moulds (1)
- individualized solutions (1)
- individualized therapy (1)
- indomethacin (1)
- indoor air pollution (1)
- inducible gene expression (1)
- inducible nitric oxide synthase (1)
- induction chemotherapy (1)
- infant (1)
- infants (1)
- infection eradication (1)
- infection model (1)
- infections: pneumonia, TB, viral (1)
- infectious disease (1)
- infectious diseases (1)
- infectivity (1)
- inflammatory arthritis (1)
- inflammatory cytokines (1)
- inflammatory markers (1)
- influenza (1)
- influenza pandemic (1)
- influenza vaccination (1)
- influenza vaccine (1)
- infomax (1)
- information decomposition (1)
- information needs (1)
- information storage (1)
- information transfer (1)
- inhalation flow profiles (1)
- inhaled steroids (1)
- inhaler (1)
- inheritance (1)
- inhibition (1)
- inhibition of DNA-binding (1)
- inhibitor of apoptosis protein family (1)
- inhibitors (1)
- injury (1)
- innate and adaptive immune response (1)
- innate immune system (1)
- innate lymphoid cells (1)
- inner ear therapy (1)
- inpatient hospital admissions (1)
- insect herbivory (1)
- insecticide (1)
- insertable cardiac monitor (1)
- insertion (1)
- insomnia (1)
- instructional interventions (1)
- insulitis (1)
- integrate and fire (1)
- integrated stress response (1)
- intensive care (1)
- intensive care unit (1)
- inter-assay precision (1)
- interactome (1)
- interaural time difference (1)
- interference (1)
- interferon regulatory factor 9 (IRF9) (1)
- interferon-free (1)
- interferon-free antiviral treatment (1)
- interferon-γ (1)
- interferons (1)
- interleukin-1 (1)
- interleukin-10 (1)
- interleukin-1β (1)
- interleukin-23 receptor (1)
- interleukin-6 (1)
- internal ribosomal entry site (IRES) (1)
- internal time (1)
- international (1)
- internet (1)
- internet- and mobile-based intervention (1)
- internet-based cognitive behavioral therapy (1)
- internet-based treatment (1)
- interneurons (1)
- interscalene brachial plexus block (1)
- interstitial brachytherapy (1)
- interstitial lung disease (1)
- intervention (1)
- intervention study (1)
- interventional radiology (1)
- intervertebral disc (1)
- intervertebral disc (IVD) (1)
- intervertebral disc degeneration (1)
- intestinal barrier (1)
- intestinal graft-versushost disease (1)
- intestinal obstruction (1)
- intoxication (1)
- intra-arterial chemotherapy (1)
- intraarterial therapy (1)
- intracellular trafficking (1)
- intracerebral haemorrhage (1)
- intracerebral hemorrhage (1)
- intracranial hemorrhage (1)
- intraperitoneal therapy (1)
- intratumoral (1)
- intraventricular chemotherapy (1)
- intravital microscopy (1)
- intrinsic DILI (1)
- intrinsic apoptosis (1)
- intrinsic drug resistance (1)
- intronic ORF (1)
- invasive growth (1)
- invasive mold infection (1)
- inverse dynamics (1)
- involuntary hospitalization (1)
- in vivo (1)
- ion channel (1)
- ionomycin (1)
- ionotropic glutamate receptors (1)
- irbesartan (1)
- irinotecan-loaded drug-eluting beads TACE (DEBIRI-TACE) (1)
- iron chelation (1)
- iron chelator (1)
- iron chelators (1)
- iron deficiency (1)
- iron homeostasis (1)
- iron metabolism (1)
- iron overload versus deprivation (1)
- iron supplements (1)
- irritable bowel syndrome (1)
- ischaemia (1)
- ischemia (1)
- ischemic stroke (1)
- ischemic type biliary lesions (1)
- isocaloric ketogenic diet (1)
- isogenic (1)
- isomeric antagonists (1)
- isovaleric acidaemia (1)
- isradipine (1)
- isušenje (1)
- itraconazole (1)
- ixekizumab (1)
- joint bleeding (1)
- joint contact forces (1)
- joint loading (1)
- joint moments (1)
- junctional adhesion molecule (1)
- juvenile brain lesion (1)
- juvenile myoclonic epilepsy (1)
- kallikrein inhibitor (1)
- kavalactones (1)
- keratinized mucosa (1)
- keratinocytes (1)
- keratoplasty (1)
- ketamine (1)
- ketogenic (1)
- ketogenic diet (1)
- ketone body (1)
- kidney disease (1)
- kidney formation (1)
- kidney function (1)
- kinesin (1)
- kinetic fingerprint (1)
- klinische Kompetenz (1)
- klinische Studie (1)
- knee joint (1)
- knockout mice (1)
- knockout mouse (1)
- kommunikative/soziale Kompetenzen (1)
- konduit (1)
- koroner arter baypas cerrahisi (1)
- kutane Larva migrans (1)
- kynureninase (1)
- kynurenine (1)
- kyphosis (1)
- l-DOPA (1)
- laceration (1)
- lacosamide (1)
- lactate (1)
- lactate dehydrogenase (1)
- laminin (1)
- laminins (1)
- lamotrigine (1)
- language (1)
- laser (1)
- laser based cell manipulation (1)
- laser microdissection (1)
- laser-capture microdissection (1)
- late lumen loss (1)
- late-life depression (1)
- latent class analysis (1)
- latent tuberculosis infection (1)
- layer 1 (1)
- layer-specificity (1)
- learning (1)
- learning curve (1)
- learning strategies (1)
- left ventricular function (1)
- left ventricular non-compaction (1)
- left ventricular trabeculation (1)
- leg alignment (1)
- legal gender reassignment (1)
- lenalidomide (1)
- length of study (1)
- lentiviral vector (1)
- leptin (1)
- leptin, leptin receptor (sOB-R) (1)
- leptomeningeal disease (1)
- leptomeningeal metastases (1)
- lethal toxin (1)
- leukapheresis (1)
- leukemia initiating cell (1)
- leukemia; solid tumors (1)
- leukocytosis (1)
- leukodystrophy (1)
- leukotriene (1)
- life cycle (1)
- life span (1)
- lifelong learning (1)
- lifespan (1)
- ligelizumab (1)
- light microscopy (1)
- light transmission aggregometry (1)
- limb girdle muscular dystrophy type 2B (LGMD2B) (1)
- liminality (1)
- linoleic acid metabolites (1)
- lipid mediator (1)
- lipid metabolism (1)
- lipid raft (1)
- lipid signaling (1)
- lipid signalling (1)
- lipid-protein interaction (1)
- lipidomic analysis (1)
- lipidomics (1)
- lipids (1)
- lipids inflammatory pain (1)
- lipiodol (1)
- lipopolyplex (1)
- lipopolysaccharide (1)
- liposomes (1)
- liquid PRF (1)
- liquid-PRF (1)
- live cell imaging (1)
- liver abscess (1)
- liver adaption (1)
- liver cancer (1)
- liver cell lines (1)
- liver damage (1)
- liver diseases (1)
- liver immunology (1)
- liver metabolism (1)
- liver transplantation center (1)
- livermetastases of colorectal cancer (1)
- living will (1)
- local anesthetic (1)
- local field potential (1)
- local inflammation (1)
- local radiotherapy (1)
- lockdown (1)
- locomotor rhythm (1)
- locoregional chemotherapy (1)
- long essay questions (1)
- long essey questions (1)
- long non-coding RNA (1)
- long noncoding RNAs (1)
- long reads (1)
- long-acting muscarinic antagonist (1)
- long-acting β2-agonists (1)
- long-term depression (1)
- long-term distress (1)
- long-term follow-up (1)
- long-term infection (1)
- long-term infusion (1)
- long-term outcome (1)
- long-term potentiation (1)
- longitudinal follow-up after epilepsy surgery (1)
- longitudinal relaxation time T1 (1)
- longitudinally extensive transverse myelitis (1)
- loss (1)
- loss of signal (1)
- low birth weight infant (1)
- low doses (1)
- low speed centrifugation concept (1)
- low-back pain (1)
- low-cost medication (1)
- low-density lipoprotein cholesterol (1)
- low-dose imaging (1)
- low-dose radiation therapy (1)
- low-risk (1)
- lower extremity arterial disease (1)
- lower urinary tract obstruction (1)
- lumican (1)
- lung (1)
- lung disease (1)
- lung disease phenotype (1)
- lung remodeling (1)
- lung transplantation (1)
- luteolin (1)
- lymph nodes (1)
- lymphangiogenesis (1)
- lymphocyte (1)
- lymphocytes (1)
- lymphoma pathogenesis (1)
- lysosomes (1)
- l‐arginine:glycine amidinotransferase (1)
- mGluR3 (1)
- mGluR5 (1)
- mPGES-1 (1)
- mRNA (1)
- mRNA active cancer immunotherapy (1)
- mRNA and protein expression (1)
- mRNA decay (1)
- mRNA export (1)
- mRNA stability (1)
- mRNA vaccine (1)
- mTOR inhibition (1)
- mTOR inhibitor (1)
- mTOR inhibitors (1)
- mTORC (1)
- macula (1)
- macular hole (1)
- magentoencephalography (MEG) (1)
- magnetic field gradient (1)
- magnetic resonance imaging of the brain (1)
- magnetoencephalography (MEG) (1)
- maintenance therapy (1)
- major adverse cardiac events (1)
- major adverse cardiovascular events (1)
- major depression (1)
- major depression (MD) (1)
- major depressive disorder (1)
- major depressive disorder (MDD) (1)
- malaria elimination (1)
- malignancy (1)
- malignant glioma (1)
- mammals (1)
- mammary cancer (1)
- mammary carcinoma (1)
- mammary carcinomas (1)
- mandatory reporting system (1)
- mantle cell lymphoma (1)
- marathon (1)
- maraton (1)
- markovianity (1)
- maspin (1)
- mass spectrometry-based proteomics (1)
- massive parallel sequencing (1)
- massive weight loss (1)
- maternal care (1)
- maternal tobacco smoke (1)
- matrikine (1)
- matrix metalloproteinase (1)
- matrix metalloproteinases (1)
- maturation (1)
- mature T-cell lymphoma (1)
- mean diffusivity (1)
- measure development/validation (1)
- mechanical stimuli (1)
- mechanism of action (1)
- mechanistic target of rapamycin (mTOR) (1)
- mechanobactericidal surfaces (1)
- medial prefrontal cortex (1)
- medial thigh lift (1)
- medical and health research (1)
- medical error (1)
- medical history (1)
- medical illustration (1)
- medical informatics initiative (1)
- medical psychologoy (1)
- medical school (1)
- medical studies admission (1)
- medical teacher (1)
- medical teaching (1)
- medication (1)
- medication reconciliation (1)
- medication review (1)
- medications (1)
- medulloblastoma (1)
- medulloblastoma resection (1)
- memantine (1)
- membrane (1)
- membrane potential (1)
- membrane protein (1)
- membrane protein complex (1)
- membrane repair (1)
- membrane structure (1)
- memebrane (1)
- memory and learning tests (1)
- memory performance (1)
- mental health (1)
- mental health services (1)
- menthol (1)
- mentoring (1)
- men’s (1)
- merkel cell carcinoma (1)
- mesenchymal (1)
- mesenchymal stem cell (1)
- mesenchymal stromal cell (1)
- meta-analysis (1)
- metabolic cancer therapy (1)
- metabolic reprogramming (1)
- metabolic syndromes (1)
- metabolites (1)
- metalloprotease (1)
- metamorphosis (1)
- metaplasticity (1)
- metastability (1)
- metastasis-directed radiotherapy (1)
- metastates (1)
- metastatic cancer (1)
- metastatic colorectal cancer (1)
- metastatic melanoma stage IV (1)
- metastatic urethral cancer (1)
- meter (1)
- methotrexate (1)
- methylation profiling (1)
- methylglyoxal (1)
- methyltransferases (1)
- miR (1)
- miR-122 (1)
- miR-143-3p (1)
- miR-181 (1)
- miR-21 (1)
- miR-375 (1)
- miRNA let-7e (1)
- miRNA-17–92 (1)
- micelles (1)
- micro CT (1)
- microRNAs (1)
- microcirculation (1)
- microdeletions (1)
- microkeratome (1)
- microlesions (1)
- microplasmin (1)
- microsaccades (1)
- microsatellite instability (1)
- microsomal ethanol-oxidizing system (MEOS) (1)
- microsurgical treatment (1)
- microtubular cytoskeleton (1)
- microtubule disruptors (1)
- microtubule dynamics (1)
- microtubule-targeting agents (1)
- microwave breast imaging (1)
- midkine (1)
- migrants (1)
- migration and invasion (1)
- mindfulness (1)
- mini gastric bypass (1)
- minimal clinically important difference (1)
- minimally invasive cardiac surgery (1)
- mino acid metabolism (first pass) (1)
- mir-148a (1)
- mismatch repair (1)
- mitochondrial bioenergetics and glycolysis (1)
- mitochondrial dynamics (1)
- mitochondrial dysfunction (1)
- mitogen-activated protein kinase (1)
- mitogenic effects (1)
- mitomycin C (1)
- mitostatin (1)
- mitotic arrest (1)
- mitotic kinases (1)
- mixed micelles (1)
- mobile air quality study (1)
- mobile phone apps (1)
- mobile tongue cancer (1)
- mobilization (1)
- model curriculum (1)
- model psychosis (1)
- moisturing cream (1)
- molecular characteristics (1)
- molecular diagnosis (1)
- molecular diagnostics (1)
- molecular dynamics (1)
- molecular dynamics simulation (1)
- molecular identification (1)
- molecular marker (1)
- molecular pathology (1)
- molecular targeted drugs (1)
- molecular targeting (1)
- molecular therapy (1)
- molecular tumor board (1)
- molecular typing (1)
- momilactone A (1)
- momilactone B (1)
- monitoring (1)
- monkey (1)
- monkeys (1)
- monoamine oxidase A (1)
- monoclonal antibody (1)
- monocrotaline (1)
- monocyte chemotactic protein 1 (MCP-1) (1)
- monogenic disorders (1)
- mononuclear cell (1)
- montelukast (1)
- morbidity (1)
- morphological filtering (1)
- morphometry (1)
- motifs (1)
- motion analysis (1)
- motion capture (1)
- motor control (1)
- motor cortex (1)
- motor neuron disease (1)
- motor task (1)
- motor-evoked potential (1)
- mountain (1)
- mouse models (1)
- movement disorders (1)
- movement pattern (1)
- movement profile (1)
- mpMRI (1)
- mtor (1)
- mucormycete (1)
- mucormycetes (1)
- mucosal inflammation (1)
- mucositis (1)
- multi-drug resistance (1)
- multidisciplinary pain treatment (1)
- multidrug-resistant Gram-negative bacteria (MRGN) (1)
- multifocal (1)
- multimedia (1)
- multimodal complex treatment (1)
- multimorbidity [MeSH] (1)
- multiple choice question (1)
- multiple choice questions (1)
- multiple chronic conditions (1)
- multiple myeloma (1)
- multiple trauma (1)
- multiplex immunofluorescence (1)
- multiresistente Gram-negativen Stäbchenbakterien (MRGN) (1)
- multisensory (1)
- multisensory integration (1)
- multisite cooperation (1)
- multiunit activity (1)
- murine model (1)
- muscle (1)
- muscle disease (1)
- muscular dystrophies (1)
- muscular dystrophy (1)
- musculoskeletal modeling (1)
- musculoskeletal pain (1)
- musician (1)
- mutated neoantigens (1)
- mutational antigenic profiling (1)
- mutations (1)
- mutually exclusive mutations (1)
- mycophenolate mofetil [MMF] (1)
- myeloid cells (1)
- myeloperoxidase (1)
- myocardial infarction (1)
- myocardial injury (1)
- myocardial perfusion (1)
- myocarditis (1)
- myocardium (1)
- myocyte enhancer factor 2 (1)
- myoferlin (1)
- myogenic tone (1)
- myogenic vasoconstriction (1)
- myositis (1)
- myotonia congenita (1)
- nadomjesci za kost (1)
- nadp (1)
- naked haplo (1)
- nanobodies (1)
- nanoparticle (1)
- nanostructures (1)
- narrative content analysis (1)
- narrative economics (1)
- narrative medicine (1)
- natriuretic peptide (1)
- natural compounds (1)
- natural cytotoxicity (1)
- natural killer T cells (1)
- natural killer cell cultivation (1)
- natural killer cell cytotoxicity (1)
- natural killer cell expansion (1)
- natural killer cell therapy (1)
- natural sciences (1)
- naturalistic sample (1)
- necrosis (1)
- needle displacement (1)
- needs assessment (1)
- negative symptoms (1)
- neglect (1)
- negligencia (1)
- nematophin (1)
- neoadjuvant treatment (1)
- neocortex development (1)
- neocortical circuits (1)
- neoepitopes (1)
- neonatal intensive care unit (1)
- neonatal septic shock (1)
- neonates (1)
- neonatology (1)
- neosexual revolution (1)
- neosexualities (1)
- neovascularization, physiologic (1)
- nerve growth factor (NGF) (1)
- nerve injury (1)
- nerve-sparing (1)
- network (1)
- network neuroscience (1)
- network topology (1)
- networks (1)
- neural adaptation (1)
- neural computation (1)
- neural development (1)
- neural dynamics (1)
- neural systems (1)
- neurale Stammzellen (1)
- neuraminidase inhibitor (1)
- neuro-ophthalmological examination (1)
- neurobiology (1)
- neuroblastoma regression (1)
- neurocognition (1)
- neurodegenerative diseases (1)
- neurodevelopmental (1)
- neurodevelopmental disorders (1)
- neuroendocrine (1)
- neurofibrillary pathology (1)
- neuroinflammation (1)
- neuroinformatics (1)
- neurological diseases (1)
- neurological emergencies (1)
- neurological impairment (1)
- neurological outcome (1)
- neuronal avalanches (1)
- neuronal maturation (1)
- neuronale Netzwerke (1)
- neuronale Vorläuferzellen (1)
- neurons (1)
- neurooncology (1)
- neuropathological diagnosis (1)
- neuropathy (1)
- neuropilin-1 (1)
- neuroprotection (1)
- neuropsychiatric disorders (1)
- neuropsychological impairment (1)
- neuropsychology (1)
- neurosurgery (1)
- neurotrophins (1)
- neurovascular bundle preservation (1)
- neutral ceramidase (Asah2) (1)
- neutral sphingomyelinase (Smpd3) (1)
- neutralization (1)
- neutralizing antibodies (1)
- neutropenia (1)
- new miRNA functions (1)
- newborn infant (1)
- newborn screening (1)
- next-generation sequencing (1)
- nicotinic acetylcholine receptors (1)
- nintedanib (1)
- nitro-fatty acids (1)
- nitrogen dioxide (1)
- nitrogen oxides (NOx) (1)
- niños (1)
- nocardia (1)
- nocardiosis (1)
- nociception (1)
- nodular lymphocyte predominant Hodgkin lymphoma (1)
- nodular sclerosis (1)
- noise intervention measures (1)
- non - pharmacological anti-infective measures (1)
- non-Poissonian (1)
- non-ST-segment elevation acute coronary syndrome (1)
- non-canonical (1)
- non-classical adhesion molecule (1)
- non-communicable disease (1)
- non-communicable diseases (1)
- non-homologous end joining (1)
- non-invasive brain stimulation (1)
- non-invasive fibrosis assessment (1)
- non-linear dynamics (1)
- non-malignant hematological diseases (1)
- non-receptor tyrosine kinase (nRTK) (1)
- non-sensory bias (1)
- non-sexual (1)
- non-small cell lung cancer (1)
- non-small-cell lung cancer (1)
- non-spatial processing (1)
- nonalcoholic fatty liver disease (1)
- nonalcoholic steatohepatitis (1)
- noncoding RNA (1)
- noninterventional (1)
- nonnucleoside polymerase inhibitor (1)
- nonrandom connectivity (1)
- nonviral gene delivery (1)
- non‐selective beta‐blocker (1)
- non‑Hodgkin's lymphoma (1)
- novel H1N1 influenza (1)
- novel psychoactive substance (1)
- nuclear envelope (1)
- nuclear hormone receptor (1)
- nuclear import (1)
- nuclear pore complex (1)
- nuclear translocation (1)
- nucleotide analogue (1)
- nucleotide metabolism (1)
- nucleus accumbens (1)
- nursery school students (1)
- nursery students (1)
- nurses (1)
- nutrient deprivation (1)
- obese (1)
- objecitvity (1)
- object perception (1)
- object tracking (1)
- observational cohort study (1)
- occupational factors (1)
- occupational stress (1)
- ocriplasmin (1)
- off-pump surgery (1)
- offene Fragen (1)
- offset times (1)
- oksidacioni stres (1)
- older patients (1)
- older people (1)
- oligodendrocyte (1)
- oligomerization (1)
- olivo-ponto-cerebellar atrophy (OPCA) (1)
- omalizumab (1)
- omphalocele (1)
- oncogenes (1)
- oncological gastrectomy (1)
- oncological outcome (1)
- oncolytic virotherapy (1)
- oncomodulation (1)
- one anastomosis gastric bypass (1)
- one health (1)
- online information processing (1)
- online learning (1)
- online reasoning patterns (1)
- online survey (1)
- online teaching (1)
- open-source (1)
- operative (1)
- optical coherence tomography (1)
- optical imaging (1)
- oral and maxillofacial surgery (1)
- oral anticoagulation (1)
- oral cancer (1)
- oral enzyme combination (1)
- oral kallikrein inhibitor (1)
- oral squamous cell carcinoma (1)
- organ dysfunction (1)
- organ failure (1)
- organ of Corti (1)
- organisation of health services (1)
- organizational development (1)
- organophosphate flame retardants (OFR) (1)
- organotypic slice cultures (1)
- orientation (1)
- orientation selectivity (1)
- orthodeoxia (1)
- orthodontic mini‐implant (1)
- orthodontist (1)
- orthopaedic surgery (1)
- orthopic liver transplantation (1)
- oscillation (1)
- oscillator (1)
- oseltamivir (1)
- osteogenic sarcoma cells (1)
- osteoimmunological changes (1)
- osteopenia (1)
- osteoporosis treatment (1)
- osteotomy (1)
- ostium (1)
- otoferlin (1)
- ouabain (1)
- outcome parameter (1)
- oval split ring resonator (1)
- ovary (1)
- overall survival (OS) (1)
- overreaching markers (1)
- own-face perception (1)
- oxLDL (1)
- oxidised lipids (1)
- oxygen (1)
- oxygen metabolism (1)
- p14 (1)
- p16 (1)
- p21 phosphorylation (1)
- p21 stability (1)
- p21-activated kinase 2 (1)
- p22phox (1)
- p38 (1)
- p44/42 MAPK (1)
- p53 activator (1)
- p62 (1)
- p67phox (1)
- p73 (1)
- p75 (1)
- p97 (1)
- pCREB (1)
- pSMAD2 (1)
- pacemaker implantation (1)
- pack-years (PY) (1)
- paclitaxel sensitization (1)
- paediatric (1)
- paediatric nephrology (1)
- pain genetics (1)
- pain management (1)
- pain medication (1)
- pain questionnaire (1)
- pain research (1)
- pain target (1)
- pain, dorsal root ganglia (1)
- paired continuous theta burst stimulation (1)
- palbociclib (1)
- palmitoylation (1)
- pancreatic surgery (1)
- pandemic preparedness (1)
- papilloma (1)
- parameter estimation (1)
- parasite identity (1)
- parathormone (PTH) (1)
- parenting (1)
- parenting students (1)
- paricalcitol (1)
- parietal cortex (1)
- parkinson’s disease (1)
- parsley (1)
- participation (1)
- particle size distribution (1)
- particulate matter (PM) (1)
- passive immunization (1)
- passive reading paradigm (1)
- passive smoke (1)
- patency (1)
- patent (1)
- patent foramen ovale (1)
- pathogenesis (1)
- pathology (1)
- patient and public involvement (1)
- patient centered care (1)
- patient perspective (1)
- patient preference (1)
- patient preferences (1)
- patient questionnaire (1)
- patient study (1)
- patient-derived xenograft (1)
- patient-reported outcome measure (1)
- patient-reported outcomes (1)
- patients (1)
- patients' experience (1)
- patient‐centred outcomes (1)
- patient’s desires (1)
- patient’s perspective (1)
- pattern (1)
- patterns of progression (1)
- paxilline (1)
- pazopanib (1)
- peanut allergy (1)
- pediatric (1)
- pediatric cancer (1)
- pediatric epilepsy (1)
- pediatric eye screening (1)
- pediatric patients (1)
- pediatrics (1)
- pedicle screws (1)
- peficitinib (1)
- peg-interferon lambda (1)
- peginterferon (1)
- peginterferon-α (1)
- pelvic injury (1)
- pelvic ring fracture (1)
- pentafluorothio group (1)
- pentose phosphate pathway (1)
- perceptual memory (1)
- perceptual organization (1)
- perforin (1)
- performance assessment (1)
- performance evaluation (1)
- performance-based funding allocation (1)
- perfusion-weighted imaging (1)
- peri-implantitis (1)
- pericardial empyema (1)
- pericarditis (1)
- pericytes (1)
- perinasal skin cancer (1)
- perinatal HIV infection (1)
- perineurium (1)
- perio-prosthetic joint infection (1)
- periodontal disease progression (1)
- periodontal diseases (1)
- periodontal probing, (1)
- periodontal risk assessment (1)
- periodontal risk calculator (1)
- perioperative ischemia (1)
- perioperative mortality (1)
- perioperative outcome (1)
- perioperative period (1)
- peripheral arterial disease (1)
- peripheral blood mononuclear cells (1)
- peripheral blood stem cell transplant (1)
- peripheral nerve (1)
- peripheral vascular diseases (1)
- perirenal (1)
- peritoneal carcinomatosis (1)
- peri‐implant lesions (1)
- peri‐implant probing (1)
- peri‐implantitis therapy (1)
- persistent atrial fibrillation (1)
- persisting pain (1)
- person-oriented approach (1)
- personalised therapy (1)
- personalized oncology (1)
- pertuzumab (1)
- pervasive developmental disorders (1)
- pessary (1)
- pet rabbit (1)
- phage (1)
- phage display (1)
- phage therapy (1)
- phagocytes (1)
- pharmacist (1)
- pharmacoepidemiology (1)
- pharmacogenetics (1)
- pharmacogenomics (1)
- pharmacologic vitreolysis (1)
- pharmacology (1)
- phase 2 clinical trials (1)
- phase 3 study (1)
- phase II trial (1)
- phase III (1)
- phase coupling (1)
- phase-1 (1)
- phenolics (1)
- phenotype (1)
- phenotype/genotype relation (1)
- phenotypic screening (1)
- phenotypic spectrum (1)
- phenylephrine (1)
- phonological processing (1)
- phosphatases (1)
- phosphatidylinositols (1)
- phosphorus (1)
- phosphorylation (1)
- photoaging (1)
- photodynamic therapy (1)
- phylogenetic analysis (1)
- physical activity counseling (1)
- physical activity promotion (1)
- physical activity recommendations (1)
- physiotherapy (1)
- pibrentasvir (1)
- pictilisib (1)
- pig (1)
- pigs (1)
- pilot study (1)
- pineal (1)
- piperidone (1)
- pirinixic acid (1)
- pirinixic acid derivative (1)
- pitch perception (1)
- pivalate (1)
- pivoloyl (1)
- pixantrone (1)
- placement (1)
- plant growth (1)
- plant resistance (1)
- plant-insect interactions (1)
- plaque psoriasis (1)
- plasma membrane MICA (1)
- plasma-derived factor VIII concentrate, prophylaxis (1)
- plasminogen (1)
- plastic (1)
- platelet (1)
- platelet aggregation (1)
- platelet count (1)
- platelet lysate (1)
- platelet rich plasma (1)
- platform switching (1)
- platform-switched (1)
- platypnea (1)
- pleiotropin (1)
- pleomorphic xanthoastrocytoma (1)
- pleuropericarditis (1)
- plus-tip (1)
- pneumocystis carinii (1)
- pneumocystis pneumonia (1)
- pneumonia (1)
- podocytes (1)
- poetry (1)
- point shear wave elastography (1)
- pol g (1)
- polarization (1)
- polishing (1)
- pollen allergy (1)
- polo-like kinase (1)
- polo-like kinase 3 (1)
- poly(I:C) (1)
- poly-L-lysine (1)
- polyamines/metabolism (1)
- polycyclic aromatic hydrocarbon (1)
- polycystic kidney (1)
- polydipsia (1)
- polyethylenimine (1)
- polylactic acid (PLA) (1)
- polylactide (1)
- polyomavirus (1)
- polyomavirus (MCPyV) (1)
- polypharmacology (1)
- polyphenols (1)
- polysomnography (1)
- polysorbate 20 (1)
- polyuria (1)
- poor condition subarachnoid hemorrhage (1)
- popliteal artery (1)
- population-based (1)
- population-based surveillance (1)
- porcine (1)
- portosystemic shunt (1)
- posaconazole (1)
- post hoc study (1)
- post-liver transplantation management (1)
- post-translational modifications (PTMs) (1)
- post-transplantation lymphoproliferative disease (1)
- post-traumatic (1)
- post-traumatic osteoarthritis (1)
- posterior fossa masses (1)
- posterior parietal cortex (1)
- posterior vitreous detachment (1)
- postmortem interval (1)
- postnatal neurogenesis (1)
- postoperative delirium (1)
- posttranslational modification (1)
- posttransnational modification (1)
- posttraumatic inflammation (1)
- post‐traumatic stress disorder (1)
- potassium channels (1)
- power dynamics (1)
- ppi1 (1)
- practical exercises (1)
- pranlukast (1)
- pre-clinical models (1)
- pre-emptive allogeneic hematopoietic stem cell transplantation (1)
- pre-school asthma (1)
- preclinical (1)
- preclinical semesters (1)
- preconditioning (1)
- prediabetes (1)
- predialysis (1)
- prediction model (1)
- predictive biomarkers (1)
- predictive timing (1)
- predictive validity (1)
- pregnant (1)
- premature infant (1)
- premature transcript termination (1)
- premotor cortex (1)
- preoperative anaemia management (1)
- preoperative assessment (1)
- preoperative preparation (1)
- preparation (1)
- preprocedure prophylaxis (1)
- preschool asthma (1)
- preschool children (1)
- preschool health examination (1)
- presenilin (PS)/gamma-secretase activity (1)
- pressure (1)
- pressure cycling technology (1)
- pressure ulcer treatment (1)
- pressurized intraperitoneal aerosol chemotherapy (PIPAC) (1)
- preterm (1)
- pretreatment (1)
- prevalence of hysterectomy (1)
- prevent smoking (1)
- preventive medicine (1)
- primary biliary cirrhosis (1)
- primary biliary diseases (1)
- primary brain tumors (1)
- primary healthcare (1)
- primary immunodeficiency (PID) (1)
- primary motor cortex (1)
- primary motor cortex (M1) (1)
- primary mouse proximal tubular cells (1)
- primary prostate cancer (1)
- primary tubular cells (1)
- prior knowledge (1)
- proactive aggression (1)
- proanthocyanidin (1)
- procedural safety (1)
- process mining (1)
- productivity (1)
- progenitor (1)
- progeria (1)
- progesterone (1)
- progestin (1)
- prognosis research (1)
- prognostic biomarker (1)
- prognostic factor (1)
- programmed cell death (1)
- programmed cell death ligand 1 (1)
- programmed cell death protein 1 (1)
- progranulin (1)
- progression-free survival (PFS) (1)
- progressive myoclonus epilepsy (1)
- progressive neoplastic disease (1)
- proinflammatory microenvironment (1)
- promotion index (1)
- pronephric development (1)
- prophylactic vaccine (1)
- propofol anesthesia (1)
- proprotein convertase subtilisin/kexin type 9 inhibition (1)
- prospective memory (1)
- prospective studies (1)
- prostaglandin E2 (1)
- prostate and breast cancer cell lines (1)
- prostate brachytherapy (1)
- prostate cancer cells (1)
- prostate volume (1)
- prostate-specific antigen (1)
- prostatic cancer (1)
- proteases (1)
- protein C (1)
- protein kinase D (1)
- protein kinases (1)
- protein phosphatase 1 (PP1) inhibition/activation (1)
- protein phosphorylation (1)
- protein stability (1)
- protein tagging (1)
- protein transduction (1)
- protein/lentiviral transduction (1)
- protein–protein interactions (1)
- proteoglycans (1)
- proteostasis (1)
- proto-oncogene proteins c-akt (1)
- protocol compliance (1)
- proton density (1)
- proton pump inhibitors (1)
- proximal tubule cells (1)
- pruritus (1)
- pseudoexfoliative syndrome (1)
- psoriatic (1)
- psychiatric disorders (1)
- psychiatry (1)
- psycho-oncology (1)
- psychological (1)
- psychological distress (1)
- psychological model (1)
- psychological questionnaires (1)
- psychometric properties (1)
- psychometrics (1)
- psychosocial adjustment (1)
- psychosocial stress (1)
- psychotherapy (1)
- pteridine (1)
- public health department (1)
- public health. (1)
- public mental health (1)
- publication (1)
- pulmonary arterial hypertension (1)
- pulmonary endarterectomy (1)
- pulmonary inflammation (1)
- pulmonary nocardiosis (1)
- pulse labeling (1)
- pulse-spreading harmonic complex (1)
- pupil dilation (1)
- pupillary reactivity (1)
- putrescine/metabolism (1)
- pyramidal cell (1)
- qPCR (1)
- qRT-PCR (1)
- qRT-PCR detection (1)
- quality control (1)
- quality indicators (1)
- quality management (1)
- quality of care (1)
- quality of health care (1)
- quantification (1)
- quantitative T1 mapping (1)
- quantitative T1‐difference maps (1)
- quantitative mass spectrometry (1)
- quantitative proteomics (1)
- quantitative sensory testing (1)
- quantum biology (1)
- quantum neurobiology (1)
- rRNA (1)
- racket sports (1)
- radiation damage response (1)
- radiation oncology (1)
- radiation theraphy (1)
- radiation therapy (1)
- radiation-induced leukemia (1)
- radical oxygen species (1)
- radical prostatecomy (1)
- radical scavenging chemicals (1)
- radiofrequency (1)
- radiofrequency ablation (1)
- radioimmunotherapy (1)
- radioimmunotherpay (1)
- radiological (1)
- radiomic (1)
- radionuclide imaging (1)
- radioresponse (1)
- radiotherapy resistance (1)
- radixin (1)
- radon therapy (1)
- randomised controlled trial (1)
- randomized (1)
- randomized controlled trial (1)
- rare disease (1)
- rare disesases (1)
- rare variant (1)
- rare variants (1)
- rat femur defect (1)
- rat model (1)
- rct (1)
- re-emerging virus (1)
- re-transplantation (1)
- reactivation (1)
- reactive aggression (1)
- reactive oxygen species (ROS) (1)
- readmission rates (1)
- reaktivne vrste kiseonika (1)
- real-world (1)
- real-world evidence (1)
- receptor (1)
- receptor for advanced glycation end product (RAGE) (1)
- receptor tyrosine kinase (1)
- recertification (1)
- recombinant vesicular stomatitis virus‐Zaire ebolavirus (1)
- recommendation (1)
- recurrence (1)
- recurrent chromosomal translocations (1)
- recurrent laryngeal nerve palsy (1)
- recurrent mutations (1)
- recurrent optic neuritis (1)
- red blood cells (1)
- redox (1)
- redox signalling (1)
- redox-linked proton translocation (1)
- redundancy (1)
- redundant information (1)
- referred pain (1)
- reflexes (1)
- refractory aGvHD (1)
- registry for primary immunodeficiency (1)
- regorafenib (1)
- regorafenib csf concentration (1)
- regulation (1)
- regulatory T cell (1)
- regulatory T cells (1)
- relapsing fever (1)
- relapsing–remitting (1)
- relaxation (1)
- relaxometry (1)
- reliable change index (1)
- remifentanil (1)
- remission (1)
- remote ischemic preconditioning (1)
- remote monitoring (1)
- removal (1)
- renal failure (1)
- renal impairment (1)
- renal ischemia reperfusion injury (1)
- renal tubular cells (1)
- renal tubular epithelial cells (1)
- renin-angiotensin system (1)
- reorganization (1)
- repeat DMEK (1)
- repeat biopsy (1)
- repeated (1)
- reperfusion injury (1)
- repetition suppression (RS) (1)
- repetitive firing (1)
- repetitive transcranial magnetic stimulation (1)
- reproduction biology (1)
- repsonse process patterns (1)
- requirements analysis (1)
- research consortium (1)
- research in academic medicine (1)
- resective surgery (1)
- reserve substance (1)
- reservoir computing (1)
- resilience (1)
- resistance-associated substitutions (RAS) (1)
- resolution (1)
- resonance (1)
- resource utilization (1)
- respiratory complex I (1)
- respiratory disease (1)
- respiratory failure (1)
- restenosis (1)
- resting EEG (1)
- resting-state functional connectivity (1)
- resting‐state (1)
- restless legs syndrome (1)
- restrictive atrial communication (1)
- resuscitation (1)
- resveratrol (1)
- retina (1)
- retinal degeneration (1)
- retinal detachment (1)
- retinoic acid-related orphan receptor gamma t (1)
- retrospective (1)
- retrospective trial (1)
- retuximab (1)
- revalidation (1)
- reverse transcription (1)
- rhabdomyosarcomas (1)
- rheumatoid (1)
- rhodocetin-αβ (1)
- rhyme (1)
- rhythm (1)
- rhythmic aptitude (1)
- rhythms (1)
- ribociclib (1)
- ribosome-inactivating protein (1)
- rice husk (1)
- ridge preservation (1)
- right heart catheter (1)
- right ventricular function (1)
- riociguat (1)
- risk assessment (1)
- risk communication (1)
- risk factor progression (1)
- risk genes (1)
- risk management (1)
- risk score (1)
- rivaroxaban (1)
- robotic heart surgery (1)
- robotik kalp cerrahis (1)
- rolipram (1)
- romske ženske (1)
- root coverage (1)
- rosacea (1)
- rosetting T cells (1)
- roughness (1)
- rub-in technique (1)
- running (1)
- running wheel (1)
- rural health program (1)
- sCD163 (1)
- sCD206 (1)
- sE-cadherin (1)
- saliva (1)
- salvage radiotherapy (1)
- salvage therapy (1)
- sarcoma (1)
- sarcopenia (1)
- scaffold size (1)
- scaffolding proteins (1)
- scavenger receptor (1)
- schizophrenia spectrum (1)
- sciatic nerve (1)
- sciatic nerve injury (1)
- sclerosing cholangitis (1)
- sclerostin (1)
- scoping review (1)
- screening routine (1)
- screening test (1)
- screw augmentation (1)
- screw loosening (1)
- second mitochondria-derived activator of caspases mimetic (1)
- secondary cancer (1)
- secondary data analysis (1)
- secondary hyperparathyroidism (sHPT) (1)
- secondary schools (1)
- seed germination (1)
- segmentation (1)
- selectin (1)
- selection (1)
- selective attention (1)
- selective autophagy (1)
- selective autophagy receptor (1)
- selective mutism, (1)
- self-administration (1)
- self-citation (1)
- self-esteem (1)
- self-management support (1)
- self-organisation (1)
- self-organized criticality (1)
- self-schema (1)
- selfish genetic element (1)
- self‐expanding (1)
- semen (1)
- sensitization (1)
- sensorimotor exercise training (1)
- sensory deprivation (1)
- sensory neurons (1)
- sensory processing (1)
- sequential ALK-inhibitor therapy (1)
- serine palmitoyltransferase 2 (Sptlc2) (1)
- serology (1)
- serositis (1)
- serotonin (1)
- serum (1)
- serum albumin deficiency (1)
- serum concentrations (1)
- severe acute respiratory syndrome coronavirus (1)
- severe asthma (1)
- severe congenital neutropenia (1)
- severe uncontrolled asthma (1)
- severe vitamin D deficiency (1)
- sexual revolution (1)
- sexually transmitted diseases (1)
- sexually transmitted infection (1)
- sex‑determining region Y-box 11 (1)
- sham (1)
- shedding (1)
- shell ginger (1)
- shock (1)
- shock filter (1)
- short linear motifs (SLiMs) (1)
- short tandem repeats (1)
- short-chain ceramide (1)
- short-term prophylaxis (1)
- shortage of family doctors (1)
- shortening of treatment (1)
- shrinkage (1)
- siRNA delivery (1)
- siRNA/RNAi (1)
- sialitis (1)
- sickle cell anemia (1)
- signal transducer and activator of transcription (1)
- signal transducer and activator of transcription 3 (1)
- signal transducer and activator of transcription-1 (1)
- signalosome (1)
- silence interfering RNA (1)
- silicone device (1)
- silk fibroin (1)
- simeprevir (1)
- single best choice question (1)
- single choice questions (1)
- single nucleotide polymorphism (1)
- single-port cholecystectomy (1)
- single‐photon emission (1)
- sinus rhythm (1)
- sirtuin1 (1)
- sirtuins (1)
- six-step technique (1)
- size of cigarettes (1)
- skill mix (1)
- skills shortage (1)
- skin conductance (1)
- skin inflammation (1)
- skin involvement (1)
- sleep apnea (1)
- sleepiness (1)
- slow-wave rhythms (1)
- slowing (1)
- smac mimetic (1)
- small compounds (1)
- small leucine-rich proteoglycan (1)
- small molecule inhibitor (1)
- small molecules (1)
- small-angle neutron scattering (1)
- smoking in pregnancy (1)
- social cognitive (1)
- social determinants (1)
- social isolation (1)
- social psychiatry (1)
- socioeconomic status (1)
- sodium bituminosulfonate (1)
- sodium channels (1)
- sofosbuvir (1)
- soft drinks (1)
- soft skills (1)
- soft tissue sarcoma (STS) (1)
- solid tumors (1)
- solitary pulmonary nodule (1)
- soluble epoxide hydrolase (1)
- soluble tumor necrosis factor receptor (1)
- solvent (1)
- solvent displacement (1)
- somatic mutations (1)
- somatoform disorder (1)
- somatostatin interneurons (1)
- sonic hedgehog (1)
- sonic hedgehog signaling (1)
- sonidegib (1)
- sound analyses (1)
- sound-induced flash illusion (1)
- sox genes (1)
- spatial (1)
- spatial interactions (1)
- spatial processing (1)
- species differences (1)
- spectral activity (1)
- spectrin (1)
- spectroscopy (1)
- speech rhythm (1)
- speech segmentation (1)
- spermidine (1)
- sphinganine 1-phosphate (1)
- sphingolipid metabolism (1)
- sphingolipid sphingosine-1-phosphate (1)
- sphingosine 1-phoshate (1)
- sphingosine 1-phosphate antagonistst/inhibitors (1)
- sphingosine 1-phosphate metabolism (1)
- sphingosine 1-phosphate receptor (1)
- sphingosine 1-phosphate signaling (1)
- sphingosine kinase (1)
- sphingosine kinase 1 (1)
- sphingosine-1-phosphate receptor (1)
- sphingosine-1-phosphate receptor 5 (1)
- spider toxin (1)
- spike train (1)
- spike train analysis (1)
- spike-in SILAC (1)
- spike-timing dependent plasticity (1)
- spike-timing dependent-like plasticity (1)
- spinal fusion (1)
- spindle assembly (1)
- spindle mispositioning (1)
- spine (1)
- spinster homology protein 2 (Spns2) (1)
- spiral ganglion (1)
- spiral ganglion cell (1)
- spiral ganglion cells (1)
- spirochete (1)
- spirometry (1)
- spontaneous portosystemic shunt (1)
- sport (1)
- sports (1)
- squamous cell carcinoma (1)
- squamous cell carcinoma of head and neck (1)
- staff capacity (1)
- staff fluctuation (1)
- stage (1)
- stage II/III colorectal cancer (1)
- standard value (1)
- standardization (1)
- standardized regression-based change norms (1)
- starvation (1)
- state exams (1)
- statedependence (1)
- statistical parametric mapping (1)
- steatosis (1)
- stellate reticulum (1)
- stem cell niche (1)
- stem cell therapy (1)
- stem cells (1)
- stem/progenitor cell expansion (1)
- stenosis (1)
- stenosis quantification (1)
- stent (1)
- stereoselectivity (1)
- stereotactic (1)
- sterile abscess (1)
- sterile α motif (SAM) (1)
- steroid control of aging (1)
- steroid-resistant aGvHD (1)
- sterol regulatory element binding protein-2 (1)
- stimulation (1)
- stimulus coding (1)
- stiripentol (1)
- stopping rule (1)
- stratification (1)
- strength (1)
- strength and conditioning mesocycle (1)
- strength training (1)
- stretching (1)
- stroke prevention (1)
- stromal-derived factor 1 (1)
- structural biology and molecular biophysics (1)
- structural covariance (1)
- structural equation modeling (1)
- structural plasticity (1)
- structure (1)
- structure–activity relationships (1)
- studentisches Lernverhalten (1)
- study protocol (1)
- subcutaneous fat (1)
- subcutaneous immunotherapy (1)
- subject selection (1)
- subjunctivity (1)
- sublingual immunotherapy (1)
- substance abuse disorder (1)
- subventricular zone (1)
- subventricular zone (SVZ) (1)
- success rate (1)
- succession (1)
- suicidality (1)
- suicide (1)
- sulfasalazine (1)
- sulfur dioxide (1)
- sulfur globules (1)
- superficial femoral artery (1)
- superiority (1)
- supervised machine-learning (1)
- supervision (1)
- supervisión (1)
- suplementacija (1)
- supplementary motor area (1)
- supplementary motor area (SMA) (1)
- supplementation (1)
- support vector machines (1)
- suprapubic catheter (1)
- surface marker reversion (1)
- surface-based morphometry (1)
- surfactant (1)
- surgical margin (1)
- surveillance (1)
- survey (1)
- sympathetic nervous system (1)
- sympathicus (1)
- symptoms (1)
- synapse (1)
- synaptic plasticity (1)
- synaptic signaling (1)
- syncope (1)
- synergistic interaction (1)
- synovial fibroblast (1)
- synoviocyte (1)
- synovium (1)
- syntax (1)
- synuclein (1)
- systematic biopsy (1)
- systematisches Review (1)
- systemic antibiotics (1)
- systemic inflammation (1)
- systemic lupus erythematosus (1)
- systemic sclerosis (1)
- szentiamide (1)
- t(6;9) (1)
- t-distributed stochastic neighbor embedding (1)
- tDCS (1)
- tRNA (1)
- tacrolimus (1)
- tailored treatment schedule (1)
- talent development (1)
- talent identification (1)
- tandem mass spectrometry (1)
- target variability (1)
- targeted biopsy (1)
- targeting (1)
- task set (1)
- task-switching training (1)
- tea (1)
- teach-the-teacher (1)
- teacher training (1)
- teacher's training (1)
- teachers' training (1)
- teaching competencies (1)
- teaching skills (1)
- tear (1)
- tehnika dekalcifikacije (1)
- telmisartan (1)
- temporal correlations (1)
- temsirolimus-resistance (1)
- terapia cognitivo conductual enfocada en trauma (1)
- teratoma (1)
- terebridae venom (1)
- terminology (1)
- test protocol (1)
- testicular cancer (1)
- testing (1)
- testis (1)
- testosterone (1)
- tetracycline (1)
- tetraether lipid (1)
- tetrahydrobiopterin (1)
- tetrahydrocannabinol (1)
- thalassemia (1)
- thalidomide (1)
- the allen institute for brain science (1)
- the small molecule inhibitor MRIA9 (1)
- theory of sexuality (1)
- theranostics (1)
- therapeutics (1)
- therapy at the end of life (1)
- thiazolidine and perhydrothiazine derivatives of aldophosphamide and I-aldophosphamide (1)
- thighplasty (1)
- thioredoxin (1)
- thiosulfate oxidation (1)
- third (1)
- thoracolumbar spine injury classification system (1)
- thoracolumbar trauma (1)
- three point bending test (1)
- three-dimensional analysis (1)
- three‐dimensional analysis (1)
- thrombocyte dysfunction (1)
- thrombocyte function (1)
- thrombocytopenia (1)
- thrombocytosis (1)
- thrombolysis (tPA) (1)
- thrombopenia (1)
- thrombopietin receptor agonist (1)
- thrombosis (1)
- thrombospondin-4 (1)
- thrombotic microangiopathy (1)
- thrombotic thrombocytopenic purpura (1)
- thyroglobulin mRNA (1)
- thyroid cancer (1)
- thyroid nodule (1)
- thyroid resection (1)
- thyroid surgery (1)
- tick (1)
- time-lapse imaging (1)
- tiotropium (1)
- tissue at risk (1)
- tissue engineering (1)
- tissue mechanics (1)
- tissue slice co-cultures (1)
- titanium (1)
- titanium particles (1)
- tobacco cessation (1)
- tobacco control (1)
- tobacco products (1)
- tobacco taxation (1)
- toc64 (1)
- tolerability (1)
- tolerance (1)
- toll-like receptors (1)
- tolvaptan (1)
- tomography (1)
- tongue edema (1)
- tooth (1)
- tooth autotransplantation (1)
- tooth transplantation (1)
- tooth wear (1)
- top-down (1)
- top-down processing (1)
- topical agent (1)
- topographic maps (1)
- top–down (1)
- total body score (1)
- total events (1)
- total flavonoids (1)
- total joint arthroplasty (TJA) (1)
- total phenols (1)
- toxic hemisphere syndrome (1)
- toxin B (1)
- tpileptogenesis (1)
- tracheobronchomalacia (1)
- tracking (1)
- tractography (1)
- traffic accident (1)
- traffic emissions (1)
- trafficking (1)
- training effects (1)
- training program (1)
- training transfer (1)
- trans-Golgi network (1)
- transapical aortic valve replacement (1)
- transarterial chemoembolization (TACE) (1)
- transbronchial biopsy (TBB) (1)
- transcatheter aortic valve replacement (1)
- transcatheter aortic valve replacement (TAVR) (1)
- transcatheter aortic valve replacement (TAVR), aortic valve stenosis (AS) (1)
- transcatheter closure (1)
- transcranial alternating current stimulation (tACS) (1)
- transcription factor (1)
- transcription factors (1)
- transcriptional profiling (1)
- transcriptional regulation of autophagy (1)
- transcriptome analysis (1)
- transcriptomics (1)
- transdifferentiation (1)
- transfemoral (1)
- transfer (1)
- transforming growth factor beta (1)
- transforming growth factor beta (TGF-β) (1)
- transforming growth factor-β (1)
- transgelin (1)
- transgenically augmented CAR NK cell (1)
- transient interactions (1)
- transient receptor potential channels (1)
- transient virtual lesion (1)
- transition (1)
- transjugular intrahepatic portosystemic shunt (TIPS) (1)
- transjugular portosystemic intrahepatic (1)
- transketolase-like protein 1 (1)
- translation (1)
- translational cancer research (1)
- translational medical research (1)
- translational medicine (1)
- translational reseach (1)
- translocation partner genes (1)
- translocon (1)
- transmission and vector control (1)
- transmission routes (1)
- transmitted founder virus (1)
- transportation (1)
- transposition (1)
- transrectal prostate biopsy (1)
- transsexualism (1)
- transurethral catheter (1)
- transverse axis (1)
- traumafocused cognitive behavioural therapy (1)
- traumatic brain injury (1)
- traumatic brain injury (TBI) (1)
- treatment choice (1)
- treatment preference (1)
- treatment-related changes (1)
- treatment-resistant (1)
- trehalose (1)
- triathlon (1)
- tricalcium phosphate (1)
- trichostatin A (1)
- trigeminal pain (1)
- triple therapy (1)
- trochee (1)
- trophiclevel (1)
- trophoblastic cell lines (1)
- trophoblasts (1)
- tropical marine sponges (1)
- troponin (1)
- trust (1)
- trustworthy AI (1)
- tryptophan (1)
- tuberculosis epidemiology (1)
- tuberous sclerosis complex (1)
- tubular regeneration (1)
- tuft cells (1)
- tumor (1)
- tumor adhesion (1)
- tumor cell proliferation (1)
- tumor dissemination (1)
- tumor growth in xenografts (1)
- tumor immune escape (1)
- tumor immune evasion (1)
- tumor invasion (1)
- tumor metabolism (1)
- tumor microenviroment (1)
- tumor microenvironment (TME) (1)
- tumor migration (1)
- tumor necrosis factor converting enzyme (1)
- tumor necrosis factor receptor superfamily member 9 (1)
- tumor pain (1)
- tumor proliferation (1)
- tumor response (1)
- tumor stroma (1)
- tumor weight (1)
- tumor xenograft (1)
- tumor-infiltrating-lymphocytes (1)
- tumor-specific antigen expressing dendritic cells (1)
- tumor‐associated macrophages (1)
- tumour (1)
- tumour growth (1)
- tumour immunology (1)
- tumour microenvironment (1)
- tumour-infiltrating lymphocytes (1)
- two-tissue compartment model (1)
- type 1 diabetes (1)
- type B (1)
- type I interferon (1)
- type I interferons (1)
- type I interferons (IFNs) (1)
- type-1-diabetes (1)
- tyrosinase inhibitor (1)
- tyrosine kinase inhibitors (1)
- tyrosine kinase inhibitors. (1)
- ubiquitin coat (1)
- ubiquitin receptor (1)
- ubiquitin-binding zinc finger (1)
- ulcerative colitis (1)
- ultra-high field MRI (1)
- unanticipated (1)
- uncertainty (1)
- understudied kinase (1)
- unfolded protein response (1)
- unguided (1)
- unilateral hip osteoarthritis (1)
- unique information (1)
- university hospitals (1)
- upper gastrointestinal cancer (1)
- urachal cancer (1)
- urethral stricture (1)
- urethroplasty (1)
- urinary diversion (1)
- urinary tract development (1)
- ursodeoxycholic acid (1)
- uterine cervical cancer (1)
- vaccination rates (1)
- vaccine acceptance (1)
- vaccine trial (1)
- vacuuming (1)
- vadimezan (1)
- validation studies (1)
- value frameworks (1)
- vancomycin (1)
- variability (1)
- vascular (1)
- vascular calcification (1)
- vascular complications (1)
- vascular disease (1)
- vascular disrupting agents (1)
- vascular dysfunction and inflammation (1)
- vascular endothelial growth factor (1)
- vascular endothelial growth factor receptor (1)
- vascular endothelial growth factor receptor 2 (1)
- vascular remodeling (1)
- vascular smooth muscle (1)
- vascular smooth muscle cells (1)
- vascular surgery (1)
- vasculogenic mimicry (1)
- vasoconstriction (1)
- vasodilation (1)
- vasopressin (1)
- vector-borne disease (1)
- velpatasvir (1)
- veneering porcelain (1)
- ventilation modes (1)
- ventral striatum (1)
- ventricular zone (VZ) (1)
- ventriculoperitoneal shunt (1)
- venturesomeness (1)
- versican (VCAN) (1)
- vertebrates (1)
- vertebroplasty (1)
- verzweigtkettige Aminosäuren (1)
- vesicovaginal septum (1)
- vesicular glutamate transporter 2 (1)
- vessel density (1)
- vessel-associated mural cells (1)
- vestibular schwannoma (1)
- viability (1)
- videos (1)
- vigilance (1)
- vincristine (1)
- violence (1)
- viral gene transfer (1)
- viral infection (1)
- viral tracing (1)
- viral vectors (1)
- virological failure (1)
- virulence (1)
- virus (1)
- virus-like particles (1)
- viscero-cutaneous (1)
- vision (1)
- vismodegib (1)
- vismodegib (GDC-0449) (1)
- visual cortex (1)
- visual illusion (1)
- visual priming (1)
- visual short-term memory (1)
- visual system (1)
- visuo-spatial attention (1)
- visuospatial attention (1)
- vitamin D deficiency (1)
- vitamin D metabolites (1)
- vitamin D receptor (1)
- vitamin D supplementation (1)
- vitamin D target genes (1)
- vitamin D3 (1)
- vitamin Dmetabolism (1)
- vitreomacular traction (1)
- vitreous samples (1)
- vocal cord dysfunction (1)
- vocal cord palsy (1)
- voice (1)
- volatile organic compounds (VOC) (1)
- volatile sedation (1)
- voltage sensitive dye imaging (1)
- voluntary training (1)
- von Willebrand disease (1)
- von Willebrand diseases (1)
- voxel-based morphometry (1)
- voxilaprevir (1)
- waking state (1)
- water parameter (1)
- wax layer (1)
- wear (1)
- western blotting (1)
- wheezing (1)
- white matter changes (1)
- white-matter (1)
- whole abdominal radiotherapy (1)
- whole genome sequencing (1)
- whole slide image (1)
- whole-brain modeling (1)
- wild animals (1)
- wild boar carcass (1)
- willingness to participate (1)
- winter survival (1)
- within-host viral modeling (1)
- women (1)
- words (1)
- work ability (1)
- work productivity (1)
- work-life balance (1)
- workplace health promotion (1)
- wound complications (1)
- xenobiotics (1)
- xenophagy (1)
- yeast-two-hybrid (Y2H) (1)
- yellow fever virus (1)
- yellow fever virus tropism (1)
- yield optimization (1)
- young people (1)
- youth football (1)
- zafirlukast (1)
- zebrafish development (1)
- zirconia (1)
- zymosan (1)
- Übernahme von Innovationen (1)
- Übertragungswege (1)
- Überwachung (1)
- ß-D-glucan (1)
- ß-tricalciumphosphate (1)
- α-amylase inhibitor (1)
- α-mannosidosis (1)
- α-particles (1)
- α-synuclein (1)
- αvβ3 integrin (1)
- β-catenin (1)
- β-lactamases (1)
- γH2AX (1)
- γδT cell (1)
- γ‐H2AX (1)
- μ-opioid receptor regulation (1)
- π-clamp (1)
- гепатит С (1)
- правила прекращения лечения (1)
- противовирусные препараты прямого действия (ПППД) (1)
- сокращение лечения (1)
- устойчивый вирусологический ответ (УВО) (1)
- “gatekeeper” mutation T315I (1)
- flow cytometry (1)
Institute
- Medizin (3561) (remove)
Background and Aims: Activation of the inflammasome NLRP3 (NOD-, LRR- and pyrin domain containing 3) contributes to the development of non-alcoholic fatty liver disease (NAFLD) and progression to non-alcoholic steatohepatitis (NASH). Therefore, this study explored the therapeutic effects of a novel and selective NLRP3 antagonist in a murine dietary model of NASH. Methods: Groups of 12-week-old ApoE-/- mice were fed ad lib for 7 weeks with a methionine/choline deficient (MCD) and western diet (WD). After 3 weeks of diet-induced injury, mice were injected i. p. with the NLRP3 antagonist IFM-514 (100 mg/kg body weight) or vehicle (0.5% carmellose) every day, 5 days/week for a further 4 weeks. Several markers of inflammation, fibrosis and steatosis were evaluated. Whole transcriptome sequencing and panel RNA expression analysis (NanoString) were performed. Results: IFM-514 inhibited IL-1β production in mice challenged with 20 mg/kg lipopolysaccharide, and in mouse and human inflammatory cells in vitro. IFM-514 inhibited hepatic inflammation in the in vivo non-alcoholic steatohepatitis model assessed by H&E staining and in the hepatic gene expression of inflammasome-related proinflammatory cytokines. This effect was associated with significant reduction in caspase-1 activation. Similarly, IFM-514 was efficacious in vivo in MDC-fed ApoE-/- mice, markedly reducing portal pressure, Sirius red staining and 4-hydroxyproline content compared to vehicle-treated mice. Moreover, IFM-514 significantly reduced hepatic steatosis in MCD-fed ApoE-/- mice, as evidenced by NAFLD scores, oil red O staining, hepatic triglycerides and gene expression. In WD treated animals, similar trends in inflammation and fibrosis were observed, although not sufficient IFM-514 levels were reached. Conclusion: Overall, IFM-514 reduced liver inflammation and fibrosis, with mild effects on liver steatosis in experimental murine NASH. Blocking of NLRP3 may be an attractive therapeutic approach for NASH patients.
Lockdown measures during the COVID-19 pandemic have led to reductions in physical activity (PA) worldwide. Leading public health organizations have recommended the use of online exercise classes (OEC) to compensate the loss of regular exercise classes. As of now, no data are available on the uptake of OEC and on users’ attitudes. The aim of the current online survey was to assess the use of and attitudes towards OEC in Germany. Respondents indicated awareness and use of OEC, and levels of agreement with statements on OEC. Frequency of awareness and use of OEC according to PA status were calculated with contingency tables and the Χ2 test. Differences between users and non-users were tested with the Student’s t-test and the Mann–Whitney U test. Data on attitudes are presented as percentages, and Spearman correlations were calculated between attitudes and activity status, frequency of use, educational attainment, age and body mass index. A total of 979 datasets were analyzed. Of the respondents, 681 were aware of and 180, 118 and 84 used them <1 per week, 1–2 per week and ≥3 per week, respectively. Significantly more active respondents were aware of and used OEC compared to less active respondents. All in all, regular OEC use was quite limited. OEC was differentially attractive to people according to PA status, frequency of use, BMI and age. Tailoring OEC to current non-users and adding motivational support might enhance the regular use of OEC.
GATA2 deficiency is a heterogeneous multi-system disorder characterized by a high risk of developing myelodysplastic syndrome (MDS) and myeloid leukemia. We analyzed the outcome of 65 patients reported to the registry of the European Working Group (EWOG) of MDS in childhood carrying a germline GATA2 mutation (GATA2mut) who had undergone hematopoietic stem cell transplantation (HSCT). At 5 years the probability of overall survival and disease-free survival (DFS) was 75% and 70%, respectively. Non-relapse mortality and relapse equally contributed to treatment failure. There was no evidence of increased incidence of graft-versus-host-disease or excessive rates of infections or organ toxicities. Advanced disease and monosomy 7 (−7) were associated with worse outcome. Patients with refractory cytopenia of childhood (RCC) and normal karyotype showed an excellent outcome (DFS 90%) compared to RCC and −7 (DFS 67%). Comparing outcome of GATA2mut with GATA2wt patients, there was no difference in DFS in patients with RCC and normal karyotype. The same was true for patients with −7 across morphological subtypes. We demonstrate that HSCT outcome is independent of GATA2 germline mutations in pediatric MDS suggesting the application of standard MDS algorithms and protocols. Our data support considering HSCT early in the course of GATA2 deficiency in young individuals.
Simple Summary
Seizures are among the most common symptoms of meningioma patients even after surgery. This study sought to identify risk factors for early and late seizures in meningioma patients and to evaluate a modified version of a score to predict postoperative seizures on an independent cohort. The data underline that there are distinct factors identifying patients with a high risk of postoperative seizures following meningioma surgery which has been already shown before. We could further show that the high proportion of 43% of postoperative seizures occur as late seizures which are more dangerous because they may happen out of hospital. The modified STAMPE2 score could predict postoperative seizures when reaching very high scores but was not generally transferable to our independent cohort.
Abstract
Seizures are among the most common symptoms of meningioma. This retrospective study sought to identify risk factors for early and late seizures in meningioma patients and to evaluate a modified STAMPE2 score. In 556 patients who underwent meningioma surgery, we correlated different risk factors with the occurrence of postoperative seizures. A modified STAMPE2 score was applied. Risk factors for preoperative seizures were edema (p = 0.039) and temporal location (p = 0.038). For postoperative seizures preoperative tumor size (p < 0.001), sensomotory deficit (p = 0.004) and sphenoid wing location (p = 0.032) were independent risk factors. In terms of postoperative status epilepticus; sphenoid wing location (p = 0.022), tumor volume (p = 0.045) and preoperative seizures (p < 0.001) were independent risk factors. Postoperative seizures lead to a KPS deterioration and thus an impaired quality of life (p < 0.001). Late seizures occurred in 43% of patients with postoperative seizures. The small sub-cohort of patients (2.7%) with a STAMPE2 score of more than six points had a significantly increased risk for seizures (p < 0.001, total risk 70%). We concluded that besides distinct risk factors, high scores of the modified STAMPE2 score could estimate the risk of postoperative seizures. However, it seems not transferable to our cohort
The aim of this study was to evaluate whether recurrent carpal tunnel syndrome (CTS) after complete and sufficient division of the transverse ligament really exists. Another goal was to analyze the underlying reasons for recurrent CTS operated on in our department. Over an observation period of eleven years, 156 patients underwent surgical intervention due to CTS. The records of each patient were analyzed with respect to baseline data (age, gender, affected hand), as were clinical signs and symptoms pre- and postoperatively. To assess long-term results, standardized telephone interviews were performed using a structured questionnaire in which the patients were questioned about persisting symptoms, if any. Of the 156 patients, 128 underwent first surgical intervention due to CTS in our department. In long-term follow-up, two-thirds of these patients had no symptoms at all; one-third of the patients described mild persisting numbness. None of the patients experienced a recurrence of CTS. The 28 patients who received their first operation outside of our department were operated on for recurrent CTS. The cause of recurrence was incomplete division of the distal part of the transverse carpal ligament in all cases. The results suggest that recurrent CTS after complete and sufficient division of the transverse ligament is very unlikely.
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases leading to an insufficient formation of functional blood cells. Disease-immanent factors as insufficient erythropoiesis and treatment-related factors as recurrent treatment with red blood cell transfusions frequently lead to systemic iron overload in MDS and AML patients. In addition, alterations of function and expression of proteins associated with iron metabolism might are increasingly recognized to be pathogenetic factors and potential vulnerabilities of these diseases. Iron is known to be involved in multiple intracellular and extracellular processes. It is essential for cell metabolism as well as for cell proliferation and closely linked to the formation of reactive oxygen species. Therefore, iron can influence the course of clonal myeloid disorders, the leukemic environment and the occurrence as well as the defense of infections. Imbalances of iron homeostasis may induce cell death of normal but also of malignant cells. New potential treatment strategies utilizing the importance of the iron homeostasis include iron chelation, modulation of proteins involved in iron metabolism, induction of leukemic cell death via ferroptosis and exploitation of iron proteins for the delivery of antileukemic drugs.
Here, we provide a summary of some of the latest findings about the function, the prognostic impact and potential treatment strategies of iron in patients with MDS and AML.
Bloodstream infections (BSI) are a frequent complication in patients with hematological and oncological diseases. However, the impact of different bacterial species causing BSI and of multiple BSI remains incompletely understood. We performed a retrospective study profiling 637 bacterial BSI episodes in hematological and oncological patients. Based on the 30-day (30d) overall survival (OS), we analyzed different types of multiple BSI and grouped BSI-associated bacteria into clusters followed by further assessment of clinical and infection-related characteristics. We discovered that polymicrobial BSI (different organisms on the first day of a BSI episode) and sequential BSI (another BSI before the respective BSI episode) were associated with a worse 30d OS. Different bacterial groups could be classified into three BSI outcome clusters based on 30d OS: favorable (FAV) including mainly common skin contaminants, Escherichia spp. and Streptococcus spp.; intermediate (INT) including mainly Enterococcus spp., vancomycin-resistant Enterococcus spp., and multidrug-resistant gram-negative bacteria (MDRGN); and adverse (ADV) including MDRGN with an additional carbapenem-resistance (MDRGN+CR). A polymicrobial or sequential BSI especially influenced the outcome in the combination of two INT cluster BSI. The presence of a polymicrobial BSI and the assignment into the BSI outcome clusters were identified as independent risk factors for 30d mortality in a Cox multivariate regression analysis. The assignment to a BSI outcome cluster and the differentiated perspective of multiple BSI open new insights into the prognosis of patients with BSI and should be further validated in other patient cohorts.
Purpose: Amblyopia with eccentric fixation, especially when not diagnosed early, is a therapeutic challenge, as visual outcome is known to be poorer than in amblyopia with central fixation. Consequently, treatment after late diagnosis is often denied. Electronic monitoring of occlusion provides us the chance to gain first focussed insight into age-dependent dose response and treatment efficiency, as well as the shift of fixation in this rare group of paediatric patients. Methods: In our prospective pilot study, we examined amblyopes with eccentric fixation during 12 months of occlusion treatment. We evaluated their visual acuity, recorded patching duration using a TheraMon®-microsensor, and determined their fixation with a direct ophthalmoscope. Dose-response relationship and treatment efficiency were calculated. Results: The study included 12 participants with strabismic and combined amblyopia aged 2.9–12.4 years (mean 6.5). Median prescription of occlusion was 7.7 h/day (range 6.6–9.9) and median daily received occlusion was 5.2 h/day (range 0.7–9.7). At study end, median acuity gain was 0.6 log units (range 0–1.6) and residual interocular visual acuity difference (IOVAD) 0.3 log units (range 0–1.8). There was neither significant acuity gain nor reduction in IOVAD after the 6th month of treatment. Children younger than 4 years showed best response with lowest residual IOVAD at study end. Efficiency calculation showed an acuity gain of approximately one line from 100 h of patching in the first 2 months and half a line after 6 months. There was a significant decline of treatment efficiency with age (p = 0.01). Foveolar fixation was achieved after median 3 months (range 1–6). Three patients (> 6 years) did not gain central fixation. Conclusion: Eccentric fixation is a challenge to therapy success. Based on electronic monitoring, our study quantified for the first time the reduction of treatment efficiency with increasing age in amblyopes with eccentric fixation. Despite some improvement in patients up to 8 years, older patients showed significantly lower treatment efficiency. In younger patients with good adherence, despite poor initial acuity, central fixation and low residual IOVAD could be attained after median 3 months. Hence, the necessity of early diagnosis and intensive occlusion should be emphasized.
Pancreatic cancer (PC) still remains a major cause of cancer-related death worldwide and alternative treatments are urgently required. A common problem of PC is the development of resistance against apoptosis that limits therapeutic success. Here we demonstrate that the prototypical Smac mimetic BV6 cooperates with the stimulator of interferon (IFN) genes (STING) ligand 2′,3′-cyclic guanosine monophosphate–adenosine monophosphate (2′3′-cGAMP) to trigger necroptosis in apoptosis-deficient PC cells. Pharmacological inhibition of key components of necroptosis signaling, such as receptor-interacting protein 1 (RIPK1), RIPK3, and mixed lineage kinase domain-like protein (MLKL), significantly rescues PC cells from 2′3′-cGAMP/BV6/zVAD.fmk-mediated cell death, suggesting the induction of necroptosis. Consistently, 2′3′-cGAMP/BV6 co-treatment promotes phosphorylation of MLKL. Furthermore, we show that 2′3′-cGAMP stimulates the production of type I IFNs, which cooperate with BV6 to trigger necroptosis in apoptosis-deficient settings. STING silencing via siRNA or CRISPR/Cas9-mediated gene knockout protects PC cells from 2′3′-cGAMP/BV6/zVAD.fmk-mediated cell death. Interestingly, we demonstrate that nuclear factor-κB (NF-κB), tumor necrosis factor-α (TNFα), and IFN-regulatory factor 1 (IRF1) signaling are involved in triggering 2′3′-cGAMP/BV6/zVAD.fmk-induced necroptosis. In conclusion, we show that activated STING and BV6 act together to exert antitumor effects on PC cells with important implications for the design of new PC treatment concepts.
Introduction: Prognosis of survivors from cardiac arrest is generally poor. Acute kidney injury (AKI) is a common finding in these patients. In general, AKI is well characterized as a marker of adverse outcome. In-hospital cardiac arrest (IHCA) represents a special subset of cardiac arrest scenarios with differential predisposing factors and courses after the event, compared to out-of-hospital resuscitations. Data about AKI in survivors after in-hospital cardiac arrest are scarce. Methods: In this study, we retrospectively analyzed patients after IHCA for incidence and risk factors of AKI and its prognostic impact on mortality. For inclusion in the analysis, patients had to survive at least 48 h after IHCA. Results: A total of 238 IHCA events with successful resuscitation and survival beyond 48 h after the initial event were recorded. Of those, 89.9% were patients of internal medicine, and 10.1% of patients from surgery, neurology or other departments. In 120/238 patients (50.4%), AKI was diagnosed. In 28 patients (23.3%), transient or permanent renal replacement therapy had to be initiated. Male gender, preexisting chronic kidney disease and a non-shockable first ECG rhythm during resuscitation were significantly associated with a higher incidence of AKI in IHCA-survivors. In-hospital mortality in survivors from IHCA without AKI was 29.7%, and 60.8% in patients after IHCA who developed AKI (p < 0.01 between groups). By multivariate analysis, AKI after IHCA persisted as an independent predictor of in-hospital mortality (HR 3.7 (95% CI 2.14–6.33, p ≤ 0.01)). Conclusion: In this cohort of survivors from IHCA, AKI is a frequent finding, with adverse impact on outcome. Therefore, therapeutic strategies to prevent AKI in post-IHCA patients are warranted.
Mitochondrial dysfunction may activate innate immunity, e.g. upon abnormal handling of mitochondrial DNA in TFAM mutants or in altered mitophagy. Recent reports showed that also deletion of mitochondrial matrix peptidase ClpP in mice triggers transcriptional upregulation of inflammatory factors. Here, we studied ClpP-null mouse brain at two ages and mouse embryonal fibroblasts, to identify which signaling pathways are responsible, employing mass spectrometry, subcellular fractionation, immunoblots, and reverse transcriptase polymerase chain reaction. Several mitochondrial unfolded protein response factors showed accumulation and altered migration in blue-native gels, prominently the co-chaperone DNAJA3. Its mitochondrial dysregulation increased also its extra-mitochondrial abundance in the nucleus, a relevant observation given that DNAJA3 modulates innate immunity. Similar observations were made for STAT1, a putative DNAJA3 interactor. Elevated expression was observed not only for the transcription factors Stat1/2, but also for two interferon-stimulated genes (Ifi44, Gbp3). Inflammatory responses were strongest for the RLR pattern recognition receptors (Ddx58, Ifih1, Oasl2, Trim25) and several cytosolic nucleic acid sensors (Ifit1, Ifit3, Oas1b, Ifi204, Mnda). The consistent dysregulation of these factors from an early age might influence also human Perrault syndrome, where ClpP loss-of-function leads to early infertility and deafness, with subsequent widespread neurodegeneration.
Mesial temporal lobe epilepsy (mTLE) is a common form of epilepsy and is characterized by recurrent spontaneous seizures originating from the temporal lobe. The majority of mTLE patients develop pharmacoresistance to available anti-epileptic drugs (AEDs) while exhibiting severe pathological changes that can include hippocampal atrophy, neuronal death, gliosis and chronic seizures. The molecular mechanisms leading to mTLE remain incompletely understood, but are known to include defects in post-transcriptional gene expression regulation, including in non-coding RNAs (ncRNAs). Circular RNAs (circRNAs) are a class of recently rediscovered ncRNAs with high levels of expression in the brain and proposed roles in diverse neuronal processes. To explore a potential role for circRNAs in epilepsy, RNA-sequencing (RNA-seq) was performed on hippocampal tissue from a rat perforant pathway stimulation (PPS) model of TLE at different post-stimulation time points. This analysis revealed 218 differentially expressed (DE) circRNAs. Remarkably, the majority of these circRNAs were changed at the time of the occurrence of the first spontaneous seizure (DOFS). The expression pattern of two circRNAs, circ_Arhgap4 and circ_Nav3, was further validated and linked to miR-6328 and miR-10b-3p target regulation, respectively. This is the first study to examine the regulation of circRNAs during the development of epilepsy. It reveals an intriguing link between circRNA deregulation and the transition of brain networks into the state of spontaneous seizure activity. Together, our results provide a molecular framework for further understanding the role and mechanism-of-action of circRNAs in TLE.
Doppler examination of the umbilical artery and the fetal middle cerebral artery is evaluated predominantly in pregnancies with fetuses in cephalic presentation and never has been elucidated in breech presentation. Evidence on the accuracy of fetal weight estimation in dependence of the fetal presentation is controversial. Nevertheless, clinical decisions including recommendations for a cesarean section or labor induction based on these examinations are applied to pregnancies with fetuses in breech presentation. The objective of this study was to investigate the influence of the fetal presentation on fetal weight estimation accuracy, umbilical artery and middle cerebral artery resistance indices (RI) in a prospective case control study. Ultrasound examinations in 305 uncomplicated term pregnancies (153 vertex presentations, 152 breech) were investigated. Non-parametric variables were compared using Pearson’s chi2 test and Wilcoxon chi2 test, depending on variable scaling. Fetal weight estimation accuracy was not significantly different between vertex presentation group (VP) (6.97%) and breech presentation group (BP) (7.96%, p = 0.099). Fetal head circumference measurements were significantly larger in BP (350 mm vs. 341 mm in VB, p > 0.0001) while abdominal circumferences were significantly smaller (VP: 338 mm, BP: 331 mm, p = 0.0039) and weight estimation was not significantly different. Umbilical artery RIs were not significantly different between VP (54.5) and BP (55.3, p = 0.354). Fetal middle cerebral artery RIs also showed no significant differences (VP: 71.2, BP: 70.7, p = 0.335). Our study shows that fetal Doppler (RI) and weight estimation ultrasound originally calibrated in cephalic pregnancies are applicable to pregnancies with fetuses in breech presentation.
Transcription factors can serve as links between tumor microenvironment signaling and oncogenesis. Interferon regulatory factor 9 (IRF9) is recruited and expressed upon interferon stimulation and is dependent on cofactors that exert in tumor-suppressing or oncogenic functions via the JAK-STAT pathway. IRF9 is frequently overexpressed in human lung cancer and is associated with decreased patient survival; however, the underlying mechanisms remain to be elucidated. Here, we used stably transduced lung adenocarcinoma cell lines (A549 and A427) to overexpress or knockdown IRF9. Overexpression led to increased oncogenic behavior in vitro, including enhanced proliferation and migration, whereas knockdown reduced these effects. These findings were confirmed in vivo using lung tumor xenografts in nude mice, and effects on both tumor growth and tumor mass were observed. Using RNA sequencing, we identified versican (VCAN) as a novel downstream target of IRF9. Indeed, IRF9 and VCAN expression levels were found to be correlated. We showed for the first time that IRF9 binds at a newly identified response element in the promoter region of VCAN to regulate its transcription. Using an siRNA approach, VCAN was found to enable the oncogenic properties (proliferation and migration) of IRF9 transduced cells, perhaps with CDKN1A involvement. The targeted inhibition of IRF9 in lung cancer could therefore be used as a new treatment option without multimodal interference in microenvironment JAK-STAT signaling.
Background: The Global Burden of Diseases Study 2017 predicted that chronic obstructive pulmonary disease (COPD) is the second leading cause of death, the fourth leading cause of premature death, and the third cause for DALYs lost in Nepal. However, data on the population-based prevalence of COPD in Nepal are very limited. This study aims to assess the prevalence of COPD and factors associated with the occurrence of COPD in Nepal.
Methods: From a nationally representative, population-based cross-sectional study on chronic non-communicable diseases, the prevalence of COPD and its associated factors was determined. Of 12,557 participants aged over 20 years, 8945 participants completed a questionnaire and spirometry. Eligible participants were also asked to answer a COPD diagnostic questionnaire for screening COPD cases, and if needed underwent pre-bronchodilator and post-bronchodilator spirometry. COPD was defined as a post-bronchodilator FEV1/FVC (forced expiratory volume in 1 s/forced vital capacity) ratio of < 0.70. Multivariate logistic regression was performed to identify factors associated with COPD. Sampling weights were used for all data analyses.
Results: The prevalence of COPD in Nepal was 11.7% (95% CI: 10.5% to 12.9 %), which increased with age, and higher in those with a low educational level, those who had smoked ≥ 50 pack-years, persons having a low body mass index (BMI), and residents of Karnali province. Multivariate analysis revealed that being aged 60 years and above, having a low BMI, low educational status, having smoked more than 50 pack-years, provincial distribution, and ethnicity were independent predictors of COPD.
Conclusion: COPD is a growing and serious public health issue in Nepal. Factor such as old age, cigarette smoking, low educational attainment, low BMI, ethnicity, and locality of residence (province-level variation) plays a vital role in the occurrence of COPD. Strategies aimed at targeting these risk factors through health promotion and education interventions are needed to decrease the burden of COPD.
Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m2 i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1–21 of 28 day cycles) followed by 10–15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91% vs. 33%) due to different tandem ASCT strategies. In the LEN and BTZ cohort, 43% and 46% of patients completed 2 years of MT as intended (p = 0.57). Progression-free survival (PFS; HR = 0.83, p = 0.18) and overall survival (OS; HR = 0.70, p = 0.15) did not differ significantly with LEN vs. BTZ MT. Patients with <nCR after first ASCT were assigned tandem ASCT in both trials. In patients with <nCR and tandem ASCT (LEN: n = 54 vs. BTZ: n = 84), LEN MT significantly improved PFS (HR = 0.61, p = 0.04) but not OS (HR = 0.46, p = 0.09). In conclusion, the significant PFS benefit after eliminating the impact of different tandem ASCT rates supports the current standard of LEN MT after ASCT.
The NADPH oxidase Nox4 is a hydrogen peroxide (H2O2)-producing enzyme, with the highest expression in the kidney. As the kidney is involved in volume and blood pressure control through sodium handling, we set out to determine the impact of a low sodium diet on these parameters in WT and Nox4-/- mice. Nox4 expression in the murine kidney was restricted to the proximal tubule. Nevertheless, low-sodium-induced weight loss and sodium sparing function was similar in WT and Nox4-/- mice, disputing an important function of renal Nox4 in sodium handling. In contrast, a low sodium diet resulted in a reduction in systolic blood pressure in Nox4-/- as compared to WT mice. This was associated with a selectively lower pressure to heart-rate ratio, as well as heart to body weight ratio. In general, a low sodium diet leads to activation of sympathetic tone and the renin angiotensin system, which subsequently increases peripheral resistance. Our observations suggest that the control by this system is attenuated in Nox4-/- mice, resulting in lower blood pressure in response to low sodium.
Patients with neuroendocrine tumors (NET) often go through a long phase between onset of symptoms and initial diagnosis. Assessment of time to diagnosis and pre-clinical pathway in patients with gastroenteropancreatic NET (GEP-NET) with regard to metastases and symptoms. Retrospective analysis of patients with GEP-NET at a tertiary referral center from 1984 to 2019; inclusion criteria: Patients ≥18 years, diagnosis of GEP-NET; statistical analysis using non-parametrical methods. Four hundred eighty-six patients with 488 tumors were identified; median age at first diagnosis (478/486, 8 unknown) was 59 years; 52.9% male patients. Pancreatic NET: 143/488 tumors; 29.3%; small intestinal NET: 145/488 tumors, 29.7%. 128/303 patients (42.2%) showed NET specific and 122/486 (25%) patients other tumor-specific symptoms. 222/279 patients had distant metastases at initial diagnosis (187/222 liver metastases). 154/488 (31.6%) of GEP-NET were incidental findings. Median time from tumor manifestation (e.g., symptoms related to NET) to initial diagnosis across all entities was 19.5 (95% CI: 12–28) days. No significant difference in patients with or without distant metastases (median 73 vs 105 days, P = .42). A large proportion of GEP-NET are incidental findings and only about half of all patients are symptomatic at the time of diagnosis. We did not find a significant influence of the presence of metastases on time to diagnosis, which shows a large variability with a median of <30 days.
Objective: To evaluate the prognostic impact of gastrointestinal involvement on the survival of children with Langerhans cell histiocytosis (GI-LCH) registered with the international clinical trials of the Histiocyte Society. Study design: This was a retrospective analysis of 2414 pediatric patients registered onto the consecutive trials DAL-HX 83, DAL-HX 90, LCH-I, LCH-II, and LCH-III. Results: Among the 1289 patients with single-system LCH, there was no single case confined to the GI tract; 114 of 1125 (10%) patients with multisystem LCH (MS-LCH) had GI-LCH at initial presentation. GI-LCH was significantly more common in children aged <2 years at diagnosis (13% vs 6% in those aged >2 years; P < .001) and in those with risk organ involvement (15% vs 6% in those without risk organ involvement; P < .001). The 5-year overall survival (OS) in patients without risk organ involvement was excellent irrespective of GI disease (98% vs 97% in patients with GI-LCH; P = .789). In patients with risk organ involvement, the 5-year OS was 51% in 70 patients with GI-LCH vs 72% in 394 patients without GI-LCH (P < .001). Conclusions: GI-LCH has an additive unfavorable prognostic impact in children with MS-LCH and risk organ involvement. The emerding need for more intensive or alternative treatments mandates prospective evaluation.
Introduction: Information on the long-term performance of biosynthetic meshes is scarce. This study analyses the performance of biosynthetic mesh (Phasix™) over 24 months.
Methods: A prospective, international European multi-center trial is described. Adult patients with a Ventral Hernia Working Group (VHWG) grade 3 incisional hernia larger than 10 cm2, scheduled for elective repair, were included. Biosynthetic mesh was placed in sublay position. Short-term outcomes included 3-month surgical site occurrences (SSO), and long-term outcomes comprised hernia recurrence, reoperation, and quality of life assessments until 24 months.
Results: Eighty-four patients were treated with biosynthetic mesh. Twenty-two patients (26.2%) developed 34 SSOs, of which 32 occurred within 3 months (primary endpoint). Eight patients (11.0%) developed a hernia recurrence. In 13 patients (15.5%), 14 reoperations took place, of which 6 were performed for hernia recurrence (42.9%), 3 for mesh infection (21.4%), and in 7 of which the mesh was explanted (50%). Compared to baseline, quality of life outcomes showed no significant difference after 24 months. Despite theoretical resorption, 10.7% of patients reported presence of mesh sensation in daily life 24 months after surgery.
Conclusion: After 2 years of follow-up, hernia repair with biosynthetic mesh shows manageable SSO rates and favorable recurrence rates in VHWG grade 3 patients. No statistically significant improvement in quality of life or reduction of pain was observed. Few patients report lasting presence of mesh sensation. Results of biosynthetic mesh after longer periods of follow-up on recurrences and remodeling will provide further valuable information to make clear recommendations.
Trial registration: Registered on clinicaltrials.gov (NCT02720042), March 25, 2016.
Introduction: Deep brain stimulation (DBS) has become a well-established treatment modality for a variety of conditions over the last decades. Multiple surgeries are an essential part in the postoperative course of DBS patients if nonrechargeable implanted pulse generators (IPGs) are applied. So far, the rate of subclinical infections in this field is unknown. In this prospective cohort study, we used sonication to evaluate possible microbial colonization of IPGs from replacement surgery. Methods: All consecutive patients undergoing IPG replacement between May 1, 2019 and November 15, 2020 were evaluated. The removed hardware was investigated using sonication to detect biofilm-associated bacteria. Demographic and clinical data were analyzed. Results: A total of 71 patients with a mean (±SD) of 64.5 ± 15.3 years were evaluated. In 23 of these (i.e., 32.4%) patients, a positive sonication culture was found. In total, 25 microorganisms were detected. The most common isolated microorganisms were Cutibacterium acnes (formerly known as Propionibacterium acnes) (68%) and coagulase-negative Staphylococci (28%). Within the follow-up period (5.2 ± 4.3 months), none of the patients developed a clinical manifest infection. Discussions/Conclusions: Bacterial colonization of IPGs without clinical signs of infection is common but does not lead to manifest infection. Further larger studies are warranted to clarify the impact of low-virulent pathogens in clinically asymptomatic patients.
Purpose: Amblyopia with eccentric fixation, especially when not diagnosed early, is a therapeutic challenge, as visual outcome is known to be poorer than in amblyopia with central fixation. Consequently, treatment after late diagnosis is often denied. Electronic monitoring of occlusion provides us the chance to gain first focussed insight into age-dependent dose response and treatment efficiency, as well as the shift of fixation in this rare group of paediatric patients. Methods: In our prospective pilot study, we examined amblyopes with eccentric fixation during 12 months of occlusion treatment. We evaluated their visual acuity, recorded patching duration using a TheraMon®-microsensor, and determined their fixation with a direct ophthalmoscope. Dose-response relationship and treatment efficiency were calculated. Results: The study included 12 participants with strabismic and combined amblyopia aged 2.9–12.4 years (mean 6.5). Median prescription of occlusion was 7.7 h/day (range 6.6–9.9) and median daily received occlusion was 5.2 h/day (range 0.7–9.7). At study end, median acuity gain was 0.6 log units (range 0–1.6) and residual interocular visual acuity difference (IOVAD) 0.3 log units (range 0–1.8). There was neither significant acuity gain nor reduction in IOVAD after the 6th month of treatment. Children younger than 4 years showed best response with lowest residual IOVAD at study end. Efficiency calculation showed an acuity gain of approximately one line from 100 h of patching in the first 2 months and half a line after 6 months. There was a significant decline of treatment efficiency with age (p = 0.01). Foveolar fixation was achieved after median 3 months (range 1–6). Three patients (> 6 years) did not gain central fixation. Conclusion: Eccentric fixation is a challenge to therapy success. Based on electronic monitoring, our study quantified for the first time the reduction of treatment efficiency with increasing age in amblyopes with eccentric fixation. Despite some improvement in patients up to 8 years, older patients showed significantly lower treatment efficiency. In younger patients with good adherence, despite poor initial acuity, central fixation and low residual IOVAD could be attained after median 3 months. Hence, the necessity of early diagnosis and intensive occlusion should be emphasized.
The aim of the current study was to analyze two major pitfalls in forensic entomological casework: delayed evidence sampling and the effect of low-temperature storage of the body. For this purpose, temperature profiles of heavily infested corpses during cooling and cases in which insect evidence was collected both at the scene and during autopsy were evaluated with regard to species composition and development stages found. The results show that the temperature in the body bags remained at higher average temperatures up to 10 °C relative to the mortuary cooler, therefore, sufficient for larval development, with significant differences in temperature between larval aggregations on one and the same body. In addition, we found large differences both in species number, species composition, and the developmental stages found at the scene and during the autopsy. These data and observations underscore the importance of sampling evidence at the scene and recording temperatures throughout the cooling period of a body.
The COVID-19 pandemic has caused strains on health systems worldwide disrupting routine hospital services for all non-COVID patients. Within this retrospective study, we analyzed inpatient hospital admissions across 18 German university hospitals during the 2020 lockdown period compared to 2018. Patients admitted to hospital between January 1 and May 31, 2020 and the corresponding periods in 2018 and 2019 were included in this study. Data derived from electronic health records were collected and analyzed using the data integration center infrastructure implemented in the university hospitals that are part of the four consortia funded by the German Medical Informatics Initiative. Admissions were grouped and counted by ICD 10 chapters and specific reasons for treatment at each site. Pooled aggregated data were centrally analyzed with descriptive statistics to compare absolute and relative differences between time periods of different years. The results illustrate how care process adoptions depended on the COVID-19 epidemiological situation and the criticality of the disease. Overall inpatient hospital admissions decreased by 35% in weeks 1 to 4 and by 30.3% in weeks 5 to 8 after the lockdown announcement compared to 2018. Even hospital admissions for critical care conditions such as malignant cancer treatments were reduced. We also noted a high reduction of emergency admissions such as myocardial infarction (38.7%), whereas the reduction in stroke admissions was smaller (19.6%). In contrast, we observed a considerable reduction in admissions for non-critical clinical situations, such as hysterectomies for benign tumors (78.8%) and hip replacements due to arthrosis (82.4%). In summary, our study shows that the university hospital admission rates in Germany were substantially reduced following the national COVID-19 lockdown. These included critical care or emergency conditions in which deferral is expected to impair clinical outcomes. Future studies are needed to delineate how appropriate medical care of critically ill patients can be maintained during a pandemic.
The microtubule (MT) cytoskeleton is crucial for cell motility and migration by regulating multiple cellular activities such as transport and endocytosis of key components of focal adhesions (FA). The kinesin-13 family is important in the regulation of MT dynamics and the best characterized member of this family is the mitotic centromere-associated kinesin (MCAK/KIF2C). Interestingly, its overexpression has been reported to be related to increased metastasis in various tumor entities. Moreover, MCAK is involved in the migration and invasion behavior of various cell types. However, the precise molecular mechanisms were not completely clarified. To address these issues, we generated CRISPR/dCas9 HeLa and retinal pigment epithelium (RPE) cell lines overexpressing or downregulating MCAK. Both up- or downregulation of MCAK led to reduced cell motility and poor migration in malignant as well as benign cells. Specifically, it’s up- or downregulation impaired FA protein composition and phosphorylation status, interfered with a proper spindle and chromosome segregation, disturbed the assembly and disassembly rate of FA, delayed cell adhesion, and compromised the plus-tip dynamics of MTs. In conclusion, our data suggest MCAK act as an important regulator for cell motility and migration by affecting the actin-MT cytoskeleton dynamics and the FA turnover, providing molecular mechanisms by which deregulated MCAK could promote malignant progression and metastasis of tumor cells.
Inflammatory diseases including psoriasis are associated with metabolic and cardiovascular comorbidities, including obesity and metabolic syndrome. Obesity is associated with greater psoriasis disease severity and reduced response to treatment. Therefore, targeting metabolic comorbidities could improve patients’ health status and psoriasis-specific outcomes. METABOLyx is a randomized controlled trial evaluating the combination of a lifestyle intervention program with secukinumab treatment in psoriasis. Here, the rationale, methodology and baseline patient characteristics of METABOLyx are presented. A total of 768 patients with concomitant moderate to severe plaque psoriasis and metabolic syndrome were randomized to secukinumab 300 mg, or secukinumab 300 mg plus a tailored lifestyle intervention program, over 24 weeks. A substudy of immunologic and metabolic biomarkers is ongoing. The primary endpoint of METABOLyx is PASI90 response at week 24. Other endpoints include patient-reported outcomes and safety. METABOLyx represents the first large scale clinical trial of an immunomodulatory biologic in combination with a standardized lifestyle intervention.
PKCζ and PKCι/λ form the atypical protein kinase C subgroup, characterised by a lack of regulation by calcium and the neutral lipid diacylglycerol. To better understand the regulation of these kinases, we systematically explored their interactions with various purified phospholipids using the lipid overlay assays, followed by kinase activity assays to evaluate the lipid effects on their enzymatic activity. We observed that both PKCζ and PKCι interact with phosphatidic acid and phosphatidylserine. Conversely, PKCι is unique in binding also to phosphatidylinositol-monophosphates (e.g., phosphatidylinositol 3-phosphate, 4-phosphate, and 5-phosphate). Moreover, we observed that phosphatidylinositol 4-phosphate specifically activates PKCι, while both isoforms are responsive to phosphatidic acid and phosphatidylserine. Overall, our results suggest that atypical Protein kinase C (PKC) localisation and activity are regulated by membrane lipids distinct from those involved in conventional PKCs and unveil a specific regulation of PKCι by phosphatidylinositol-monophosphates.
Objective: We aimed to estimate the incidence of cerebral sinus and venous thrombosis (CVT) within 1 month from first dose administration and the frequency of vaccine-induced immune thrombotic thrombocytopenia (VITT) as the underlying mechanism after vaccination with BNT162b2, ChAdOx1, and mRNA-1273, in Germany. Methods: A web-based questionnaire was e-mailed to all departments of neurology. We requested a report of cases of CVT occurring within 1 month of a COVID-19 vaccination. Other cerebral events could also be reported. Incidence rates of CVT were calculated by using official statistics of 9 German states. Results: A total of 45 CVT cases were reported. In addition, 9 primary ischemic strokes, 4 primary intracerebral hemorrhages, and 4 other neurological events were recorded. Of the CVT patients, 35 (77.8%) were female, and 36 (80.0%) were younger than 60 years. Fifty-three events were observed after vaccination with ChAdOx1 (85.5%), 9 after BNT162b2 (14.5%) vaccination, and none after mRNA-1273 vaccination. After 7,126,434 first vaccine doses, the incidence rate of CVT within 1 month from first dose administration was 0.55 (95% confidence interval [CI] = 0.38–0.78) per 100,000 person-months (which corresponds to a risk of CVT within the first 31 days of 0.55 per 100,000 individuals) for all vaccines and 1.52 (95% CI = 1.00–2.21) for ChAdOx1 (after 2,320,535 ChAdOx1 first doses). The adjusted incidence rate ratio was 9.68 (95% CI = 3.46–34.98) for ChAdOx1 compared to mRNA-based vaccines and 3.14 (95% CI = 1.22–10.65) for females compared to non-females. In 26 of 45 patients with CVT (57.8%), VITT was graded highly probable. Interpretation: Given an incidence of 0.02 to 0.15 per 100,000 person-months for CVT in the general population, these findings point toward a higher risk for CVT after ChAdOx1 vaccination, especially for women.
Introduction: Surgical practices constitute a common topic of complaint among medical students. The aim of this study is to analyze the type of surgical training that students receive in medical school and the impact of SARS-CoV-2 pandemic.
Methods: A survey based on the National Spanish Agency for the Quality of Evaluation and Accreditation (ANECA) guidelines was spread on social media between medical students and physicians waiting to start their residency. The time spent in surgical practices, the number of times that certain abilities were performed, and the desire of choosing a surgical specialty were analyzed.
Results: 1053 surveys were analyzed. Significant differences between the number of months that students rotate and the number of procedures performed as they gained seniority were found. A weak positive correlation between the number of months rotating and the number of procedures performed was found. The desire of choosing a surgical specialty was not associated with the time spent in surgical practice. SARS-CoV-2 pandemic has reduced the time spent in surgical practice and some of the surgical procedures performed.
Conclusion: The amount of surgical procedures performed by students is below the requirements of ANECA guidelines. A different level of dexterity between 6th year students’ group affected by SARS-CoV-2 pandemic and physicians’ group should not be expected because of the low number of procedures performed by both groups. Students’ role in the operating room and the need for different systems of skills learning should be reconsidered.
Invasive fungal disease (IFD) in hematopoietic stem cell transplantation is associatedwith high morbidity and mortality. As the antifungal host response determines risk and outcomeof IFD, there is growing interest in adoptive immunotherapy using T cells or natural killer (NK)cells. Although the NK-92 cell line has been tested as anticancer therapy in clinical trials, data onthe antifungal activity of NK-92 cells are lacking. Here, we show that the NK-92 cell line exhibitsconsiderable fungal damage on all medically important fungi tested, such as different species ofAspergillus,Candida, mucormycetes, andFusarium. The extent of fungal damage differs acrossvarious species of mucormycetes andFusarium, whereas it is comparable across different species ofAspergillusandCandida. Interferon (IFN)-γlevels in the supernatant were lower when NK-92 cells areco-incubated withAspergillus fumigatus,Candida albicans, orRhizopus arrhizuscompared to the levelswhen NK-92 cells are incubated alone. Different to primary human NK cells, no increase of perforinlevels in the supernatant was observed when the fungi were added to NK-92 cells. Ourin vitrodatademonstrated that the NK-92 cell line could be a feasible tool for antifungal immunotherapy, butdata of animal models are warranted prior to clinical trials.
Abstract In the middle of the twentieth century, the from North America sooty bark disease (SBD) of maples was first discovered in England and has spread in the last decades in Central Europe, in particular. The trigger of SBD is the mould fungus Cryptostroma (C.) corticale. The most common infested maple is the sycamore, Acer pseudoplatanus, a common tree in woods and parks. The disease is characterised by peeling of the outer layer of the bark and brownish-black spores under the peeled off bark. These spores can cause maple bark disease (MBD) in humans, a hypersensitivity pneumonitis (HP) with similar symptoms like COPD, allergic asthma, influenza or flu-like infections and interstitial pneumonia. Persons who have intensive respectively occupational contact with infested trees or wood, e.g., woodman, foresters, sawyers or paper mill workers, are at risk in particular. Since C. corticale favours hot summers and host trees weakened by drought, SBD will increasingly spread in the future due to ongoing climate change. Consequently, the risk of developing MBD will increase, too. As with all HPs, e.g., farmer’s lung and pigeon breeder’s disease, the diagnosis of MBD is intricate because it has no clear distinguishing characteristics compared to other interstitial lung diseases. Therefore, the establishment of consistent diagnosis guidelines is required. For correct diagnosis and successful therapy, multidisciplinary expertise including pulmonologists, radiologists, pathologists and occupational physicians is recommended. If MBD is diagnosed in time, the removal of the triggering fungus or the infested maple wood leads to complete recovery in most cases. Chronic HP can lead to lung fibrosis and a total loss of lung function culminating in death. HP and, thus, MBD, is a disease with a very high occupational amount. To avoid contact with spores of C. corticale, persons working on infested wood or trees have to wear personal protective equipment. To protect the public, areas with infested maples have to be cordoned off, and the trees should be removed. This is also for impeding further spreading of the spores.
Background: To test the effect of variant histology relative to urothelial histology on stage at presentation, cancer specific mortality (CSM) and overall mortality (OM) after chemotherapy use, in urethral cancer.
Materials and Methods: Within the Surveillance, Epidemiology and End Results (2004–2016) database, we identified 1,907 primary variant histology urethral cancer patients. Kaplan-Meier plots, Cox regression analyses, cumulative incidence-plots, multivariable competing-risks regression models and propensity score matching for patient and tumor characteristics were used.
Results:Of 1,907 eligible urethral cancer patients, urothelial histology affected 1,009 (52.9%) vs. squamous cell carcinoma (SCC) 455 (23.6%) vs. adenocarcinoma 278 (14.6%) vs. other histology 165 (8.7%) patients. Urothelial histological patients exhibited lower stages at presentation than SCC, adenocarcinoma or other histology patients. In urothelial histology patients, five-year CSM was 23.5% vs. 34.4% in SCC (Hazard Ratio (HR) 1.57) vs. 40.7% in adenocarcinoma (HR 1.69) vs. 43.4% in other histology (HR 1.99, p<0.001). After matching in multivariate competing-risks regression models, variant histology exhibited 1.35-fold higher CSM than urothelial. Finally, in metastatic urethral cancer, lower OM was recorded after chemotherapy in general, including metastatic adenocarcinoma and other variant histology subtypes, except metastatic SCC.
Conclusion: Adenocarcinoma, SCC and other histology subtypes affect fewer patients than urothelial histology. Presence of variant histology results in higher CSM. Finally, chemotherapy for metastatic urethral cancer improves survival in adenocarcinoma and other variant histology subtypes, but not in SCC.
Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning with the first discovery of leukemia and the description of the Philadelphia Chromosome and ending with the current goal of achieving treatment-free remission after targeted therapies, we describe here the journey of CML, focusing on molecular pathways relating to signaling, metabolism and the bone marrow microenvironment. We highlight current strategies for combination therapies aimed at eradicating the CML stem cell; hopefully the final destination of this long voyage.
Human babesiosis in Europe
(2021)
Babesiosis is attracting increasing attention as a worldwide emerging zoonosis. The first case of human babesiosis in Europe was described in the late 1950s and since then more than 60 cases have been reported in Europe. While the disease is relatively rare in Europe, it is significant because the majority of cases present as life-threatening fulminant infections, mainly in immunocompromised patients. Although appearing clinically similar to human babesiosis elsewhere, particularly in the USA, most European forms of the disease are distinct entities, especially concerning epidemiology, human susceptibility to infection and clinical management. This paper describes the history of the disease and reviews all published cases that have occurred in Europe with regard to the identity and genetic characteristics of the etiological agents, pathogenesis, aspects of epidemiology including the eco-epidemiology of the vectors, the clinical courses of infection, diagnostic tools and clinical management and treatment.
Background: The benefit of adjuvant therapy in synovial sarcoma (SS) treatment is under debate. Long-term follow-up data are missing.
Methods: SS patients treated in the consecutive trials CWS-81, CWS-86, CWS-91, CWS-96, CWS-2002-P, and the SoTiSaR-registry till 2013 were analyzed.
Results: Median age of 185 patients was 13.9 years (0.1–56)—with median follow-up of 7.4 years for 163 survivors. Most tumors (76%) were located in extremities. Size was < 3 cm in 58 (31%), 3–5 cm in 59 (32%), 5–10 cm in 42 (23%), and > 10 cm in 13 (7%) (13 missing). In 84 (45%) tumors, first excision was complete (R0 corresponding to IRS-I-group) and in 101 (55%) marginal (R1 corresponding to IRS-II-group). In a subsequent surgical intervention during chemotherapy, R0-status was accomplished in 23 additional IRS-II-group patients with secondary surgery. Radiotherapy was administered to 135 (73%), thereof 62 with R0-status and 67 R1-status (6 missing information). Adjuvant chemotherapy was administered to all but six patients. 5-year event-free (EFS) and overall survival (OS) was 82.9% ± 5.7 (95%CI) and 92.5% ± 3.9. Local and metastatic relapse-free survival was 91.3% ± 4.3 and 92.3% ± 4.1 at 5 years, respectively. In the multivariate analysis, tumor size and no chemotherapy were independently associated with EFS. Size and site were associated with OS. In a detailed analysis of local and metastatic events, tumor size was associated with an independent risk for developing metastases. No independent factor for suffering local recurrence could be identified.
Discussion: Omission of chemotherapy in a non-stratified way seems not justified. Size governs survival due to high linear association with risk of suffering metastatic recurrence in a granular classification.
The genetic background of pain is becoming increasingly well understood, which opens up possibilities for predicting the individual risk of persistent pain and the use of tailored therapies adapted to the variant pattern of the patient’s pain-relevant genes. The individual variant pattern of pain-relevant genes is accessible via next-generation sequencing, although the analysis of all “pain genes” would be expensive. Here, we report on the development of a cost-effective next generation sequencing-based pain-genotyping assay comprising the development of a customized AmpliSeq™ panel and bioinformatics approaches that condensate the genetic information of pain by identifying the most representative genes. The panel includes 29 key genes that have been shown to cover 70% of the biological functions exerted by a list of 540 so-called “pain genes” derived from transgenic mice experiments. These were supplemented by 43 additional genes that had been independently proposed as relevant for persistent pain. The functional genomics covered by the resulting 72 genes is particularly represented by mitogen-activated protein kinase of extracellular signal-regulated kinase and cytokine production and secretion. The present genotyping assay was established in 61 subjects of Caucasian ethnicity and investigates the functional role of the selected genes in the context of the known genetic architecture of pain without seeking functional associations for pain. The assay identified a total of 691 genetic variants, of which many have reports for a clinical relevance for pain or in another context. The assay is applicable for small to large-scale experimental setups at contemporary genotyping costs.
Objective To explore factors that potentially impact external validation performance while developing and validating a prognostic model for hospital admissions (HAs) in complex older general practice patients.
Study design and setting Using individual participant data from four cluster-randomised trials conducted in the Netherlands and Germany, we used logistic regression to develop a prognostic model to predict all-cause HAs within a 6-month follow-up period. A stratified intercept was used to account for heterogeneity in baseline risk between the studies. The model was validated both internally and by using internal-external cross-validation (IECV).
Results Prior HAs, physical components of the health-related quality of life comorbidity index, and medication-related variables were used in the final model. While achieving moderate discriminatory performance, internal bootstrap validation revealed a pronounced risk of overfitting. The results of the IECV, in which calibration was highly variable even after accounting for between-study heterogeneity, agreed with this finding. Heterogeneity was equally reflected in differing baseline risk, predictor effects and absolute risk predictions.
Conclusions Predictor effect heterogeneity and differing baseline risk can explain the limited external performance of HA prediction models. With such drivers known, model adjustments in external validation settings (eg, intercept recalibration, complete updating) can be applied more purposefully.
Trial registration number PROSPERO id: CRD42018088129.
The increasing use of targeted therapy (TT) has resulted in prolonged disease control and survival in many metastatic cancers. In parallel, stereotactic radiotherapy (SRT) is increasingly performed in patients receiving TT to obtain a durable control of resistant metastases, and thereby to prolong the time to disseminated disease progression and switch of systemic therapy. The aims of this study were to analyze the safety and efficacy of SRT combined with TT in metastatic cancer patients and to assess the influence of continuous vs. interrupted TT during metastasis-directed SRT. The data of 454 SRTs in 158 patients from the international multicenter database (TOaSTT) on metastatic cancer patients treated with SRT and concurrent TT (within 30 days) were analyzed using Kaplan–Meier and log rank testing. Toxicity was defined by the CTCAE v4.03 criteria. The median FU was 19.9 mo (range 1–102 mo); 1y OS, PFS and LC were 59%, 24% and 84%, respectively. Median TTS was 25.5 mo (95% CI 11–40). TT was started before SRT in 77% of patients. TT was interrupted during SRT in 44% of patients, with a median interruption of 7 (range 1–42) days. There was no significant difference in OS or PFS whether TT was temporarily interrupted during SRT or not. Any-grade acute and late SRT-related toxicity occurred in 63 (40%) and 52 (33%) patients, respectively. The highest toxicity rates were observed for the combination of SRT and EGFRi or BRAF/MEKi, and any-grade toxicity was significantly increased when EGFRi (p = 0.016) or BRAF/MEKi (p = 0.009) were continued during SRT. Severe (≥grade 3) acute and late SRT-related toxicity were observed in 5 (3%) and 7 (4%) patients, respectively, most frequently in patients treated with EGFRi or BRAF/MEKi and in the intracranial cohort. There was no significant difference in severe toxicity whether TT was interrupted before and after SRT or not. In conclusion, SRT and continuous vs. interrupted TT in metastatic cancer patients did not influence OS or PFS. Overall, severe toxicity of combined treatment was rare; a potentially increased toxicity after SRT and continuous treatment with EGFR inhibitors or BRAF(±MEK) inhibitors requires further evaluation.
Background: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making. Methods: Between January 2017–June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional IHC staining for diagnostic purpose. Final pathologic results after radical prostatectomy (RP) were analyzed regarding the effect of IHC at biopsy. Results: Of 606 biopsies, 350 (58.7%) received additional IHC staining. Of those, prostate cancer (PCa) was found in 208 patients (59.4%); while in 142 patients (40.6%), PCa could be ruled out through IHC. IHC patients harbored significantly more often Gleason 6 in biopsy (p < 0.01) and less suspicious baseline characteristics than patients without IHC. Of 185 patients with positive IHC and PCa detection, IHC led to a change in biopsy results in 81 (43.8%) patients. Of these patients with changes in biopsy results due to IHC, 42 (51.9%) underwent RP with 59.5% harboring ≥pT3 and/or Gleason 7–10. Conclusions: Patients with IHC stains had less suspicious characteristics than patients without IHC. Moreover, in patients with positive IHC and PCa detection, a change in biopsy results was observed in >40%. Patients with changes in biopsy results partly underwent RP, in which 60% harbored significant PCa.
Background: Cumulative anticholinergic exposure, also known as anticholinergic burden, is associated with a variety of adverse outcomes. However, studies show that anticholinergic effects tend to be underestimated by prescribers, and anticholinergics are the most frequently prescribed potentially inappropriate medication in older patients. The grading systems and drugs included in existing scales to quantify anticholinergic burden differ considerably and do not adequately account for patients’ susceptibility to medications. Furthermore, their ability to link anticholinergic burden with adverse outcomes such as falls is unclear. This study aims to develop a prognostic model that predicts falls in older general practice patients, to assess the performance of several anticholinergic burden scales, and to quantify the added predictive value of anticholinergic symptoms in this context.
Methods: Data from two cluster-randomized controlled trials investigating medication optimization in older general practice patients in Germany will be used. One trial (RIME, n = 1,197) will be used for the model development and the other trial (PRIMUM, n = 502) will be used to externally validate the model. A priori, candidate predictors will be selected based on a literature search, predictor availability, and clinical reasoning. Candidate predictors will include socio-demographics (e.g. age, sex), morbidity (e.g. single conditions), medication (e.g. polypharmacy, anticholinergic burden as defined by scales), and well-being (e.g. quality of life, physical function). A prognostic model including sociodemographic and lifestyle-related factors, as well as variables on morbidity, medication, health status, and well-being, will be developed, whereby the prognostic value of extending the model to include additional patient-reported symptoms will be also assessed. Logistic regression will be used for the binary outcome, which will be defined as “no falls” vs. “≥1 fall” within six months of baseline, as reported in patient interviews. Discussion: As the ability of different anticholinergic burden scales to predict falls in older patients is unclear, this study may provide insights into their relative importance as well as into the overall contribution of anticholinergic symptoms and other patient characteristics. The results may support general practitioners in their clinical decision-making and in prescribing fewer medications with anticholinergic properties.
The present guidelines comprise relevant aspects of the use of compression therapy with medical compression stockings (MCS), phlebological compression bandages (PCB), and medical adaptive compression systems (MAC) based on an extensive literature search based on the state of scientific knowledge as of December 2018.
These guidelines were prepared by experts within the framework of an electronic consensus process and a consensus conference which took place in Bielefeld, Germany, on September 27, 2018, on the initiative of the German Society of Phlebology (DGP) and the Professional Association of Phlebologists (BVP). The guidelines were adopted by the boards and advisory councils of the DGP and the BVP, and of the participating professional associations, after preparation by the group of experts and extensive debate, on December 31, 2018.
These guidelines do not cover compression therapy with medical thrombosis prophylaxis stockings (MTPS) or with intermittent pneumatic compression (IPC), which are treated in other guidelines (AWMF 003-001, S3; AWMF 037-001, S1).
The recommendations of the AWMF guidelines “Diagnostics and Treatment of Lymphedema” (registration number 058-001) and “Lipedema” (registration number 037-012) shall also be taken into account where appropriate: https://www.awmf.org/uploads/tx_szleitlinien/058-001l_S2k_Diagnostik_und_Therapie_der_Lymphoedeme_2017-05.pdf, https://www.awmf.org/uploads/tx_szleitlinien/037-012l_S1_Lipoedem_2016-01.pdf.
Cutaneous T cell lymphomas (CTCLs) represent a heterogeneous group of T cell lymphomas that primarily affect the skin. The most frequent forms of CTCL are mycosis fungoides and Sézary syndrome. Both are characterized by frequent recurrence, developing chronic conditions and high mortality with a lack of a curative treatment. In this study, we evaluated the effect of short-chain, cell-permeable C6 Ceramide (C6Cer) on CTCL cell lines and keratinocytes. C6Cer significantly reduced cell viability of CTCL cell lines and induced cell death via apoptosis and necrosis. In contrast, primary human keratinocytes and HaCaT keratinocytes were less affected by C6Cer. Both keratinocyte cell lines showed higher expressions of ceramide catabolizing enzymes and HaCaT keratinocytes were able to metabolize C6Cer faster and more efficiently than CTCL cell lines, which might explain the observed protective effects. Along with other existing skin-directed therapies, C6Cer could be a novel well-tolerated drug for the topical treatment of CTCL.
Introduction: Ischemic and hemorrhagic strokes in the brainstem and cerebellum with injury to the functional loop of the Guillain-Mollaret triangle (GMT) can trigger a series of events that result in secondary trans-synaptic neurodegeneration of the inferior olivary nucleus. In an unknown percentage of patients, this leads to a condition called hypertrophic olivary degeneration (HOD). Characteristic clinical symptoms of HOD progress slowly over months and consist of a rhythmic palatal tremor, vertical pendular nystagmus, and Holmes tremor of the upper limbs. Diffusion Tensor Imaging (DTI) with tractography is a promising method to identify functional pathway lesions along the cerebello-thalamo-cortical connectivity and to generate a deeper understanding of the HOD pathophysiology. The incidence of HOD development following stroke and the timeline of clinical symptoms have not yet been determined in prospective studies—a prerequisite for the surveillance of patients at risk. Methods and Analysis: Patients with ischemic and hemorrhagic strokes in the brainstem and cerebellum with a topo-anatomical relation to the GMT are recruited within certified stroke units of the Interdisciplinary Neurovascular Network of the Rhine-Main. Matching lesions are identified using a predefined MRI template. Eligible patients are prospectively followed up and present at 4 and 8 months after the index event. During study visits, a clinical neurological examination and brain MRI, including high-resolution T2-, proton-density-weighted imaging, and DTI tractography, are performed. Fiberoptic endoscopic evaluation of swallowing is optional if palatal tremor is encountered. Study Outcomes: The primary endpoint of this prospective clinical multicenter study is to determine the frequency of radiological HOD development in patients with a posterior fossa stroke affecting the GMT at 8 months after the index event. Secondary endpoints are identification of (1) the timeline and relevance of clinical symptoms, (2) lesion localizations more prone to HOD occurrence, and (3) the best MR-imaging regimen for HOD identification. Additionally, (4) DTI tractography data are used to analyze individual pathway lesions. The aim is to contribute to the epidemiological and pathophysiological understanding of HOD and hereby facilitate future research on therapeutic and prophylactic measures.
Effects of foam rolling duration on tissue stiffness and perfusion: a randomized cross-over trial
(2021)
Despite its beneficial effects on flexibility and muscle soreness, there is still conflicting evidence regarding dose-response relationships and underlying mechanisms of foam rolling (FR). This study aimed to investigate the impact of different FR protocols on tissue perfusion and tissue stiffness. In a randomized crossover trial, two FR protocols (2x1 min, 2x3 min) were applied to the right anterior thigh of twenty healthy volunteers (11 females, 25 ± 4 years). Tissue perfusion (near infrared spectroscopy, NIRS) and stiffness (Tensiomyography, TMG and Myotonometry, MMT) were assessed before and after FR application. Variance analyses revealed a significant interaction of FR duration and tissue perfusion (F[1,19] = 7.098, p = 0.015). Local blood flow increased significantly from pre to post test (F[1,19] = 7.589, p = 0.013), being higher (Δ +9.7%) in the long-FR condition than in the short-FR condition (Δ +2.8%). Tissue stiffness (MMT) showed significant main effects for time (F[1,19] = 12.074, p = 0.003) and condition (F[1,19] = 7.165, p = 0.015) with decreases after short-FR (Δ -1.6%) and long-FR condition (Δ -1.9%). However, there was no time*dose-interaction (F[1,19] = 0.018, p = 0.895). No differences were found for TMG (p > 0.05). FR-induced changes failed to exceed the minimal detectable change threshold (MDC). Our data suggest that increased blood flow and altered tissue stiffness may mediate the effects of FR although statistical MDC thresholds were not achieved. Longer FR durations seem to be more beneficial for perfusion which is of interest for exercise professionals designing warm-up and cool-down regimes. Further research is needed to understand probable effects on parasympathetic outcomes representing systemic physiological responses to locally applied FR stimulations.
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.
Background: This study aims to test the effect of the 10 most common nonurological primary cancers (skin, rectal, colon, lymphoma, leukemia, pancreas, stomach, esophagus, liver, lung) on overall mortality (OM) after secondary prostate cancer (PCa). Material and Methods: Within the Surveillance, Epidemiology, and End Results (SEER) database, patients with 10 most common primary cancers and concomitant secondary PCa (diagnosed 2004–2016) were identified and were matched in 1:4 fashion (age, year at diagnosis, race/ethnicity, treatment type, TNM stage) with primary PCa controls. OM was compared between secondary and primary PCa patients and was stratified according to primary cancer type, as well as according to time interval between primary cancer vs. secondary PCa diagnoses. Results: We identified 24,848 secondary PCa patients (skin, n = 3,871; rectal, n = 798; colon, n = 3,665; lymphoma, n = 2,583; leukemia, n = 1,102; pancreatic, n = 118; stomach, n = 361; esophagus, n = 219; liver, n = 160; lung, n = 1,328) vs. 531,732 primary PCa patients. Secondary PCa characteristics were less favorable than those of primary PCa patients (PSA and grade), and smaller proportions of secondary PCa patients received active treatment. After 1:4 matching, all secondary PCa exhibited worse OM than primary PCa patients. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis and subsequent secondary PCa. Conclusion: Patients with secondary PCa are diagnosed with less favorable PSA and grade. Even after matching for PCa characteristics, secondary PCa patients still exhibit worse survival. However, the survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary cancer diagnosis.
Surviving death: emerging concepts of RIPK3 and MLKL ubiquitination in the regulation of necroptosis
(2021)
Lytic forms of programmed cell death, like necroptosis, are characterised by cell rupture and the release of cellular contents, often provoking inflammatory responses. In the recent years, necroptosis has been shown to play important roles in human diseases like cancer, infections and ischaemia/reperfusion injury. Coordinated interactions between RIPK1, RIPK3 and MLKL lead to the formation of a dedicated death complex called the necrosome that triggers MLKL-mediated membrane rupture and necroptotic cell death. Necroptotic cell death is tightly controlled by post-translational modifications, among which especially phosphorylation has been characterised in great detail. Although selective ubiquitination is relatively well-explored in the early initiation stages of necroptosis, the mechanisms and functional consequences of RIPK3 and MLKL ubiquitination for necrosome function and necroptosis are only starting to emerge. This review provides an overview on how site-specific ubiquitination of RIPK3 and MLKL regulates, fine-tunes and reverses the execution of necroptotic cell death.
Long non-coding RNA aerrie controls DNA damage repair via YBX1 to maintain endothelial cell function
(2021)
Aging is accompanied by many physiological changes. These changes can progressively lead to many types of cardiovascular diseases. During this process blood vessels lose their ability to maintain vascular homeostasis, ultimately resulting in hypertension, stroke, or myocardial infarction. Increase in DNA damage is one of the hallmarks of aging and can be repaired by the DNA signaling and repair system. In our study we show that long non-coding RNA Aerrie (linc01013) contributes to the DNA signaling and repair mechanism. Silencing of Aerrie in endothelial cells impairs angiogenesis, migration, and barrier function. Aerrie associates with YBX1 and together they act as important factors in DNA damage signaling and repair. This study identifies Aerrie as a novel factor in genomic stability and as a binding partner of YBX1 in responding to DNA damage.
Endothelial cells can acquire a mesenchymal phenotype through a process called Endothelial-to-Mesenchymal transition (EndMT). This event is found in embryonic development, but also in pathological conditions. Blood vessels lose their ability to maintain vascular homeostasis and ultimately develop atherosclerosis, pulmonary hypertension, or fibrosis. An increase in inflammatory signals causes an upregulation of EndMT transcription factors, mesenchymal markers, and a decrease in endothelial markers. In our study, we show that the induction of EndMT results in an increase in long non-coding RNA AERRIE expression. JMJD2B, a known EndMT regulator, induces AERRIE and subsequently SULF1. Silencing of AERRIE shows a partial regulation of SULF1 but showed no effect on the endothelial and mesenchymal markers. Additionally, the overexpression of AERRIE results in no significant changes in EndMT markers, suggesting that AERRIE is marginally regulating mesenchymal markers and transcription factors. This study identifies AERRIE as a novel factor in EndMT, but its mechanism of action still needs to be elucidated.
Cancer stem cells (CSCs) are nowadays one of the major focuses in tumor research since this subpopulation was revealed to be a great obstacle for successful treatment. The identification of CSCs in pediatric solid tumors harbors major challenges because of the immature character of these tumors. Here, we present CD34, CD90, OV-6 and cell-surface vimentin (csVimentin) as reliable markers to identify CSCs in hepatoblastoma cell lines. We were able to identify CSC characteristics for the subset of CD34+CD90+OV-6+csVimentin+-co-expressing cells, such as pluripotency, self-renewal, increased expression of EMT markers and migration. Treatment with Cisplatin as the standard chemotherapeutic drug in hepatoblastoma therapy further revealed the chemo-resistance of this subset, which is a main characteristic of CSCs. When we treated the cells with the Hsp90 inhibitor 17-AAG, we observed a significant reduction in the CSC subset. With our study, we identified CSCs of hepatoblastoma using CD34, CD90, OV-6 and csVimentin. This set of markers could be helpful to estimate the success of novel therapeutic approaches, as resistant CSCs are responsible for tumor relapses.
Background:
Specialised palliative home-care supports patients with life-limiting diseases in their familiar surroundings. The number of palliative care teams and patients being cared for is increasing worldwide. To assess and improve quality, it is needed to understand, how specialised palliative home-care can be provided successfully. For this purpose we examined the views of all involved stakeholders.
Aim:
To identify the issues that patients, their relatives and involved health professionals view as important in ensuring the success of specialised palliative home-care.
Design:
We used a qualitative design based on participant observations, interviews and focus groups following the principles of a Grounded Theory approach.
Setting/participants:
All specialised palliative home-care teams (n = 22) caring for adults in Hesse, Germany, participated. We conducted participant observations (n = 5), and interviewed patients (n = 14), relatives (n = 14) and health professionals working in or collaborating with specialised palliative home-care (n = 30). We also conducted focus groups (n = 4) with health professionals including a member check.
Results:
Successful specialised palliative home-care needs to treat complex symptoms, and provide comprehensive care including organisation of care, involving relatives and addressing issues of death and dying. Sense of security for patients and relatives is key to enable care at home. Care delivery preferences include a focus on the quality of relationships, respect for individuality and the facilitation of self-determination.
Conclusions:
Consideration of the identified key issues can help to ensure successful specialised palliative home-care. Knowledge of these should also be considered when researching and assessing quality of care.
Trial registration:
German Clinical Trials Register DRKS-ID: DRKS00012421; http://www.germanctr.de.
Genes encoding endocannabinoid and sphingolipid metabolism pathways were suggested to contribute to the genetic risk towards attention deficit hyperactivity disorder (ADHD). The present pilot study assessed plasma concentrations of candidate endocannabinoids, sphingolipids and ceramides in individuals with adult ADHD in comparison with healthy controls and patients with affective disorders. Targeted lipid analyses of 23 different lipid species were performed in 71 mental disorder patients and 98 healthy controls (HC). The patients were diagnosed with adult ADHD (n = 12), affective disorder (major depression, MD n = 16 or bipolar disorder, BD n = 6) or adult ADHD with comorbid affective disorders (n = 37). Canonical discriminant analysis and CHAID analyses were used to identify major components that predicted the diagnostic group. ADHD patients had increased plasma concentrations of sphingosine-1-phosphate (S1P d18:1) and sphinganine-1-phosphate (S1P d18:0). In addition, the endocannabinoids, anandamide (AEA) and arachidonoylglycerol were increased. MD/BD patients had increased long chain ceramides, most prominently Cer22:0, but low endocannabinoids in contrast to ADHD patients. Patients with ADHD and comorbid affective disorders displayed increased S1P d18:1 and increased Cer22:0, but the individual lipid levels were lower than in the non-comorbid disorders. Sphingolipid profiles differ between patients suffering from ADHD and affective disorders, with overlapping patterns in comorbid patients. The S1P d18:1 to Cer22:0 ratio may constitute a diagnostic or prognostic tool.
The dismal prognosis of pediatric and young adult patients with high-risk rhabdomyosarcoma (RMS) underscores the need for novel treatment options for this patient group. In previous studies, the tumor-associated surface antigen ERBB2 (HER2/neu) was identified as targetable in high-risk RMS. As a proof of concept, in this study, a novel treatment approach against RMS tumors using a genetically modified natural killer (NK)-92 cell line (NK-92/5.28.z) as an off-the-shelf ERBB2-chimeric antigen receptor (CAR)-engineered cell product was preclinically explored. In cytotoxicity assays, NK-92/5.28.z cells specifically recognized and efficiently eliminated RMS cell suspensions, tumor cell monolayers, and 3D tumor spheroids via the ERBB2-CAR even at effector-to-target ratios as low as 1:1. In contrast to unmodified parental NK-92 cells, which failed to lyse RMS cells, NK-92/5.28.z cells proliferated and became further activated through contact with ERBB2-positive tumor cells. Furthermore, high amounts of effector molecules, such as proinflammatory and antitumoral cytokines, were found in cocultures of NK-92/5.28.z cells with tumor cells. Taken together, our data suggest the enormous potential of this approach for improving the immunotherapy of treatment-resistant tumors, revealing the dual role of NK-92/5.28.z cells as CAR-targeted killers and modulators of endogenous adaptive immunity even in the inhibitory tumor microenvironment of high-risk RMS.
Evaluation of 2‑methoxyestradiol serum levels as a potential prognostic marker in malignant melanoma
(2021)
Experimental findings indicated that 2‑methoxyestradiol (2‑ME), an endogenous metabolite of 17β‑estradiol, may exhibit anti‑tumorigenic properties in various types of tumour, such as melanoma and endometrial carcinoma. In patients with endometrial cancer, the serum levels of 2‑ME are decreased compared with those in healthy controls, and this finding has been associated with a poor outcome. The aim of the present study was to examine whether the serum levels of 2‑ME are decreased in patients with melanoma, and whether this decrease may be correlated with disease stage and, therefore, serve as a prognostic indicator. ELISA was used to detect serum levels of 2‑ME in patients with stage I‑IV malignant melanoma (MM). A cohort of 78 patients with MM was analysed, along with 25 healthy controls, among whom 15 were women in the second trimester of pregnancy (positive control). As expected, significantly elevated levels of serum 2‑ME were observed in pregnant control patients compared with those in patients with MM and healthy controls. There was no observed correlation between 2‑ME serum levels in patients with MM and disease stage, tumour thickness, lactate dehydrogenase or S100 calcium‑binding protein B levels. In addition, the 2‑ME levels of patients with MM did not differ significantly from those of normal healthy controls. Overall, the findings of the present study indicated that the 2‑ME serum levels in patients with MM were not decreased, and there was no correlation with early‑ or advanced‑stage disease. Therefore, in contrast to published results on endometrial cancer, endogenous serum 2‑ME levels in MM were not found to be correlated with tumour stage and did not appear to be a suitable prognostic factor in MM.
Tiotropium as an add-on treatment option for severe uncontrolled asthma in preschool patients
(2021)
Background: Toddlers with asthma suffer disproportionally more than school-aged children from exacerbations with emergency visits and hospital admissions despite inhaled corticosteroid (ICS) treatment. A recent trial for children ≤ 5 years showed tolerability of tiotropium and potential to reduce asthma-related events.
Methods: We conducted a retrospective analysis of electronic outpatient records (2017‒2019) of children < 6 years treated with ICS plus long-acting β2-agonists (LABAs) plus tiotropium as an add-on for uncontrolled severe asthma. The primary endpoint was a comparison of systemic corticosteroid (SCS) prescriptions 6 months before and after ICS/LABA/tiotropium start. Secondary endpoints included physician visits, hospitalisations and antibiotic prescriptions. We compared outcomes with children without asthma matched for age, sex, season and screening date.
Results: Compared with a mean 2.42 (95% CI: 1.75, 3.36) SCS courses per patient within 6 months prior to ICS/LABA/tiotropium, 0.74 (95% CI: 0.25, 1.08) SCS courses per patient were prescribed within 6 months after starting ICS/LABA/tiotropium (P< 0.001). Physician visits dropped from 9.23 (95% CI: 7.15, 12.72) to 5.76 (95% CI: 3.10, 7.70) per patient (P< 0.01). Nineteen hospitalisations were recorded 6 months before ICS/LABA/tiotropium compared with one hospitalisation after (P< 0.01). A mean 1.79 antibiotic courses (95% CI: 1.22, 2.23) per patient were prescribed before ICS/LABA/tiotropium compared with 0.74 (95% CI: 0.22, 1.00) after ICS/LABA/tiotropium (P< 0.001). Hospitalisation rates for patients at observation end were not statistically different from healthy controls before/after matching.
Interpretation: Our retrospective study showed that adding tiotropium to ICS/LABA is a new treatment option for patients with severe preschool asthma; however, larger confirmatory studies are needed.
A new and readily available pentafluorothiophenyl-substituted N-methyl-piperidone curcuminoid 1a was prepared and investigated for its anti-proliferative, pro-apoptotic and cancer stem cell-differentiating activities against a panel of human tumor cell lines derived from various tumor entities. The compound 1a was highly anti-proliferative and reached IC50 values in the nanomolar concentration range. 1a was superior to the known anti-tumorally active curcuminoid EF24 (2) and its known N-ethyl-piperidone analog 1b in all tested tumor cell lines. Furthermore, 1a induced a noticeable increase of intracellular reactive oxygen species in HT-29 colon adenocarcinoma cells, which possibly leads to a distinct increase in sub-G1 cells, as assessed by cell cycle analysis. A considerable activation of the executioner-caspases 3 and 7 as well as nuclei fragmentation, cell rounding, and membrane protrusions suggest the triggering of an apoptotic mechanism. Yet another effect was the re-organization of the actin cytoskeleton shown by the formation of stress fibers and actin aggregation. 1a also caused cell death in the adherently cultured glioblastoma cell lines U251 and Mz54. We furthermore observed that 1a strongly suppressed the stem cell properties of glioma stem-like cell lines including one primary line, highlighting the potential therapeutic relevance of this new compound.
Background: The aim of this pilot study was to analyze the work of neurologists regarding static posture (> 4 s) and to identify awkward postures. Methods: A total of 9 neurologists (assistant physicians; 3 male, 6 female) participated in this study. Kinematic data were collected using the computer-assisted acquisition and long-term analysis of musculoskeletal loads (CUELA; IFA, Sankt Augustin, Germany) system. Daily work (“office work,” “measures on patients,” and “other activities”) was analyzed with a computer-based task analysis. Results: During ”measures on patients,” more than 80% of the total percentage of non-neutral posture was assumed with a flexed position of the head and entire back, both during “blood collection” (4.7% of the time) and while “placing intravenous catheters” (8.3% of the time). In contrast, long static postures (> 30 s) in the head and neck area, including the thoracic spine, were adopted during “office work.” Despite the increased total percentage of non-neutral attitudes during measures on patients, the time share of 3.4% of the total working time is so small that the risk for developing musculoskeletal disorders (MSD) is negligible. In contrast, office work, which comprises 50.8% of the total working time and longer static postures, has a potential risk for the development of MSD. Conclusion: The present study is the first kinematic pilot analysis in the field of in-patient neurological assistants. Non-neutral as well as static postures in everyday work could be identified. Potential MSD can be reduced by optimizing the working height and by taking regular breaks to loosen the musculoskeletal system.
The discovery of clustered regularly interspaced short palindromic repeats and their associated proteins (Cas) has revolutionized the field of genome and epigenome editing. A number of new methods have been developed to precisely control the function and activity of Cas proteins, including fusion proteins and small-molecule modulators. Proteolysis-targeting chimeras (PROTACs) represent a new concept using the ubiquitin-proteasome system to degrade a protein of interest, highlighting the significance of chemically induced protein-E3 ligase interaction in drug discovery. Here, we engineered Cas proteins (Cas9, dCas9, Cas12, and Cas13) by inserting a Phe-Cys-Pro-Phe (FCPF) amino acid sequence (known as the π-clamp system) and demonstrate that the modified CasFCPF proteins can be (1) labeled in live cells by perfluoroaromatics carrying the fluorescein or (2) degraded by a perfluoroaromatics-functionalized PROTAC (PROTAC-FCPF). A proteome-wide analysis of PROTAC-FCPF-mediated Cas9FCPF protein degradation revealed a high target specificity, suggesting a wide range of applications of perfluoroaromatics-induced proximity in the regulation of stability, activity, and functionality of any FCPF-tagging protein.
The Kinase Chemogenomic Set (KCGS): an open science resource for kinase vulnerability identification
(2021)
We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS), current Version 1.0, is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens.
In patients with von Willebrand disease (vWD) the interest in age-related comorbidities has grown, because the life expectancy of these patients has increased. The research question of this study was whether patients with vWD show a different endothelial function compared to the general population. A total of 37 patients with type 1 (n = 23), type 2 (n = 10) and type 3 (n = 4) vWD, 14 controls and 38 patients with coronary artery disease (CAD) were included in this study. Five markers of endothelial dysfunction (MOED) were determined. Moreover, the endothelial function was examined using the Itamar Endo-PAT. The reactive hyperemia index (RHI) was calculated from the results. The markers soluble intercellular adhesion molecule-1 (p = 0.171), P-Selectin (p = 0.512), interleukin-6 (p = 0.734) and monocyte chemoattractant protein-1 (p = 0.761) showed higher levels in patients with vWD, but were not significantly different compared to the control group. RHI was impaired in CAD-patients (1.855), whereas vWD patients had mean results of 1.870 and controls 2.112 (p = 0.367). In this study, the endothelial function measurements of patients with von Willebrand disease were not significantly different compared to healthy controls.
Background: Dentists (Ds) and dental assistants (DAs) have a high lifetime prevalence of musculoskeletal disorders (MSDs). In this context, it is assumed that they have an increased intake of substances such as pain medication. Currently, there exist no data on the use of medication among Ds and DAs with MSDs in Germany. Methods: The online questionnaire (i.e., the Nordic Questionnaire) analysed the medical therapies used by 389 Ds (240 f/149 m) and 406 DAs (401 f/5 m) to treat their MSDs. Results: Ds (28.3–11.5%) and DAs (29.4–10.3%) with MSDs took medication depending on the affected body region. A trend between the Ds and DAs in the intake of drug therapy and the frequency was found for the neck region (Ds: 21.1%, DAs: 28.7%). A single medication was taken most frequently (Ds: 60.0–33.3%, DAs: 71.4–27.3%). The frequency of use varied greatly for both occupational groups depending on the region affected. Conclusion: Ds and DAs perceived the need for medical therapies because of their MSDs. Painkillers such as ibuprofen and systemic diclofenac were the medications most frequently taken by both occupational groups. The intake of pain killers, most notably for the neck, should prevent sick leave.
Background: dental professionals suffer frequently from musculoskeletal disorders (MSD). Dentists and dental assistants work closely with each other in a mutually dependent relationship. To date, MSD in dental assistants have only been marginally investigated and compared to their occurrence in dentists. Therefore, the aim of this study was to compare the prevalence of MSD between dentists and dental assistants by considering occupational factors, physical activity and gender. Methods: This was a cross-sectional observational study. A Germany-wide survey, using a modified version of the Nordic Questionnaire and work-related questions, was applied. In total, 2548 participants took part, of which 389 dentists (240 females and 149 males) and 322 dental assistants (320 females and 2 males) were included in the analysis. Data were collected between May 2018 and May 2019. Differences between the dentists and dental assistants were determined by using the Chi2 test for nominal and the Wilcoxon–Mann–Whitney U test for both ordinal and non-normally distributed metric data. Results: A greater number of dental assistants reported complaints than dentists in all queried body regions. Significant differences in the most affected body regions (neck, shoulders, wrist/hands, upper back, lower back and feet/ankles) were found for the lifetime prevalence, annual prevalence and weekly prevalence. Data from the occupational factors, physical activity and gender analyses revealed significant differences between dentists and dental assistants. Conclusions: Dental assistants appear to be particularly affected by MSD when compared to dentists. This circumstance can be explained only to a limited extent by differences in gender distribution and occupational habits between the occupations.
Introduction Occurrence of inaccurate or delayed diagnoses is a significant concern in patient care, particularly in emergency medicine, where decision making is often constrained by high throughput and inaccurate admission diagnoses. Artificial intelligence-based diagnostic decision support system have been developed to enhance clinical performance by suggesting differential diagnoses to a given case, based on an integrated medical knowledge base and machine learning techniques. The purpose of the study is to evaluate the diagnostic accuracy of Ada, an app-based diagnostic tool and the impact on patient outcome.
Methods and analysis The eRadaR trial is a prospective, double-blinded study with patients presenting to the emergency room (ER) with abdominal pain. At initial contact in the ER, a structured interview will be performed using the Ada-App and both, patients and attending physicians, will be blinded to the proposed diagnosis lists until trial completion. Throughout the study, clinical data relating to diagnostic findings and types of therapy will be obtained and the follow-up until day 90 will comprise occurrence of complications and overall survival of patients. The primary efficacy of the trial is defined by the percentage of correct diagnoses suggested by Ada compared with the final discharge diagnosis. Further, accuracy and timing of diagnosis will be compared with decision making of classical doctor–patient interaction. Secondary objectives are complications, length of hospital stay and overall survival.
Ethics and dissemination Ethical approval was received by the independent ethics committee (IEC) of the Goethe-University Frankfurt on 9 April 2020 including the patient information material and informed consent form. All protocol amendments must be reported to and adapted by the IEC. The results from this study will be submitted to peer-reviewed journals and reported at suitable national and international meetings.
Trial registration number DRKS00019098.
The function of the cerebral cortex essentially depends on the ability to form functional assemblies across different cortical areas serving different functions. Here we investigated how developmental hearing experience affects functional and effective interareal connectivity in the auditory cortex in an animal model with years-long and complete auditory deprivation (deafness) from birth, the congenitally deaf cat (CDC). Using intracortical multielectrode arrays, neuronal activity of adult hearing controls and CDCs was registered in the primary auditory cortex and the secondary posterior auditory field (PAF). Ongoing activity as well as responses to acoustic stimulation (in adult hearing controls) and electric stimulation applied via cochlear implants (in adult hearing controls and CDCs) were analyzed. As functional connectivity measures pairwise phase consistency and Granger causality were used. While the number of coupled sites was nearly identical between controls and CDCs, a reduced coupling strength between the primary and the higher order field was found in CDCs under auditory stimulation. Such stimulus-related decoupling was particularly pronounced in the alpha band and in top–down direction. Ongoing connectivity did not show such a decoupling. These findings suggest that developmental experience is essential for functional interareal interactions during sensory processing. The outcomes demonstrate that corticocortical couplings, particularly top-down connectivity, are compromised following congenital sensory deprivation.
Objective: Dravet syndrome (DS) is a rare but severe drug-resistant epilepsy. Before the approval of fenfluramine (FFA) for the treatment of seizures in DS, patients in Germany could receive treatment under a compassionate use program (CUP). Methods: We conducted a multicenter, retrospective, observational study to describe the efficacy, tolerability, and retention of FFA within the CUP. Patients received add-on therapy with oral FFA gradually titrated to a target dose between .13 and .7 mg/kg/day. Results: Overall, 78 patients with DS (median age = 8.0 years, range = 2.1–46.0; 53% female, median concomitant antiseizure medications [ASMs] = 3) were treated with FFA for a median duration of 255.5 days (range = 31–572). Responder rates (a ≥50% reduction; n = 78) and seizure-freedom rates at 3 months were 68% and 14% for total seizures, respectively, and 67% and 23% for generalized tonic–clonic seizures. Responder rates were consistent at 6 and 12 months (n = 66 and n = 43, respectively). Median seizure days per month significantly decreased from 10.0 (range = .5–30) to 3.0 (range = 0–30) in the 3-month period before and after FFA treatment (p < .001). Significantly fewer patients reported at least one episode of status epilepticus (28% vs. 14% patients before and after FFA initiation, p = .005). During FFA treatment, 35 (45%) patients were able to discontinue a concomitant ASM. At the last follow-up date, 66 (85%) patients remained on treatment with FFA. The most common adverse events were somnolence (36%), decreased appetite (22%), and ataxia (8%). Forty-eight (62%) patients were reported as having a meaningful global clinical improvement. Significance: In a large cohort of patients, FFA demonstrated efficacy across a range of outcomes including clinically significant reductions in convulsive seizures, and was well tolerated, providing valuable information for real-world practice.
Key Points: Seventy-eight patients with Dravet syndrome were treated with FFA at multiple centers within the CUP in Germany; FFA had a good retention rate over a sustained period; 85% of patients remained on treatment with FFA for a median duration of 255.5 days; FFA was associated with clinically meaningful reductions in total and convulsive seizures, seizure days per month, and episodes of status epilepticus; FFA was associated with reductions in the number or dose of concomitant antiseizure medications in 68% of patients; FFA was well tolerated, with the main adverse events being somnolence (36%), decreased appetite (22%), and ataxia (8%).
Background: Various studies have been made about the most effective and safest type of treatment for vertebral compression fractures (VCFs). Long-term results are needed for qualitative evaluation.
Purpose: The purpose of the study is to evaluate the effectiveness of percutaneous vertebroplasty (PVP) and percutaneous kyphoplasty (PKP) procedures for VCFs.
Materials and Methods: Forty-nine patients who received either PVP or PKP between 2002 and 2015 returned a specially developed questionnaire and were included in a cross-sectional outcome analysis. The questionnaire assessed pain development by use of a visual analog scale (VAS). Imaging data (CT scans) were retrospectively analyzed for identification of cement leakage.
Results: Patients’ VAS scores significantly decreased after treatment (7.0 ± 3.4 => 3.7 ± 3.4), (p < 0.001). The average pain reduction in patients treated with PVP was −3.3 ± 3.8 (p < 0.001) (median −3.5) and −4.0 ± 3.9 (p < 0.001) (median −4.5) in patients treated with PKP. Fifteen Patients (41.7%) receiving PVP and four patients (30.7%) receiving PKP experienced recurrence of pain. Cement leakage occurred in 10 patients (22.73%). Patients with cement leakage showed comparable VAS scores after treatment (6.8 ± 3.5 => 1.4 ± 1.6), (p = 0.008). Thirty-nine patients reported an increase in mobility (79.6%) and 41 patients an improvement in quality of life (83.7%).
Conclusion: Pain reduction by means of PVP or PKP in patients with VCFs was discernible over the period of observation. Percutaneous vertebroplasty and PKP contribute to the desired treatment results. However, the level of low pain may not remain constant.
Aqueous solutions of a nonionic surfactant (either Tween20 or BrijL23) and an anionic surfactant (sodium dodecyl sulfate, SDS) are investigated, using small-angle neutron scattering (SANS). SANS spectra are analysed by using a core-shell model to describe the form factor of self-assembled surfactant micelles; the intermicellar interactions are modelled by using a hard-sphere Percus–Yevick (HS-PY) or a rescaled mean spherical approximation (RMSA) structure factor. Choosing these specific nonionic surfactants allows for comparison of the effect of branched (Tween20) and linear (BrijL23) surfactant headgroups, both constituted of poly-ethylene oxide (PEO) groups. The nonionic–anionic surfactant mixtures are studied at various concentrations up to highly concentrated samples (ϕ ≲ 0.45) and various mixing ratios, from pure nonionic to pure anionic surfactant solutions. The scattering data reveal the formation of mixed micelles already at concentrations below the critical micelle concentration of SDS. At higher volume fractions, excluded volume effects dominate the intermicellar structuring, even for charged micelles. In consequence, at high volume fractions, the intermicellar structuring is the same for charged and uncharged micelles. At all mixing ratios, almost spherical mixed micelles form. This offers the opportunity to create a system of colloidal particles with a variable surface charge. This excludes only roughly equimolar mixing ratios (X≈ 0.4–0.6) at which the micelles significantly increase in size and ellipticity due to specific sulfate–EO interactions.
The hexosamine biosynthetic pathway (HBP) is essential for the production of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the building block of glycosaminoglycans, thus playing a crucial role in cartilage anabolism. Although O-GlcNAcylation represents a protective regulatory mechanism in cellular processes, it has been associated with degenerative diseases, including osteoarthritis (OA). The present study focuses on HBP-related processes as potential therapeutic targets after cartilage trauma. Human cartilage explants were traumatized and treated with GlcNAc or glucosamine sulfate (GS); PUGNAc, an inhibitor of O-GlcNAcase; or azaserine (AZA), an inhibitor of GFAT-1. After 7 days, cell viability and gene expression analysis of anabolic and catabolic markers, as well as HBP-related enzymes, were performed. Moreover, expression of catabolic enzymes and type II collagen (COL2) biosynthesis were determined. Proteoglycan content was assessed after 14 days. Cartilage trauma led to a dysbalanced expression of different HBP-related enzymes, comparable to the situation in highly degenerated tissue. While GlcNAc and PUGNAc resulted in significant cell protection after trauma, only PUGNAc increased COL2 biosynthesis. Moreover, PUGNAc and both glucosamine derivatives had anti-catabolic effects. In contrast, AZA increased catabolic processes. Overall, “fueling” the HBP by means of glucosamine derivatives or inhibition of deglycosylation turned out as cells and chondroprotectives after cartilage trauma.
In den Bürgerwissenschaften, auch bekannt unter dem englischen Begriff Citizen Science, existiert eine Vielzahl an Forschungsansätzen und Methoden. Während diese in vielen wissenschaftlichen Disziplinen gut etabliert sind, finden sich augenscheinlich relativ wenige davon in der medizinischen und Gesundheitsforschung. Allerdings zeigt ein Blick in die Praxis, dass bürgerwissenschaftliche Ansätze in der Medizin und Gesundheitsforschung durchaus praktiziert werden, jedoch häufig unter anderen Namen. Der Artikel bietet aus interdisziplinärer Perspektive einen (selektiven) Überblick über Begriffe, reflektiert diese und die dahinterstehenden Methoden und diskutiert sie vergleichend. Im Fokus steht dabei der Grad der Beteiligung der Bürger*innen bzw. Patient*innen an wissenschaftlicher Forschung.
Immune profile and radiological characteristics of progressive multifocal leukoencephalopathy
(2021)
Background and purpose: Progressive multifocal leukoencephalopathy (PML) constitutes a severe disease with increasing incidence, mostly in the context of immunosuppressive therapies. A detailed understanding of immune response in PML appears critical for the treatment strategy. The aim was a comprehensive immunoprofiling and radiological characterization of magnetic resonance imaging (MRI) defined PML variants.
Methods: All biopsy-confirmed PML patients (n = 15) treated in our department between January 2004 and July 2019 were retrospectively analysed. Data from MRI, histology as well as detailed clinical and outcome data were collected. The MRI-defined variants of classical (cPML) and inflammatory (iPML) PML were discriminated based on the intensity of gadolinium enhancement. In these PML variants, intensity and localization (perivascular vs. parenchymal) of inflammation in MRI and histology as well as the cellular composition by immunohistochemistry were assessed. The size of the demyelinating lesions was correlated with immune cell infiltration.
Results: Patients with MRI-defined iPML showed a stronger intensity of inflammation with an increased lymphocyte infiltration on histological level. Also, iPML was characterized by a predominantly perivascular inflammation. However, cPML patients also demonstrated certain inflammatory tissue alterations. Infiltration of CD163-positive microglia and macrophage (M/M) subtypes correlated with PML lesion size.
Conclusions: The non-invasive MRI-based discrimination of PML variants allows for an estimation of inflammatory tissue alterations, although exhibiting limitations in MRI-defined cPML. The association of a distinct phagocytic M/M subtype with the extent of demyelination might reflect disease progression.
Substantial evidence shows that physical activity and fitness play a protective role in the development of stress related disorders. However, the beneficial effects of fitness for resilience to modern life stress are not fully understood. Potentially protective effects may be attributed to enhanced resilience via underlying psychosocial mechanisms such as self-efficacy expectations. This study investigated whether physical activity and fitness contribute to prospectively measured resilience and examined the mediating effect of general self-efficacy. 431 initially healthy adults participated in fitness assessments as part of a longitudinal-prospective study, designed to identify mechanisms of resilience. Self-efficacy and habitual activity were assessed in parallel to cardiorespiratory and muscular fitness, which were determined by a submaximal step-test, hand strength and standing long jump test. Resilience was indexed by stressor reactivity: mental health problems in relation to reported life events and daily hassles, monitored quarterly for nine months. Hierarchical linear regression models and bootstrapped mediation analyses were applied. We could show that muscular and self-perceived fitness were positively associated with stress resilience. Extending this finding, the muscular fitness–resilience relationship was partly mediated by self-efficacy expectations. In this context, self-efficacy expectations may act as one underlying psychological mechanism, with complementary benefits for the promotion of mental health. While physical activity and cardiorespiratory fitness did not predict resilience prospectively, we found muscular and self-perceived fitness to be significant prognostic parameters for stress resilience. Although there is still more need to identify specific fitness parameters in light of stress resilience, our study underscores the general relevance of fitness for stress-related disorders prevention.
The COVID-19 pandemic and resulting measures can be regarded as a global stressor. Cross-sectional studies showed rather negative impacts on people’s mental health, while longitudinal studies considering pre-lockdown data are still scarce. The present study investigated the impact of COVID-19 related lockdown measures in a longitudinal German sample, assessed since 2017. During lockdown, 523 participants completed additional weekly online questionnaires on e.g., mental health, COVID-19-related and general stressor exposure. Predictors for and distinct trajectories of mental health outcomes were determined, using multilevel models and latent growth mixture models, respectively. Positive pandemic appraisal, social support, and adaptive cognitive emotion regulation were positively, whereas perceived stress, daily hassles, and feeling lonely negatively related to mental health outcomes in the entire sample. Three subgroups (“recovered,” 9.0%; “resilient,” 82.6%; “delayed dysfunction,” 8.4%) with different mental health responses to initial lockdown measures were identified. Subgroups differed in perceived stress and COVID-19-specific positive appraisal. Although most participants remained mentally healthy, as observed in the resilient group, we also observed inter-individual differences. Participants’ psychological state deteriorated over time in the delayed dysfunction group, putting them at risk for mental disorder development. Consequently, health services should especially identify and allocate resources to vulnerable individuals.
A high incidence of thromboembolic events associated with high mortality has been reported in severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infections with respiratory failure. The present study characterized post-transcriptional gene regulation by global microRNA (miRNA) expression in relation to activated coagulation and inflammation in 21 critically ill SARS-CoV-2 patients. The cohort consisted of patients with moderate respiratory failure (n = 11) and severe respiratory failure (n = 10) at an acute stage (day 0–3) and in the later course of the disease (>7 days). All patients needed supplemental oxygen and severe patients were defined by the requirement of positive pressure ventilation (intubation). Levels of D-dimers, activated partial thromboplastin time (aPTT), C-reactive protein (CRP), and interleukin (IL)-6 were significantly higher in patients with severe compared with moderate respiratory failure. Concurrently, next generation sequencing (NGS) analysis demonstrated increased dysregulation of miRNA expression with progression of disease severity connected to extreme downregulation of miR-320a, miR-320b and miR-320c. Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis revealed involvement in the Hippo signaling pathway, the transforming growth factor (TGF)-β signaling pathway and in the regulation of adherens junctions. The expression of all miR-320 family members was significantly correlated with CRP, IL-6, and D-dimer levels. In conclusion, our analysis underlines the importance of thromboembolic processes in patients with respiratory failure and emphasizes miRNA-320s as potential biomarkers for severe progressive SARS-CoV-2 infection.
Hematopoietic stem cell transplantation (HSCT) has been proposed as a promising therapeutic opportunity to improve immunity and prevent hematologic malignancies in Ataxia-telangiectasia (A-T). However, experience in the transplantation strategy for A-T patients is still scarce. The aim of this study was to investigate whether different approaches of HSCT are feasible in regard to graft versus host response and sufficient concerning functional immune reconstitution. Atm-deficient mice were treated with a clinically relevant non-myeloablative host-conditioning regimen and transplanted with CD90.2-depleted, green fluorescent protein (GFP)-expressing, and ataxia telangiectasia mutated (ATM)-competent bone marrow donor cells in a syngeneic, haploidentical or allogeneic setting. Like syngeneic HSCT, haploidentical HSCT, but not allogeneic HSCT extended the lifespan of Atm-deficient mice through the reduction of thymic tumors and normalized T-cell numbers. Donor-derived splenocytes isolated from transplanted Atm-deficient mice filled the gap of cell loss in the naïve T-cell population and raised CD4 cell functionality up to wild-type level. Interestingly, HSCT using heterozygous donor cells let to a significantly improved survival of Atm-deficient mice and increased CD4 cell numbers as well as CD4 cell functionality equivalent to HSCT using with wild-type donor cells. Our data provided evidence that haploidentical HSCT could be a feasible strategy for A-T, possibly even if the donor is heterozygous for ATM. However, this basic research cannot substitute any research in humans.
The estimation of the minimum time since death is one of the main applications of forensic entomology. This can be done by calculating the age of the immature stage of necrophagous flies developing on the corpse, which is confined to approximately 2–4 weeks, depending on temperature and species of the first colonizing wave of flies. Adding the age of the adult flies developed on the dead body could extend this time frame up to several weeks when the body is in a building or closed premise. However, the techniques for accurately estimating the age of adult flies are still in their beginning stages or not sufficiently validated. Here we review the current state of the art of analysing the aging of flies by evaluating the ovarian development, the amount of pteridine in the eyes, the degree of wing damage, the modification of their cuticular hydrocarbon patterns, and the increasing number of growth layers in the cuticula. New approaches, including the use of age specific molecular profiles based on the levels of gene and protein expression and the application of near infrared spectroscopy, are introduced, and the forensic relevance of these methods is discussed.
Purpose: To investigate short-term (3 months follow-up) changes in visual quality following Descemet membrane endothelial keratoplasty (DMEK) for Fuchs endothelial dystrophy (FED). Methods: In this prospective institutional case series, 51 patients that underwent DMEK for FED were included. Assessment included the Quality of Vision (QoV) questionnaire preoperatively, at 1 month, and 3 months after surgery. Secondary outcome measures were anterior segment parameters acquired by Scheimpflug imaging, corrected distance visual acuity (CDVA), and endothelial cell density (ECD). Results: Glare, hazy vision, blurred vision, and daily fluctuation in vision were the symptoms mostly reported preoperatively. All symptoms demonstrated a significant reduction of item scores for severity, frequency, and bothersome in the course after DMEK (P < 0.01). Glare and fluctuation in vision remained to some extent during the follow-up period (median score = 1). Preoperatively, corneal densitometry correlated moderately to weakly with severity of hazy vision (rs = 0.39; P = 0.03) and frequency (rs = 0.26; P = 0.02) as well as severity (rs = 0.27; P = 0.03) of blurry vision. CDVA and central corneal thickness (CCT) did not correlate with visual complains. Conclusions: Following DMEK for FED, patient-reported visual symptoms assessed by the QoV questionnaire represent a useful tool providing valuable information on the impact of DMEK on visual quality that cannot be directly estimated by morphological parameters and visual acuity only.
Purpose: To compare the effective lens position (ELP), anterior chamber depth (ACD) changes, and visual outcomes in patients with and without pseudoexfoliation syndrome (PEX) after cataract surgery.
Design: Prospective, randomized, fellow-eye controlled clinical case series.
Methods: This prospective comparative case series enrolled 56 eyes of 56 consecutive patients with (n = 28) or without PEX (n = 28) and clinically significant cataract who underwent standard phacoemulsification and were implanted with single-piece acrylic posterior chamber intraocular lenses (IOLs). The primary outcome parameters were the ACD referring to the distance between the corneal anterior surface and the lens anterior surface, which is an indicator of the postoperative axial position of the IOL (the so-called ELP) and distance corrected visual acuity (DCVA).
Results: Before surgery, the ACD was 2.54 ± 0.42 mm in the PEX group and 2.53 ± 0.38 mm in the control group (p = 0.941). Postoperatively, the ACD was 4.29 ± 0.71 mm in the PEX group and 4.33 ± 0.72 mm in the normal group, respectively (p = 0.533). There was no significant difference in ACD changes between groups (PEX group: 1.75 ± 0.74 mm, control group: 1.81 ± 0.61 mm, p = 0.806) and DCVA pre- (p = 0.469) and postoperatively (PEX group: 0.11 ± 0.13 logMAR, control group: 0.09 ± 0.17 logMAR, p = 0.245) between groups.
Conclusion: Preoperative and postoperative ACD, as an indicator of ELP, between PEX eyes and healthy eyes after cataract surgery showed no significant difference. Phacoemulsification induced similar changes in eyes with PEX compared to healthy eyes.
Astrocytes contribute to many higher brain functions. A key mechanism in glia-to-neuron signalling is vesicular exocytosis; however, the identity of exocytosis organelles remains a matter of debate. Since vesicles derived from the trans-Golgi network (TGN) are not considered in this context, we studied the astrocyte TGN by immunocytochemistry applying anti-Rab6A. In mouse brain, Rab6A immunostaining is found to be unexpectedly massive, diffuse in all regions, and is detected preferentially and abundantly in the peripheral astrocyte processes, which is hardly evident without glial fibrillary acid protein (GFAP) co-staining. All cells positive for the astrocytic markers glutamine synthetase (GS), GFAP, aldehyde dehydrogenase 1 family member L1 (Aldh1L1), or SRY (sex determining region Y)-box 9 (SOX9) were Rab6A+. Rab6A is excluded from microglia, oligodendrocytes, and NG2 cells using cell type-specific markers. In human cortex, Rab6A labelling is very similar and associated with GFAP+ astrocytes. The mouse data also confirm the specific astrocytic labelling by Aldh1L1 or SOX9; the astrocyte-specific labelling by GS sometimes debated is replicated again. In mouse and human brain, individual astrocytes display high variability in Rab6A+ structures, suggesting dynamic regulation of the glial TGN. In summary, Rab6A expression is an additional, global descriptor of astrocyte identity. Rab6A might constitute an organelle system with a potential role of Rab6A in neuropathological and physiological processes.
Objective: The COVID-19 pandemic made it necessary to convert a course on history taking, in theory and practice, to an online format over a very short time. A key question was whether, and if so to what extent, basic theory and, in particular, the practical skills required to conduct medical interviews can be learned online.
Methodology/project description: The teaching program in basic theory was didactically redesigned and asynchronously placed on a learning platform, while the practical program, which consisted of training in conducting history-taking interviews, took place with the help of video conferencing software during synchronous sessions. For the practical sessions, the lecturers received organizational and technical support.
Results: Based on initial evaluation results, a positive picture of the conversion has emerged since the course was completed. The need to restructure the course and use new teaching methods because of the COVID-19 pandemic was well accepted by lecturers and students, and the course content was successfully adapted to an online format.
Conclusion: Overall, the online format enabled the learning objectives of the course to be successfully achieved. For topics such as non-verbal communication, the evaluation results indicated that a classroom format is preferable. Asynchronous theory teaching was generally very well received. Blended learning formats thus represent an appropriate means of teaching how to conduct medical interviews. Overall, online courses on conducting medical interviews provide students with the opportunity to become acquainted with the use of digital formats to conduct doctor-patient interviews, and to develop the relevant skills.
Local anesthetics are commonly administered by nuchal infiltration to provide a temporary interscalene brachial plexus block (ISB) in a surgical setting. Although less commonly reported, local anesthetics can induce central nervous system toxicity. In this case study, we present three patients with acute central nervous system toxicity induced by local anesthetics applied during ISB with emphasis on neurological symptoms, key neuroradiological findings and functional outcome. Medical history, clinical and imaging findings, and outcome of three patients with local anesthetic-induced toxic left hemisphere syndrome during left ISB were analyzed. All patients were admitted to our neurological intensive care unit between November 2016 and September 2019. All three patients presented in poor clinical condition with impaired consciousness and left hemisphere syndrome. Electroencephalography revealed slow wave activity in the affected hemisphere of all patients. Seizure activity with progression to status epilepticus was observed in one patient. In two out of three patients, cortical FLAIR hyperintensities and restricted diffusion in the territory of the left internal carotid artery were observed in magnetic resonance imaging. Assessment of neurological severity scores revealed spontaneous partial reversibility of neurological symptoms. Local anesthetic-induced CNS toxicity during ISB can lead to severe neurological impairment and anatomically variable cerebral lesions.
Endothelial cells play a critical role in the adaptation of tissues to injury. Tissue ischemia induced by infarction leads to profound changes in endothelial cell functions and can induce transition to a mesenchymal state. Here we explore the kinetics and individual cellular responses of endothelial cells after myocardial infarction by using single cell RNA sequencing. This study demonstrates a time dependent switch in endothelial cell proliferation and inflammation associated with transient changes in metabolic gene signatures. Trajectory analysis reveals that the majority of endothelial cells 3 to 7 days after myocardial infarction acquire a transient state, characterized by mesenchymal gene expression, which returns to baseline 14 days after injury. Lineage tracing, using the Cdh5-CreERT2;mT/mG mice followed by single cell RNA sequencing, confirms the transient mesenchymal transition and reveals additional hypoxic and inflammatory signatures of endothelial cells during early and late states after injury. These data suggest that endothelial cells undergo a transient mes-enchymal activation concomitant with a metabolic adaptation within the first days after myocardial infarction but do not acquire a long-term mesenchymal fate. This mesenchymal activation may facilitate endothelial cell migration and clonal expansion to regenerate the vascular network.
Purpose: Scientific and clinical achievements in radiation, medical, and surgical oncology are changing the landscape of interdisciplinary oncology. The German Society for Radiation Oncology (DEGRO) working group of young clinicians and scientists (yDEGRO) and the DEGRO representation of associate and full professors (AKRO) are aware of the essential role of radiation oncology in multidisciplinary treatment approaches. Together, yDEGRO and AKRO endorsed developing a German radiotherapy & radiation oncology vision 2030 to address future challenges in patient care, research, and education. The vision 2030 aims to identify priorities and goals for the next decade in the field of radiation oncology. Methods: The vision development comprised three phases. During the first phase, areas of interest, objectives, and the process of vision development were defined jointly by the yDEGRO, AKRO, and the DEGRO board. In the second phase, a one-day strategy retreat was held to develop AKRO and yDEGRO representatives’ final vision from medicine, biology, and physics. The third phase was dedicated to vision interpretation and program development by yDEGRO representatives. Results: The strategy retreat’s development process resulted in conception of the final vision “Innovative radiation oncology Together – Precise, Personalized, Human.” The first term “Innovative radiation oncology” comprises the promotion of preclinical research and clinical trials and highlights the development of a national committee for strategic development in radiation oncology research. The term “together” underpins collaborations within radiation oncology departments as well as with other partners in the clinical and scientific setting. “Precise” mainly covers technological precision in radiotherapy as well as targeted oncologic therapeutics. “Personalized” emphasizes biology-directed individualization of radiation treatment. Finally, “Human” underlines the patient-centered approach and points towards the need for individual longer-term career curricula for clinicians and researchers in the field. Conclusion: The vision 2030 balances the ambition of physical, technological, and biological innovation as well as a comprehensive, patient-centered, and collaborative approach towards radiotherapy & radiation oncology in Germany.
The role and timing of radiotherapy (RT) in prostate cancer (PCa) patients treated with radical prostatectomy (RP) remains controversial. While recent trials support the oncological safety of early salvage RT (SRT) compared to adjuvant RT (ART) in selected patients, previous randomized studies demonstrated that ART might improve recurrence-free survival in patients at high risk for local recurrence based on adverse pathology. Although ART might improve survival, this approach is characterized by a risk of overtreatment in up to 40% of cases. SRT is defined as the administration of RT to the prostatic bed and to the surrounding tissues in the patient with PSA recurrence after surgery but no evidence of distant metastatic disease. The delivery of salvage therapies exclusively in men who experience biochemical recurrence (BCR) has the potential advantage of reducing the risk of side effects without theoretically compromising outcomes. However, how to select patients at risk of progression who are more likely to benefit from a more aggressive treatment after RP, the exact timing of RT after RP, and the use of hormone therapy and its duration at the time of RT are still open issues. Moreover, what the role of novel imaging techniques and genomic classifiers are in identifying the most optimal post-operative management of PCa patients treated with RP is yet to be clarified. This narrative review summarizes most relevant published data to guide a multidisciplinary team in selecting appropriate candidates for post-prostatectomy radiation therapy.
Focal therapy is a modern alternative to selectively treat a specific part of the prostate harboring clinically significant disease while preserving the rest of the gland. The aim of this therapeutic approach is to retain the oncological benefit of active treatment and to minimize the side-effects of common radical treatments. The oncological effectiveness of focal therapy is yet to be proven in long-term robust trials. In contrast, the toxicity profile is well-established in randomized controlled trials and multiple robust prospective cohort studies. This narrative review summarizes the relevant evidence on complications and their management after focal therapy. When compared to whole gland treatments, focal therapy provides a substantial benefit in terms of adverse events reduction and preservation of genito-urinary function. The most common complications occur in the peri-operative period. Urinary tract infection and acute urinary retention can occur in up to 17% of patients, while dysuria and haematuria are more common. Urinary incontinence following focal therapy is very rare (0–5%), and the vast majority of patients recover in few weeks. Erectile dysfunction can occur after focal therapy in 0–46%: the baseline function and the ablation template are the most important factors predicting post-operative erectile dysfunction. Focal therapy in the salvage setting after external beam radiotherapy has a significantly higher rate of complications. Up to one man in 10 will present a severe complication.
The activity of the Salt inducible kinase 2 (SIK2), a member of the AMP-activated protein kinase (AMPK)-related kinase family, has been linked to several biological processes that maintain cellular and energetic homeostasis. SIK2 is overexpressed in several cancers, including ovarian cancer, where it promotes the proliferation of metastases. Furthermore, as a centrosome kinase, SIK2 has been shown to regulate the G2/M transition, and its depletion sensitizes ovarian cancer to paclitaxel-based chemotherapy. Here, we report the consequences of SIK2 inhibition on mitosis and synergies with paclitaxel in ovarian cancer using a novel and selective inhibitor, MRIA9. We show that MRIA9-induced inhibition of SIK2 blocks the centrosome disjunction, impairs the centrosome alignment, and causes spindle mispositioning during mitosis. Furthermore, the inhibition of SIK2 using MRIA9 increases chromosomal instability, revealing the role of SIK2 in maintaining genomic stability. Finally, MRIA9 treatment enhances the sensitivity to paclitaxel in 3D-spheroids derived from ovarian cancer cell lines and ovarian cancer patients. Our study suggests selective targeting of SIK2 in ovarian cancer as a therapeutic strategy for overcoming paclitaxel resistance.
Of the 16 non-structural proteins (Nsps) encoded by SARS CoV-2, Nsp3 is the largest and plays important roles in the viral life cycle. Being a large, multidomain, transmembrane protein, Nsp3 has been the most challenging Nsp to characterize. Encoded within Nsp3 is the papain-like protease domain (PLpro) that cleaves not only the viral polypeptide but also K48-linked polyubiquitin and the ubiquitin-like modifier, ISG15, from host cell proteins. We here compare the interactors of PLpro and Nsp3 and find a largely overlapping interactome. Intriguingly, we find that near full length Nsp3 is a more active protease compared to the minimal catalytic domain of PLpro. Using a MALDI-TOF based assay, we screen 1971 approved clinical compounds and identify five compounds that inhibit PLpro with IC50s in the low micromolar range but showed cross reactivity with other human deubiquitinases and had no significant antiviral activity in cellular SARS-CoV-2 infection assays. We therefore looked for alternative methods to block PLpro activity and engineered competitive nanobodies that bind to PLpro at the substrate binding site with nanomolar affinity thus inhibiting the enzyme. Our work highlights the importance of studying Nsp3 and provides tools and valuable insights to investigate Nsp3 biology during the viral infection cycle.
Introduction: Reliable and cost-effective diagnostics for hepatitis E virus (HEV) infection are necessary. The aim of our study was to investigate which diagnostic test is most accurate to detect HEV infection in immunocompetent and immunosuppressed patients in a real world setting. Patients and Methods: We performed a retrospective analysis of 1165 patients tested for HEV antibodies and HEV PCR at the same time point. Clinical, laboratory and virological data were taken from patient charts. HEV IgA was measured in a subgroup of 185 patients. Results: HEV RNA was detectable in 61 patients (5.2%); most of them (n = 49, 80.3%/n = 43, 70.5%) were HEV IgM+ and IgG+; however, 12 patients (19.6%) were HEV RNA positive/HEV IgM negative and 17 patients (27.8%) were HEV RNA positive/HEV IgG negative. Ten HEV RNA positive patients (16.4%) had neither HEV IgG nor IgM antibodies. Importantly, all of them were immunosuppressed. HEV IgA testing was less sensitive than HEV IgM for HEV diagnosis. Conclusions: HEV infection can be overlooked in patients without HEV specific antibodies. Performing PCR is necessary to diagnose or exclude HEV infection in immunocompromised hosts. In immunocompetent patients, a screening based on HEV antibodies (IgG/IgM) is sufficient.
Human cytomegalovirus (CMV) is a significant cause of morbidity and mortality in patient groups at risk. We have previously shown that the anti-CMV IgG seroprevalence in an urban region of Germany has changed over the last decades. Overall, a decline from 63.7 to 57.25% had been observed between 1988–1997 and 1998–2008 (p < 0,001). Here, we continuously follow the trends to the most recent decade 2009 to 2018. In a retrospective analysis, we determined the seroprevalence of CMV IgG antibodies in our patient cohort, stratified by gender and selected groups at risk (e.g., patients with HIV infection; women of childbearing age). The overall prevalence of anti-CMV IgG non-significantly declined further from 57.25% in 1998–2008 to 56.48% in 2009–2018 (p = 0.881). Looking at gender differences, overall CMV seroprevalence in males declined to 52.82% (from 55.54% in 1998–2008; p = 0.0254), while it non-significantly increased in females to 59.80%. The high seroprevalence in patients with a known HIV infection further increased from 87.46% in 1998–2008 to 92.93% in the current period (p = 0.9999). In women of childbearing age, no significant changes over the last three decades could be observed. The CMV seroprevalence in oncological patients was determined to be 60.64%. Overall, the former significant decline of CMV seroprevalence between the decades 1988–1997 and 1998–2008 in this urban region of Germany slowed down to a non-significant decrease of 0.77% (1998–2008 vs. 2009–2018). This might be an indicator that CMV seroprevalence has reached a plateau.
Background: The newly introduced German pediatric screening examination at the end of the third year of life (U7a) incorporates visual function testing in particular; there is no ophthalmic screening during childhood in Germany. The purpose of this study is to investigate the relationship between participation in U7a and visual function at the preschool health examination (PHE) in the sixth year of life. Methods: This study evaluated PHE data from school enrollment years 2009/2010 to 2014/2015 of Rhineland-Palatinate, Germany. Visual acuity (VA) at PHE was assessed with Rodenstock visual acuity test device (tumbling E) wearing glasses if present. The relationship between participation in U7a and VA <0.7 at PHE was calculated for reduced monocular and binocular VA using multiple logistic regression adjusted for potential confounders. Results: Data from 189,704 children (91,041 girls) in 35 out of 36 districts were included. The first children to participate in U7a were enrolled in 2011/2012 school year. In total, 90,339 children (47.6%) had U7a before PHE, while 99,365 (52.4%) had not. VA <0.7 in at least one eye was measured at PHE in 8429 (4.4%) children, and in both eyes in 4345 (2.3%) children. Participation in U7a was not associated with VA <0.7 at PHE (odds ratio 0.99; 95% confidence interval: 0.94–1.04). Conclusions: The proportion of children with VA <0.7 at PHE was high. No beneficial effect of newly introduced German U7a pediatric screening examination was found for reduced VA at PHE.
URPOSE: Today, the majority of medical graduates in countries such as the UK, the US or Germany are female. This poses a major problem for workforce planning especially in urology. We here use first the first time the previously established Brüggmann Groneberg (BG) index to assess if female academic career options advance in urology.
METHODS: Different operating parameters (student population, urology specialist population, urology chair female:male (f:m) ratio) were collected from the Federal Office of Statistics, the Federal Chamber of Physicians and the medical faculties of 36 German universities. Four time points were monitored (2000, 2005, 2010 and 2015). From these data, female to male (f:m) ratios and the recently established career advancement (BG) index have been calculated.
RESULTS: The German hospital urology specialists' f:m ratios were 0.257 (499 female vs. 1944 male) for 2015, 0.195 for 2010, 0.133 for 2005 and 0.12 for 2000. The career advancement (BG) index was 0.0007 for 2000, 0,0005 for 2005, 0.094 for 2010 and 0.073 for 2015. The decrease from 2010 to 2015 was due to an increase in the f:m ratio of hospital urologists and female medical students.
CONCLUSION: The BG index clearly illustrated that there is an urgent need for special academic career funding programs to counteract gender problems in urology. The BG index has been shown to be an excellent tool to assess female academic career options and will be very helpful to assess and document positive or negative changes in the next decades.
In the absence of an active prophylactic vaccine against HIV-1, passively administered, broadly neutralizing antibodies (bnAbs) identified in some chronically infected persons were shown to prevent HIV-1 infection in animal models. However, passive administration of bnAbs may not be suited to prevent sexual HIV-1 transmission in high-risk cohorts, as a continuous high level of active bnAbs may be difficult to achieve at the primary site of sexual transmission, the human vagina with its acidic pH. Therefore, we used Lactobacillus, a natural commensal in the healthy vaginal microbiome, to express bn nanobodies (VHH) against HIV-1 that we reported previously. After demonstrating that recombinant VHHA6 expressed in E. coli was able to protect humanized mice from mucosal infection by HIV-1Bal, we expressed VHHA6 in a soluble or in a cell-wall-anchored form in Lactobacillus rhamnosus DSM14870. This strain is already clinically applied for treatment of bacterial vaginosis. Both forms of VHHA6 neutralized a set of primary epidemiologically relevant HIV-1 strains in vitro. Furthermore, VHHA6 was still active at an acidic pH. Thus, lactobacilli expressing bn VHH potentially represent an attractive vector for the passive immunization of women in cohorts at high risk of HIV-1 transmission.
The aim of this observational study was to follow-up patients with bedtime basal insulin (NPH insulin) added to metformin. In 285 patients with type 2 diabetes, a therapy with bedtime basal insulin added to metformin was started due to failure to achieve a glycaemic goal. Up until July 2019, 272 patients (95.4%) were followed-up (59.5 y, 92.6 kg, diabetes duration 6.6 y, HbA1c 8.4%/68.6 mmol/mol). HbA1c decreased by −1.2% and bodyweight by −1.7 kg after a duration of 31.7 ± 29.1 (range 2–133) months. Severe hypoglycaemia did not occur. In 144/272 patients (52.9%), the therapeutic goal for HbA1c was achieved over 32.7 months. In 69/272 patients (25.4%), the HbA1c target was achieved over 25.0 months (afterwards, therapy with basal insulin was discontinued because HbA1c was under target). In 36/272 patients (13.2%), the HbA1c goal was achieved until the submission of this manuscript (mean duration of treatment 57.4 ± 28.2 (range 13–121) months). Over 90% of patients with type 2 diabetes and failure of metformin reached their HbA1c goal with additional basal insulin at bedtime over several years in association with a reduction of bodyweight and without any event of severe hypoglycaemia.
Access to specialized care is essential for people with Parkinson´s disease (PD). Given the growing number of people with PD and the lack of general practitioners and neurologists, particularly in rural areas in Germany, specialized PD staff (PDS), such as PD nurse specialists and Parkinson Assistants (PASS), will play an increasingly important role in the care of people with PD over the coming years. PDS have several tasks, such as having a role as an educator or adviser for other health professionals or an advocate for people with PD to represent and justify their needs. PD nurse specialists have been established for a long time in the Netherlands, England, the USA, and Scandinavia. In contrast, in Germany, distinct PDS models and projects have been established. However, these projects and models show substantial heterogeneity in terms of access requirements, education, theoretical and practical skills, principal workplace (inpatient vs. outpatient), and reimbursement. This review provides an overview of the existing forms and regional models for PDS in Germany. PDS reimbursement concepts must be established that will foster an implementation throughout Germany. Additionally, development of professional roles in nursing and more specialized care in Germany is needed.
Ferroptosis, a newly discovered form of cell death mediated by reactive oxygen species (ROS) and lipid peroxidation, has recently been shown to have an impact on various cancer types; however, so far there are only few studies about its role in hepatocellular carcinoma (HCC). The delicate equilibrium of ROS in cancer cells has found to be crucial for cell survival, thus increased levels may trigger ferroptosis in HCC.In our study, we investigated the effect of different ROS modulators and ferroptosis inducers on a human HCC cell line and a human hepatoblastoma cell line. We identified a novel synergistic cell death induction by the combination of Auranofin and buthionine sulfoxime (BSO) or by Erastin and BSO at subtoxic concentrations. We found a caspase-independent, redox-regulated cell death, which could be rescued by different inhibitors of ferroptosis. Both cotreatments stimulated lipid peroxidation. All these findings indicated ferroptotic cell death. Both cotreatments affected the canonical ferroptosis pathway through GPX4 downregulation. We also found an accumulation of Nrf2 and HO-1, indicating an additional effect on the non-canonical pathway. Our results implicate that targeting these two main ferroptotic pathways simultaneously can overcome chemotherapy resistance in HCC.
Simple Summary: Pseudoprogression detection in glioblastoma patients remains a challenging task. Although pseudoprogression has only a moderate prevalence of 10–30% following first-line treatment of glioblastoma patients, it bears critical implications for affected patients. Non-invasive techniques, such as amino acid PET imaging using the tracer O-(2-[18F]-fluoroethyl)-L-tyrosine (FET), expose features that have been shown to provide useful information to distinguish tumor progression from pseudoprogression. The usefulness of FET-PET in IDH-wildtype glioblastoma exclusively, however, has not been investigated so far. Recently, machine learning (ML) algorithms have been shown to offer great potential particularly when multiparametric data is available. In this preliminary study, a Linear Discriminant Analysis-based ML algorithm was deployed in a cohort of newly diagnosed IDH-wildtype glioblastoma patients (n = 44) and demonstrated a significantly better diagnostic performance than conventional ROC analysis. This preliminary study is the first to assess the performance of ML in FET-PET for diagnosing pseudoprogression exclusively in IDH-wildtype glioblastoma and demonstrates its potential.
Abstract: Pseudoprogression (PSP) detection in glioblastoma remains challenging and has important clinical implications. We investigated the potential of machine learning (ML) in improving the performance of PET using O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) for differentiation of tumor progression from PSP in IDH-wildtype glioblastoma. We retrospectively evaluated the PET data of patients with newly diagnosed IDH-wildtype glioblastoma following chemoradiation. Contrast-enhanced MRI suspected PSP/TP and all patients underwent subsequently an additional dynamic FET-PET scan. The modified Response Assessment in Neuro-Oncology (RANO) criteria served to diagnose PSP. We trained a Linear Discriminant Analysis (LDA)-based classifier using FET-PET derived features on a hold-out validation set. The results of the ML model were compared with a conventional FET-PET analysis using the receiver-operating-characteristic (ROC) curve. Of the 44 patients included in this preliminary study, 14 patients were diagnosed with PSP. The mean (TBRmean) and maximum tumor-to-brain ratios (TBRmax) were significantly higher in the TP group as compared to the PSP group (p = 0.014 and p = 0.033, respectively). The area under the ROC curve (AUC) for TBRmax and TBRmean was 0.68 and 0.74, respectively. Using the LDA-based algorithm, the AUC (0.93) was significantly higher than the AUC for TBRmax. This preliminary study shows that in IDH-wildtype glioblastoma, ML-based PSP detection leads to better diagnostic performance.
Motivation: Calculating the magnitude of treatment effects or of differences between two groups is a common task in quantitative science. Standard effect size measures based on differences, such as the commonly used Cohen's, fail to capture the treatment-related effects on the data if the effects were not reflected by the central tendency. The present work aims at (i) developing a non-parametric alternative to Cohen’s d, which (ii) circumvents some of its numerical limitations and (iii) involves obvious changes in the data that do not affect the group means and are therefore not captured by Cohen’s d.
Results: We propose "Impact” as a novel non-parametric measure of effect size obtained as the sum of two separate components and includes (i) a difference-based effect size measure implemented as the change in the central tendency of the group-specific data normalized to pooled variability and (ii) a data distribution shape-based effect size measure implemented as the difference in probability density of the group-specific data. Results obtained on artificial and empirical data showed that “Impact”is superior to Cohen's d by its additional second component in detecting clearly visible effects not reflected in central tendencies. The proposed effect size measure is invariant to the scaling of the data, reflects changes in the central tendency in cases where differences in the shape of probability distributions between subgroups are negligible, but captures changes in probability distributions as effects and is numerically stable even if the variances of the data set or its subgroups disappear.
Conclusions: The proposed effect size measure shares the ability to observe such an effect with machine learning algorithms. Therefore, the proposed effect size measure is particularly well suited for data science and artificial intelligence-based knowledge discovery from big and heterogeneous data.
Objective: Value frameworks in oncology have not been validated for the assessment of treatments in haematological malignancies, but to avoid overlaps and duplications it appears reasonable to build up experience on existing value frameworks, such as the European Society for Medical Oncology—Magnitude of Clinical Benefit Scale (ESMO-MCBS).
Methods: Here we present the results of the first feasibility testing of the ESMO-MCBS v1.1 for haematological malignancies based on the grading of 80 contemporary studies for acute leukaemia, chronic leukaemia, lymphoma, myeloma and myelodysplastic syndromes. The aims were (1) to evaluate the scorability of data, (2) to evaluate the reasonableness of the generated grades for clinical benefit using the current version and (3) to identify shortcomings in the ESMO-MCBS v1.1 that require amendments to improve the efficacy and validity of the scale in grading new treatments in the management of haematological malignancies.
Results: In general, the ESMO-MCBS v1.1 was found to be widely applicable to studies in haematological malignancies, generating scores that were judged as reasonable by European Hematology Association (EHA) experts. A small number of studies could either not be graded or were not appropriately graded. The reasons, related to the differences between haematological and solid tumour malignancies, are identified and described.
Conclusions: Based on the findings of this study, ESMO and EHA are committed to develop a version of the ESMO-MCBS that is validated for haematological malignancies. This development process will incorporate all of the usual stringencies for accountability of reasonableness that have characterised the development of the ESMO-MCBS including field testing, statistical modelling, evaluation for reasonableness and openness to appeal and revision. Applying such a scale will support future public policy decision-making regarding the value of new treatments for haematological malignancies and will provide insights that could be helpful in the design of future clinical trials.
Background: Culture-derived mesenchymal stromal cells (MSCs) exhibit variable characteristics when manufactured using different methods and different source materials. The purpose of this study was to assess the impact on MSC characteristics when different laboratories propagated MSCs from cultures initiated with BM aliquots derived from the same donor source material.
Methods and Methods: Five aliquots from each of three different BM donors were distributed to five independent laboratories. Three laboratories plated whole BM and two laboratories a mononuclear BM cell fraction. Four laboratories cultured in media supplemented with fetal bovine serum (FBS) and one laboratory used human platelet lysate (hPL). Initial cell seeding densities (i.e., P0) ranged from 19.7 × 103/cm2–282 × 103/cm2 and for second seeding (i.e., P1) 0.05 × 103–5.1 × 103 cells/cm2. Post-thawed MSCs from each laboratory were analyzed for cell viability, immunophenotype, tri-lineage differentiation, fibroblast colony-forming units (CFU-F), gene expression, and immunosuppressive activity.
Results: Transit times from BM collection to receipt by laboratories located in the United States ranged from 16.0–30.0 h and from 41.5–71.5 h for a laboratory in Asia. Post-thaw culture derived MSCs rom BM #1, #2, and #3 exhibited viabilities that ranged from 74–92%, 61–96%, and 23–90%, respectively. CFU activity from BM #1, #2, and #3 per 200 MSCs plated averaged 45.1 ± 21.4, 49.3 ± 26.8 and 14.9 ± 13.3, respectively. No substantial differences were observed in immunophenotype, and immunosuppressive activities. Global gene expression profiles of MSCs revealed transcriptome differences due to different inter-laboratory methods and to donor source material with the center effects showing greater molecular differences than source material.
Conclusion: Functional and molecular differences exist among MSCs produced by different centers even when the same BM starting material is used to initiate cultures. These results indicated that manufacturing of MSCs by five independent centers contributed more to MSC variability than did the source material of the BM used in this study. Thus, emphasizing the importance of establishing worldwide standards to propagate MSCs for clinical use.